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Executive Summary
Problem
Provider Opinion about Guidance Provided by a Prostate Cancer Screening Educational
Pamphlet, a quality improvement initiative, addresses the non evidence-based practice of
uninformed prostate cancer screening at the Denver Veteran Affairs Medical Center (VAMC).
The population of interest is primary care providers (PCPs) in two Denver VAMC primary care
clinics, Firm A Clinic and Saturday Intake Clinic. The intervention is the detailed prostate cancer
screening educational pamphlet and corresponding discussions. The comparison is the frequency
of prostate cancer screening informed decision making in Firm B, another Denver VAMC
primary care clinic, without the guidance of the pamphlet. The outcome of interest is PCPs
opinion about the pamphlet offering guidance with prostate cancer informed decision making.
Purpose
Patients will continue to request prostate specific antigen (PSA) tests until providers educate
them about the pros and cons of screening. The mission of this project is to ensure that Denver
VAMC PCP’s are fully aware of the latest research and guidelines regarding prostate cancer
screening in order to provide accurate information to male veterans in deciding about PSA
testing by having them review the educational pamphlet that reflects current evidence- based
practice.
Goals
Denver VAMC PCPs must meet the following goals in order for the mission to occur: (a) to be
knowledgeable about the latest prostate cancer screening research and guidelines; (b) to explain
the risk of prostate cancer to male veterans;(c) to explain the risks, benefit, alternatives, and
uncertainties of PSA screening to veterans; (d) to consider the male veteran’s values in deciding
about PSA screening; and (e) to engage the male veteran in decision making at the desired level.
Objectives
The outcome objectives are the means by which Denver VAMC PCPs will engage in the type of
shared decision making that practice guidelines recommend. The measurable project objectives
include (a) design and print a prostate cancer screening educational pamphlet using the latest
evidence based practice, (b) educate providers in Firm A Clinic and Saturday Clinic about the
practice issue, and (c) measure perceptions of PCPs regarding use of the detailed prostate cancer
screening pamphlet via a survey. A comparison group, PCPs in Firm B Clinic, provides a link to
current practices.
Plan, Outcomes and Results
Outlook email messages were sent to all PCPS. The detailed pamphlet was tested by three PCPs
in Firm A Clinic and five PCPs in Saturday Clinic. The eight completed surveys indicated that
the brochure did offer Denver PCPs guidance in informing patients about prostate cancer
screening. All eight PCPs found the detailed pamphlet informative, with appropriate graphics,
and a user friendly format. Some physicians in Firm B do not routinely order PSAs because it is
no longer a clinical reminder, but other PCPs order PSAs because of fear of liability.
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Provider Opinion about Guidance Provided by a Prostate Cancer Screening
Educational Pamphlet

The following proposal is a quality improvement initiative, or small scale intervention,
linked to Denver Veteran Affairs Medical Center (VAMC) primary care providers’ (PCPs)
assessment of a prostate cancer screening educational pamphlet (Cassarett, Karlawish, &
Sugarman, 2000). Prostate Cancer Informed Decision Making, the original Capstone Project,
was changed to Informed Decision Making with the Guidance of Two Prostate Cancer Screening
Educational Pamphlets, and changed again, to Provider Opinion about Guidance Provided by a
Prostate Cancer Screening Educational Pamphlet. Each revision resulted in simplification, with
less data needing to be collected and analyzed, including excluding the need for private
information. In other words, measuring the two patient categorical outcomes of informed versus
not informed, and prostate specific antigen (PSA) drawn versus PSA not drawn, was replaced by
measuring the two provider categorical outcomes of basic or detailed pamphlet preference (see
Appendices B and C), and guidance offered versus guidance not offered, by the two prostate
cancer screening educational pamphlets. The final revision resulted in measuring PCPs’
assessment of the detailed pamphlet, an ordinal level of measurement ranking the responses to
survey questions. In retrospect, the change makes good sense because in order for patient’s
behavior to change, provider’s behavior must change first. Patients will continue to request PSA
screens until providers educate them about the pros and cons of screening; therefore, educating
providers is the logical place to start the implementation of the evidence-based practice of
prostate cancer screening informed decision making.
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Problem Recognition and Definition

Statement of Purpose

The obligation of a Doctorate of Nursing Practice (DNP) is to change patient care
practices that do not promote health and well-being. This challenge is particularly relevant to the
practice of prostate cancer screening with a PSA blood test. Providing a detailed prostate cancer
screening educational pamphlet to PCPs in two Denver VAMC Clinics is one way to ensure
that PCPs will inform Denver male veterans about the pros and cons of prostate cancer screening
before PSA testing is offered. The outcome of interest is PCPs’ opinion on whether the detailed
pamphlet offered guidance regarding prostate cancer informed decision making.
Attempting to identify individuals in a broad segment of the population for latent
conditions is a double edged sword because some may benefit while others may be diagnosed
and treated for cancer unnecessarily (Schwartz, Woloshin, Fowler, & Welch, 2004). This
approach to healthcare is particularly true for cancer screening, especially prostate cancer
screening (Schwartz et al.). The healthcare profession has developed a culture that believes
searching for cancer is prudent preventative care, and consequently, prostate cancer screening
continues without good evidence (Adami, Baron, & Rothman, 1994). Searching for indolent
cancer does not promote health and well-being (Perez- Stable, 2009). One way to reverse this
practice is to inform men about the pros and cons of screening before offering a PSA test (Krist,
Woolf, Johnson, & Kerns, 2007). This project proposes that providers need to learn about the
pros and cons of prostate cancer screening, including the recommendation for informed decision
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making, in order for screening behaviors to change (Partin et al., 2004). The impact of this
evidence-based practice is to decrease the identification of latent prostate cancers and the
corresponding treatments, resulting in increased morbidity and decreased quality of life for male
veterans.
Problem Statement

Cancer is a heterogeneous disease caused by the development of abnormal cells that
divide (Encarta, n.d.). Some cancers are life threatening while others are clinically dormant
(Paul & Kunz, 2010). Distinguishing between aggressive and latent cancers is not initially easy;
therefore, patients are often diagnosed with a cancer which may have regressed, grown slowly,
or not spread (Paul & Kunz). For instance, prostate cancer is the second most common cancer in
men besides skin cancer, but the lifetime risk of dying from it is only 2.9% (Hallberg, 2011).
Enthusiasm for cancer screening in the United States, promoted by the press and various
treatment centers, leads many patients to opt for screening despite false-positive test results and
the possibility of unnecessary treatments (Schwartz et al., 2004).
Secondary prevention by screening for prostate cancer with a prostate specific antigen
(PSA) test is not evidence-based practice. The goal of secondary prevention is to decrease
morbidity and mortality by detecting prevalent, clinically significant cancers before they become
symptomatic (Fitzgerald, 2005). Diagnosing and treating preclinical and clinically dormant
prostate cancers does not meet the criterion for screening because the benefit of testing does not
outweigh the harm (Perez- Stable, 2009). In other words, the benefit of saving a one life does
not balance the harm of needless treatment of 48 men (Schroeder, Hugosson, Roobol, M. et al.,
2009).
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The PSA test was originally used to monitor the response to treatment in patients with
prostate cancer (Albin, 2010). Mass population PSA testing was initiated in the late 1980’s
without well conducted trials to support the benefit of screening (Adami, Baron, & Rothman,
1994). The PSA test was touted as having high sensitivity and specificity, when in fact its ability
to identify correctly those who have the disease (sensitivity) is overestimated, and its ability to
identify correctly those who do not have the disease (specificity) is underestimated (Hoffman,
Fletcher & Rind, 2010). The PSA test, the outcome measure, cannot discriminate between
individuals with and without prostate cancer, the outcome evaluated; thus, the PSA test has a
poor predictive value.
The lack of definitive data on prostate cancer screening outcomes and the risk of
overdiagnosis and treatment have made prostate cancer screening a controversial issue
(Hoffman, et al., 2010). The vast majority of prostate cancers currently detected in the United
States are asymptomatic, found on routine PSA testing, and are clinically localized (U.S.
Department of Health &Human Services, 2008). The modest absolute reduction in mortality
from prostate cancer over time comes at the cost of diagnosing and aggressively treating
nonprogressive cancers (Pignone, 2009).

Additionally, the harms of screening start

immediately; whereas, the potential benefits are not realized for years to come (Pignone). For
example, many men diagnosed with prostate cancer as a result of screening will not experience
clinical problems for years, even without treatment (Hoffman, Fetcher, O’ Leary, & Rind, 2011).
However, undergoing curative radical prostatectomy and radiation therapies for localized, lowrisk disease can lead to immediate complications including long-time life risks such as
impotence and incontinence (Goldhagen, 2011). These risks are devastating, especially for
those destined to die with, instead of from, prostate cancer.
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The American Urologic Association (AUA), American Cancer Society (ACS), U.S.
Preventative Services Task Force (USPSTF), and other major medical organizations recommend
that providers discuss the risks and benefits of prostate cancer screening before PSA testing is
performed by way of shared or informed decision making (Woolf & Krist, 2009). According
to Krist et al. (2007), per the USPSTF, “A decision is shared when the patient (1) understands the
risk of the disease to be prevented; (2) understands the preventive service, including risk, benefit,
alternatives, and uncertainties; (3) weighs his values regarding the decision; and (4) is engaged in
the decision at the desired level” (p. 112-113). Recent data shows that few providers are doing
this (Gaster et al., 2010). The problem then is that prostate cancer screening is routinely done
without informed decision making, and this is not in line with evidenced based practice.
PICO

Evidence-based practice studies often detail the specifics of the study using a
patient/population, intervention, comparison, outcome of interest (PICO) format (Houser &
Oman, 2011). The question is, does the detailed prostate cancer screening pamphlet guide
providers with informed decision making regarding PSA testing?
P: The population of interest is PCPs in the Saturday Intake Clinic and Firm A Primary Care
Clinic.
I: The intervention is the detailed prostate cancer screening educational pamphlet and
corresponding discussions.
C: The comparison is the frequency of prostate cancer screening informed decision making in
Denver VAMC Firm B Primary Care Clinic without the guide of the pamphlet.
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O: The outcome of interest is PCPs opinion about the pamphlet offering guidance with prostate
cancer informed decision making.

Project Significance, Scope, and Rationale

The USPSTF states that the evidence is insufficient to recommend for or against prostate
cancer screening; men age 75 years or older should not be screened, and shared decision making
should include discussion of potential risks

(Lin, Lipsitz, Miller, & Janakiraman, 2007). In

October of 2011, the USPSTF revised their guidelines recommending against screening for
prostate cancer with a PSA test, regardless of age, race, or family history (Hoffman et al., 2011).
Despite the recommendations, shared decision making is not routine practice because the patient
requests the test, the provider favors testing, the PSA is simply added to a requisition for other
blood tests, or a PSA is ordered without the patient understanding its purpose and consequences
(Woolf & Krist, 2009). Provider reasons for not discussing the risks and benefits of screening
include lack of time and competing demands, forgetfulness, limited patient health literacy, and
fear of liability (Guerra, Jacobs, Holmes, & Shea, 2007).
Since the emerging role of the DNP is to ensure integration and application of evidencebased practice to patient care, a nurse-sensitive outcome area is to ensure informed decision
making about prostate cancer screening at the Denver VAMC. In order for screening behaviors
to change, health care provider’s behaviors need to change, and that requires education.
Providers need to know that the existing evidence from randomized control trials does not
support the routine use of screening for prostate cancer with prostate specific antigen, with or
without digital rectal exam (Djulbegovic et al., 2010). The detailed prostate cancer screening
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pamphlet will educate providers about the limitations of prostate cancer screening with the
ultimate goal of patient informed decision making resulting in decreased interest in PSA testing
with subsequent improved health outcomes (Casserett, Karlawish, & Sugarman, 2000).
Theoretical Foundation for Project and Change

A DNP is educated to improve health care by looking at the whole picture through
empiric science, personal knowing, ethics, and aesthetics. Emancipatory knowing integrates the
four fundamental patterns of knowing. Praxis, the process of emancipatory knowing, involves
instituting healthcare changes designed to provide the highest level of care (Chinn & Kramer,
2008). Prostate cancer screening and treatment was born out of empiric knowledge. This
practice leads to nearsighted care because the other forms of knowing were omitted. Adami
(2010) sums up the practice of prostate cancer screening well, “Although cancer screening is
intuitively appealing, the logistic complexities, ethical dilemmas and potential harms of
intervention in healthy populations are often underestimated” (p.300). Therefore, patients need
to be asked if they would be willing to accept a high risk of side effects from treatment in return
for a small chance of living longer, along with other personal knowing, ethical, and aesthetic
questions. For example, does the patient want to know if he has prostate cancer, even if the
cancer might never do him any harm, or, how important is sex in his life? (Hoffman et al.,
2011).
A conceptual model outlines the Capstone Project starting with the initial model and two
revisions (see Appendices D, E, and F). The final model was started with the outcome,
provider’s opinion about guidance provided by the pamphlet. The population was further defined
by concepts borrowed from the Health Belief Model, a model developed by Rosenstock in 1966,
and furthered by Becker and colleagues in the 1970s and 1980s, to explain preventative
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behaviors (Kane & Radosevich, 2011). The intervention, prostate cancer screening educational
pamphlet, was appropriately given a less impressive spot than the perceived threat of prostate
cancer, depicted in the large oval. The perceived threat of prostate cancer, propagated by the
mass media and other cancer screening enthusiasts, results in misinformed decision making
(Ablin, 2010).
The Health Belief Model suggests that an individual’s perception about the seriousness
and susceptibility of prostate cancer is the driving force behind screening. The perceived threat
of prostate cancer is modified by age, education level, social class, personality, mass media,
knowing a prostate cancer victim, philosophy of life, and advice from family, friends, and other
health care providers. A belief in the efficacy of prostate cancer treatment leads to screening
(Kane & Radosevich, 2011). In fact, most Americans believe that finding cancer early saves
lives, and 56% of those surveyed want screening for clinically irrelevant cancers (Perez-Stable,
2009). On the other hand, studies of prostate cancer screening decision aides consistently show
that enhanced knowledge is associated with decreased interest in screening (Hoffman et al.,
2009). For example, one study randomly assigned 176 men to usual care, a face-to-face
discussion of PSA testing, a videotape, or a combination of videotape and discussion. PSA
testing was selected by 98 percent of men assigned to usual care compared to 50 percent of men
that were assigned to combined discussion and videotape intervention (Frosch, Kaplan, & Felitti,
2001).
The concept of causal inferences in epidemiology is similar to the exploration of benefits
and harms of treatment in outcomes research (Kane & Radosevich, 2011). One or more of nine
guidelines can be used for judging whether an association is causal; however, a temporal
relationship is the most important because it clarifies the order between exposure and disease and
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the length of interval between the two (Gordis, 2009). The temporal relationship of prostate
cancer diagnosis and disease specific morbidity or mortality is important not only for clarifying
the order in which the two occur but also in regard to the length of the interval between diagnosis
and disease specific morbidity or mortality (Gordis). In other words, a positive PSA test leading
to a positive prostate biopsy is not temporally related to morbidity or mortality because some
prostate cancers grow so slowly they wound never have caused symptoms (Lin et al., 2008).
The causal guidelines inferences were modified in 1986 to include categorization of the
evidence by the quality of its source (Gordis, 2009). The USPSTF uses an eight step analytic
plan to evaluate the evidence for a screening program by reviewing relevant randomized trials.
By assessing the strength of evidence the USPSTF moves from causal inferences to policy
recommendations (Gordis). Since 2002, the USPSTF has maintained that the evidence is
insufficient to recommend for or against screening; since 2008, the USPSFT has maintained that
the evidence is sufficient to recommend against screening for men 75 years and older (Lin et al.,
2008), and since October, 2011, the USPSTF has recommended that the evidence is sufficient to
recommend against screening healthy men (Bankhead, 2011).
Only a small part of the causal chain was depicted while constructing this conceptual
model with the outcome of provider’s opinion about guidance provided by the prostate cancer
educational pamphlet. Unfortunately, an educational pamphlet is not enough to end the
continued practice of prostate cancer screening in asymptomatic men because there are
multideterminants of health preference which comprise the entire causal process (Earp & Ennett,
1991). One major determinant of health preference is a person’s belief, including a commitment
to prostate cancer screening, despite false-positive test results or the possibility that testing could
lead to unnecessary treatment (Schwartz, Woloshin, Fowler, & Welch, 2004).
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Literature Selection/ Systematic Process Supports Problem

Prostate cancer diagnosis and treatment is a therapy/harm clinical question. In order to
prove or disprove prostate cancer screening efficacy, a systematic review of randomized
controlled trial was searched for in the health sciences databases (Houser & Oman, 2011). The
trials revealed that there is no strong evidence that PSA testing decreases mortality; there is no
evidence about the best treatment for clinically localized prostate cancer (Clements et al., 2007),
and patient/provider treatment preferences reflect geography and perceptions more than
evidence-based recommendations (U.S. Department of Health & Human Services, 2008).
In 2009, two ongoing randomized trials of PSA screening provided the first quantitative
estimates of the survival benefits due to early detection (primary empirical resources). The
prostate arm of the National Cancer Institute-sponsored Prostate, Lung, Colorectal, and Ovarian
(PLCO) Cancer Screening Trial found no survival benefits from annual PSA screening combined
with digital rectal exam (Andriole et al., 2009). A larger similar trial, the European Randomized
Study of Screening for Prostate Cancer (ERSPC), initiated in the early 1990s, with men aged 50
to 74 years, found a 20% reduction in prostate cancer screening every four years (Schroder et al.,
2009). This finding means that 1410 men needed to be screened, and 48 men needed to receive
early treatment, in order to prevent one cancer death at ten years (Adami, 2010).
The Cochrane Collaboration updated their 2006 Screening for prostate cancer (Review)
in 2010 (secondary empirical resource). The database included electronic searches of the
PROSTATE registrar, MEDLINE, EMBASE, CANCERLIT, NHSEED and hand searching of
five prominent urology and cancer journals. Inclusion criteria included comparing mass
screening for prostate cancer to no screening and exclusion criteria included not being a
randomized controlled trial. A meta-analysis of five randomized controlled trials, selected from a
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review of 205 potentially relevant articles, concluded that prostate cancer screening did not
significantly decrease prostate cancer-specific mortality. Only the European trial reported a
reduction in mortality as outlined above (Ilic, O’Connor, Green, & Wilt, 2010).
A high level of evidence is needed when making clinical treatment decisions that involve
a high risk-benefit ratio, such as a potential cancer diagnosis leading to controversial treatment,
therefore it is imperative to have solid evidence supporting clinical practice guidelines (Houser
& Oman, 2011). The USPSTF, responsible for developing clinical practice guidelines for
prevention and screening, ranks studies by their quality and evidence, followed by estimates of
the balance of benefits and harms. Critical gaps in the 2002 USPSTF review prompted the 2007
evidence update (secondary empirical resource). Articles in PubMed and the Cochrane Library
from January, 2002 to July, 2007 were searched for evidence on health outcomes associated with
PSA screening , harms of screening for prostate cancer, and the natural history of PSA-detected,
nonpalpable localized prostate cancer. Three hundred ninety, 420, and 91 potentially relevant
articles were identified to address the three respective areas of concern. Sixty eight articles were
obtained for full text review and ten articles met inclusion criteria. The USPSTF concluded that
PSA screening is associated with psychological harms and its potential benefits remain uncertain
(Lin, et al., 2008, p.194).
Prostate cancer data in the U.S. is retrieved from individual state population-based or
central cancer registries designed to provide outcome data to help improve patient care (Garvin,
2007). The Surveillance, Epidemiology, and End Results (SEER) Program was established after
the National Cancer Act of 1971 mandated systematic collection of cancer data for use in the
prevention, diagnosis, and treatment of cancer (Garvin). The SEER program collects cancer
incidence and survival data from nine states, five metropolitan areas, and the Alaska Tumor
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Registry encompassing about 26 percent of the U.S. population. Patient demographics, primary
tumor site, stage at diagnosis, first course of treatment, and follow-up for vital statistics are the
data collected (NCI, February 2010).
Stephenson et al. (1996) hypothesized that when an increase in incidence is observed
following the introduction of a screening test, a subsequent decrease in incidence is bound to
happen as prevalent cases are removed from the population and screening intensity decreases, a
phenomenon they called a cull effect. The method used to test their hypothesis involved
comparing prostate cancer rates from the SEER national registry to the age-adjusted prostate
carcinoma trends which they tracked from the population-based Utah Cancer Registry. The
authors concluded that the Utah Cancer Registry Data from 1993 and 1994 indicates that the
incidence of prostate carcinoma is rapidly decreasing after similarly rapid increases. The rapid
and highly correlated rise in prostate cancer incidence observed in both SEER and the Utah
incidence rates between 1988 and 1991 raised concerns about the diagnosis and treatment of
clinically insignificant cancers and increased invasive prostate cancer treatment without good
evidence (Stephenson et al.).
The exhaustive medical literature review was halted after the same patterns and
references kept recurring. The repeating themes correlate with the key points identified by
England’s National Health Service Prostate Cancer Risk Management Programme (PCRMP) for
men to be aware of prior to taking a PSA test:
•

The PSA test facilitates the early detection of prostate cancer at a stage when potentially
curative treatments can be offered.

•

There is currently no strong evidence that PSA testing reduces mortality from prostate
cancer.
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•

Not all men with raised PSA will have prostate cancer/the PSA test will not detect all
prostate cancers.

•

Prostate cancer is diagnosed through a prostate biopsy which can be uncomfortable or
painful.

•

Prostate biopsies will not detect all prostate cancers.

•

Prostate cancers range from aggressive to slow growing forms – slow growing tumors
may not result in symptoms or shorten life expectancy.

•

There is no evidence about the optimum treatment for localized prostate cancer.

•

Some treatments for prostate cancer can have significant side effects (Clements et al.,
2007, Table 1).
Establishing prostate cancer screening efficacy and safety involves both clinical and

epidemiological research. Distinguishing causation from association, establishing validity of
outcome measures, estimating lead time, and studying the natural history of disease are
epidemiological studies relevant to prostate cancer screening. Epidemiologists unanimously use
the PSA as an example of a test with poor validity and consistently insinuate that it was
irresponsible to introduce prostate cancer screening without well-conducted randomized trials
because now it is virtually impossible to conduct those studies (Gordis, 2009).
Three epidemiologists from the University of Washington and the Fred Hutchinson
Cancer Research Center in Seattle estimated lead time and overdiagnosis associated with PSA
screening (primary qualitative descriptive epidemiologic study). These researchers
conceptualized the observed incidence of prostate cancer as the sum of secular trends (incidence
without PSA testing) and the excess incidence over and above the secular trend (incidence based
on screening and unknown lead times). The authors developed two likelihood models to estimate
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mean lead time under specified distributional assumptions and with a smooth secular trend. This
novel likelihood approach allowed the authors to make formal inferences about the lead time and
overdiagnosis associated with PSA screening in the U.S. and provided a first glimpse of a secular
trend in disease incidence (Telesca, Etzioni, & Gulaiti, 2007).
Telesca et al. (2007) contend that one of the main costs associated with the PSA test is
that it markedly increases overdiagnosis by detecting cancers that would not otherwise have been
diagnosed within the patient’s life. The cost is related to the lead time, or the time by which
screening advances diagnosis, resulting in overdiagnosis, because death from other causes
precedes the date of symptomatic disease and/or occurs during the lead time. The authors also
provided some provocative insights about racial disparities in prostate cancer with estimated lead
times of 4.50 years for whites and 6.43 years for blacks. In addition to black men’s aggressive
clinically detected cancers, blacks may be subject to a higher frequency of latent disease because
the higher incidence of aggressive prostate cancer in blacks was based on data from symptomatic
disease cases prior to the PSA era (Telesca et al., p.15).
Prevalence is the proportion of the population affected by a disease at a moment in time;
it is not a measure of risk since it does not take into account the duration of the disease.
Incidence is a measure of risk because it is the number of new cases of a disease that occur
during a specified period of time (Gordis, 2009). Another relevant epidemiologic article studied
these concepts using a novel highly technical method to estimate the asymptomatic incidence
and duration of prostate cancer; according to Etzioni, Cha, Feuer, and Davidov (1998), “Prostate
cancer is known as a disease with extremely high prevalence relative to its clinical incidence in
the population” (p. 775). It is precisely this combination of asymptomatic incidence and duration
that is of interest to researchers trying to explain the natural history of prostate cancer and how it
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can lead to effective screening strategies. Comparison of the lifetime risks of preclinical and
clinical disease confirmed that prostate cancer is a slow growing disease and approximately 50 to
75 percent of new cases are likely to remain asymptomatic (Etzioni et al., p. 784).
Adami (2009), a Harvard epidemiologist and former surgeon, who currently researches
various cancers, predicts that historians may consider the prostate cancer pseudo-epidemic “a
disaster of contemporary medicine” (p. 298). In 1994, Adami questioned the ethics of a prostate
cancer screening trial, “To intervene in healthy people is not ethical without the widespread
evidence of a net benefit- the evidence for which, in our opinion, is still uncertain” (p. 959). He
works closely with Swedish researchers and concurs with the growing number of health agencies
that advise against prostate cancer screening with a PSA (Adami).
The next step in the prostate cancer screening review was to explore the literature on
informed decision making. The previously mentioned article by Clements et al. (2007) from the
United Kingdom (UK) is an open access article, which means it can be reproduced and
distributed as long as it is correctly cited. The National Screening Committee in the UK
recommends against prostate cancer screening but the public concern about prostate cancer led
the Department of Health to introduce the PCRMP in 2001. The program recommends that the
PSA be available to interested men provided they are aware of the pros and cons. This qualitative
study used semi-structured interviews with 21 general practitioners (GPs) from 18 GP practices
in Oxfordshire to explore GPs’ reports of consultations with asymptomatic men. The study
concluded that despite GPs’ understanding of the importance of informed decision making, the
information provided was inconsistent because of provider preferences and their need to counter
most men’s positive opinion about screening. The authors contend that written information and a
return visit would provide a more balanced picture, and they discussed how providing
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information to patients about clinical issues that are not evidence based is problematic (Clements
et al., Discussion section, para. 3).
The National Survey of Medical Decisions (DECISIONS Study), an original
investigation by Hoffman et al. (2009), evaluated the medical decision–making process for PSA
testing. The study design was a random-digit-dial survey of a national probability sample of
3010 English-speaking adults 40 years and older. A telephone survey of a subsample of 375
men who had either undergone PSA testing or discussed prostate cancer screening with a
provider in the past two years was reported. This study was the first to systematically use the
same survey methodology to assess one of nine common medical decisions ranging from
initiating antihypertensive to screening for prostate, colorectal, or breast cancer. The conclusion
of these authors was that health care provider’s opinions strongly influenced screening decisions
and shared decision making was lacking because subjects had limited knowledge, did not
receive both sides of the story, and their preferences were not routinely considered (Hoffman et
al.).
Another study by Partin et al. (2004), about informed decision making, was a randomized
trial examining the effect of two prostate cancer screening educational interventions done at four
Midwestern Veteran Affairs medical facilities (University of Minnesota). One thousand, one
hundred fifty-two male veterans age 50 and older with primary care appointments were
randomized to usual care, pamphlets, or a video. Two weeks prior to their primary care
appointment, subjects received a mailed pamphlet, video, or no educational interventions. One
week after their appointment, subjects completed a phone survey to assess knowledge,
preferences, and decision making participation. VA utilization databases were used to assess
PSA testing rates two weeks and one year post target appointment. The Social Cognitive Theory
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was the conceptual model employed. Based on the results, pamphlet subjects were more likely
than controls to discuss screening with their provider but video subjects were not. Video and
pamphlet subjects were less likely to intend to have a PSA, relative to controls. PSA testing
rates did not differ significantly across groups at one year. Possible confounding variables
include PSA tests being drawn without patient knowledge, provider enthusiasm for screening,
and a wash between those that were affected by the education, resulting in decreased screening
for some and increased screening for others. Providers need to receive the intervention as well as
the patients in order for screening behaviors to change (Partin et al.).

Market/Risk Analysis

Project Strengths, Weaknesses, Opportunities, Threats
The timing is this Capstone Project’s strength because the latest studies and USPSTF
clinical practice guidelines are finally confirming and recommending what has been researched
and gently recommended for twenty years; namely, prostate cancer screening is not supported
by randomized clinical trials (Andriole et al., 2009; Djulbegovic et al., 2010; Ilic et al., 2010) and
“healthy men do not need prostate cancer screening with PSA because the test does not save
lives and often leads to unnecessary testing, interventions, and treatment” (Bankhead, 2011, para.
1). The prostate cancer screening educational pamphlet will arrive just in time to educate
providers, patients, and families about the confirmed futility of wide-spread prostate cancer
screening among asymptomatic men (Adami, 2010).

The Project’s weakness is the lack of enthusiasm among physician stakeholders. The
Assistant to the Chief of Staff delegated the Project to the Chief of Ambulatory Care, and both
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physicians warned not to proceed with the Project without their approval, including review by
Urology. Unfortunately, the Chief of Ambulatory Care backed out of the Project because he
believes in prostate cancer screening, and the Chief of Urology was indifferent. Curb-side
advice from two VAMC oncologists was that PSA screening saves lives (T. Braun & E. Pajon,
personal communication, July, 2011).
Driving /Restraining Forces

The driving force to the Project is the continuation of wide-spread PSA testing among
asymptomatic men despite limited evidence of benefit and overwhelming evidence of harm
(Adami, 2010). Providing information to patients about prostate cancer screening, when there is
no established evidence base, is problematic (Clements et al., 2007). Asking a patient to decide
if he wants PSA testing after the personal recommendation of a “highly qualified” television talk
show host is absurd when thousands of doctors cannot settle the dispute (Suss, 2008). The
restraining force to the Project is the flip side of the driving force, which is the United States
commitment to cancer screening (Schwartz et al., 2004). Even though PSA testing cannot
detect prostate cancer and, more importantly, it cannot distinguish between lethal and latent
cancers (Ablin, 2010), the organizational culture still fosters wide-spread testing for PSA among
asymptomatic men.
Zaccagnini and White state (2011), “As the lines between quality improvement activities
and research blur, the tendency for these projects to undergo review by IRBs is stronger than in
the past” (p. 456). The Capstone Project, a quality improvement initiative or small scale
intervention linked to the assessment of a prostate cancer screening educational pamphlet,
required approval by three institutions, including two internal review boards ; therefore,
restraining forces to the project included the time required to complete the Regis, VA, and

19

Colorado Multiple Institutional Review Board (COMIRB) training followed by Regis IRB, VA,
and COMIRB applications and approvals (see Appendices O,P,Q , R, and S). Training included
four Collaborative Institutional Training Initiatives (CITI) and VA privacy training (see
Appendices N and O). Finally, approval by the VA Research and Development (R & D)
Committee was required after IRB approval (see Appendix T).
Barriers to providers’ discussions of prostate cancer screening fell under the category of
patient, provider, or system. The barriers included health literacy, cognitive dysfunction, and
mental illness, forgetfulness or provider’s belief about screening, and lack of time, lack of
consensus within the medical profession, and fear of litigation (Guerra et al., 2007). Fear of
liability is a valid concern because the structure of the U.S. legal system supports local screening
practices and not ordering a PSA test can be considered a malpractice error of omission (Guerra
et al., 2007). For example, in July 2003, a Virginia jury found a family practice guilty of
malpractice when a patient decided against PSA screening, after informed decision making, and
subsequently was found to have a high PSA and terminal prostate cancer (Merenstein, 2004).
Need, Resources, and Sustainability

There is a need for prostate cancer screening informed decision making at the Denver
VAMC because random PSA blood tests are currently done without standard education on the
pros and cons of screening. According to the latest guidelines, patients should receive education
about the pros and cons of prostate screening before proceeding or not proceeding with testing
(Woolf & Krist, 2009).

In order for screening behaviors to change, providers need to learn

about the pros and cons of prostate cancer screening, including the recommendation for informed
decision making (Partin, M. et al., 2004). A detailed prostate cancer screening educational
pamphlet will help educate and guide providers.
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The Denver VAMC is part of the Eastern Colorado Health Care System (ECHCS), which
is part of the VA, the largest integrated health-care system in the country (DeYoe, 2011). There
are 319 providers in the ECHCS including physicians, dentists, nurse practitioners, and other
licensed independent practitioners. All enrolled veterans are eligible for preventative care
services, ambulatory diagnostic and treatment services, hospital inpatient diagnostic and
treatment services, and prescription drugs prescribed by a VA provider. Prevention includes
immunizations, physical examinations (including eye and hearing exams), health care
assessments, screening tests, and health education programs. Medical, surgical, mental health
and substance abuse are provided as outpatient and inpatient services (Hughes, 2011; U.S.
Department of VA, 2011). It is clear to see from the preceding description that the VA plays a
major role in prostate cancer screening.
The population that needs to be informed is Denver VAMC male patients starting at age
45 years old for high risk patients and 50 years old for all others. High risk patients are firstdegree family relatives with prostate cancer because heritable factors account for 42% of the risk
(Gordis, 2009, p. 279), and race because blacks have the highest risk (Perez-Stable, 2009,
Prostate Cancer section, para 2). The setting is Denver VAMC primary care, with overlap into
other clinics where prostate specific antigen (PSA) blood tests could potentially be ordered, such
as specialty clinics (Hughes, 2011).
The corporate workload database for the VA is located nationally in the Austin
Computerized Data Center. Statistics for the Denver VAMC are incorporated within the ECHCS.
There are 400,664 veterans in the ECHCS primary service area (DeYoe, 2011, p. 39); from
October 1, 2009 to September 30, 2010, a total of 67, 832 veterans were seen as outpatients
(eligibility categories help explain why less than one fifth of the veterans utilize the ECHCS).
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The number 67,832 reflects all patients, not all visits, since each patient may be seen multiple
times; the number includes 6,976 females, 60,854 males, and two unknowns. The Denver
VAMC cared for 57, 330 patients, including 51,250 males and 6,080 females. The average age
for all Denver VAMC patients is 58 years with following breakdown: age 24 or less, 873 ; age
25 to 34, 5,456 ; age 35 to 44, 5,335; age 45 to 54, 8,834 ; age 55 to 64, 17,942 ; age 65 to 74,
10,257 ; age 75 to 84, 6,038 ; age 85 to 94, 2,527 ; and, age 94+, 68 (A. Carver, personal
communication, March 30, 2011).
Most prostate cancers detected in the U.S. are asymptomatic, clinically localized, and
found on routine PSA testing (U.S. Department of Health & Human Services, 2008); this
correlates with the new cases of prostate cancer at the Denver VA. Prostate cancer data for 2008
to 2010 was obtained from the ECHCS Tumor Registry. There were 209 cases of prostate
cancer diagnosed since 2008 except for new patients arriving with the diagnosis. At least 75% of
the cases were clinically localized. The largest groups of men to receive the diagnosis (76%)
were in their fifties and sixties (N. Jones, personal communication, April, 20, 2011; Hughes,
2011).
The project is sustainable because the above population description illustrates the greatest
number of veterans falling within the group that providers need to educate, namely male veterans
from age 45 years and above. Providers undoubtedly will be bombarded with questions about
why PSA screening is no longer recommended in healthy men (Hallberg, 2011). The pamphlet
will provide providers with the tool to explain the reasons behind the latest recommendations.
The ultimate goal is to have the pamphlet distributed though-out the clinics with yearly updates.
Stakeholders and Project Team
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The group with an investment in the Project includes the patients, providers, and system.
The Project was initiated to protect patients against unnecessary invasive diagnostics and
treatments. Educating providers about the latest research and guidelines will ensure patient
protection through informed decision making. The system includes Project approval by the Regis
University, the Denver VAMC, and the University of Colorado Denver IRBs. Completion of
CITI courses in the Protection of Human Research Subjects and Health Insurance Portability and
Accountability Act (HIPPA) is required by the three institutions; the VAMC also requires
completion of a security course on the VA Talent Management System.
The project team includes eight Denver VAMC PCPs, including four providers in the
Saturday Intake Clinic and four providers in the Firm A Clinic. The ECHCS Medical Media
Program Manager is responsible for the pamphlet design and production. The author is involved
with distributing the pamphlets and informing the providers about the Project. The data
collection and interpretation is carried out by the author with oversight by a PhD-prepared RN
mentor.
Cost Benefit Analysis

The Food and Drug Administration approved the PSA test for prostate cancer screening
in 1994 (Albin, 2010). Each year approximately 30 million American men undergo PSA
screening with an annual bill of at least three billion dollars, much of it paid by Medicare and the
VA (Albin, 2010, para 1, 3). The cost of prostate cancer screening is overdiagnosis, or the
detection of disease through screening that would not otherwise have been detected within the
patient’s lifetime (Telesca et al., 2007). The USPSTF cites a false positive test rate of up to 80%
which can lead to unnecessary biopsies and therapies with possible adverse side effects of
incontinence and impotence (Schepman, 2011, para 4). The cost of making and distributing the
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educational pamphlet and asking selected PCPs about their opinion on guidance provided by the
pamphlet is miniscule; the benefit is less interest in prostate cancer with subsequent positive
health and financial outcomes.

Project Objectives

Mission/Vision/Goals
A population needs assessment revealed that there is a need for a change in screening
practices at the Denver VAMC (Jacobsen & O’Connor, 1999). In other words, the time has
come to close the gap between what is, and what should be, in performing, prostate cancer
screening at the Denver VAMC (Hughes, 2011). The preceding analysis identified Denver
VAMC’s current prostate cancer screening practices; the mission, vision and goals provide
directions to where the Denver VAMC should be regarding prostate cancer screening practices
(Kruschke & Stoeckel, 2011).
The mission statement asks what the Denver VA PCPS do, who they do it for, and why they
do it (Kruschke & Stoeckel, 2011). The mission of this project is to ensure that Denver VAMC
PCPs are fully aware of the latest research and guidelines regarding prostate cancer screening in
order to provide accurate information to male veterans starting at age 50 years, or 45 years for
high risk patients. The vision statement provides an inspirational image of the future (Kruschke
& Stoeckel). The vision of this Project is for PCPs to practice health care ethically by rejecting
unproven prostate screening behaviors in favor of scientific evidence. Denver VAMC PCPs must
meet the following goals in order for the mission and vision to occur:
•

To be knowledgeable about the latest prostate cancer screening research and guidelines.
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•

To explain the risk of prostate cancer to male veterans.

•

To explain PSA screening to male veterans, including the risks, benefit, alternatives, and
uncertainties.

•

To consider the male veteran’s values in deciding about PSA screening.

•

To engage the male veteran in decision making at the desired level (Krist et al., 2007).

The preceding goals are simply the steps of shared decision making recommended by the
USPSTF (Krist et al.)
Process/Outcomes Objectives
Objectives are the means by which goals are met; according to Kruschke & Stoeckel
(2011), they are “specific, measurable, achievable action items that are realistic and time-bound”
(p. 17). Outcome objectives state a specific time frame for achievement of the intended
outcome; whereas, process objectives clearly outline the steps needed to achieve the outcomes
objectives (Zaccagnini and White, 2011). The Project findings and results are organized by
objective; therefore, measurable objectives are needed to form data collection. The outcome
objectives for Provider Opinion about Guidance Provided by a Prostate Cancer Screening
Educational Pamphlet are the means by which Denver PCPs will use the steps of shared decision
making recommended by the USPSTF. The measurable Project objectives include:

1.

Design and print a prostate cancer screening educational pamphlet using data from a

systematic review of randomized controlled trials of prostate cancer screening efficacy. Include
the first quantitative estimates of the survival benefits due to early detection provided by the two
large ongoing randomized clinical trials of PSA testing, the ERSPC study and the prostate arm of
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the National Cancer Institute-sponsored PLCO Cancer Screening Trial (Andriole et al., 2009;
Schroeder, Hugosson, Roobol et al., 2009).
2.

Educate providers in Firm A Clinic and Saturday Intake Clinic about the prostate cancer

screening practice issue by sending weekly messages about the latest USPSTF guidelines, major
medical organization’s recommendations and attached relevant articles via Office Outlook.
3.

Measure participating PCPs perceptions of guidance provided by the detailed prostate

cancer screening pamphlet using the eight question survey.

The Time Table of Accomplishments (see Appendix L) clearly outlines the process by
which the outcome objectives were achieved. It is clear to see from the list of accomplishments
that the process needed to achieve the Capstone Project outcomes objectives entails one step
forward, and two steps back, but constant movement toward meeting the mission of ensuring that
Denver VAMC PCPs are fully aware of the latest research and guidelines regarding prostate
cancer screening in order to provide accurate information to male veterans.

Evaluation Plan

A logic model illustrates how and why a project will work (Kellogg, 2004). The initial
Prostate Cancer Screening Informed Decision Making Logic Model (see Appendix G) was
simplified after VA IRB pre-review on September 14, 2011 and simplified again after the oral
presentation in the DNP Capstone Project class NR 706B. The Logic Models (see Appendix H
and I) provide clarity and focus on specifics. “If…then…” statements connect the program’s
parts depicted in rows under the columns of Resources/Inputs, Activities, Outputs, Outcomes,
and Impacts (Kellogg). Reading the Model from left to right starts with the first two columns,
the planned work, and ends with the intended results, the last three columns (Kellogg).
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The outputs, outcomes, and impacts of PCPs in two VA clinics utilizing the prostate
cancer screening educational brochure to help guide prostate cancer screening informed decision
making, followed by all Denver VAMC PCPs using the brochure, are the most important
components to monitor because they gauge the success of the Project. The ultimate success of
this Project will be when the vision for PCPs to practice health care ethically, by rejecting
unproven prostate screening behaviors in favor of scientific evidence, is realized. In reality,
proving that the proposed change took place is easier said than done because life is complicated
with influences and forces beyond one’s control. Therefore, demonstrating progress toward the
ultimate impact of less interest in PSA screening, leading to less incidence of prostate cancer,
and leading to improved quality of life is more about documenting this Project’s contribution,
rather than documenting that the change actually occurred in a given time period (Kellogg,
2004).
Population/Sampling Parameters/Setting
A convenience sample of VAMC PCPs in the Saturday Intake Clinic and PCPs in Firm A
Clinic comprise the study group. The comparison data is the incidence of prostate cancer
screening informed decision making with PCPs in Firm B Clinic, the comparison group, without
the guide of the pamphlet. The outcome of interest to be quantified are the providers’ opinions
measured on an interval scale of yes, somewhat or maybe, or no about whether the detailed
prostate cancer screening educational pamphlet offered guidance for informed decision making.
The outcomes of interest to be qualified are PCPs’ discussions about their current prostate cancer
screening practices as well as the responses from PCPs in the comparison group. There will be
no inclusion or exclusion criteria to control for the extraneous variable of the providers’ initial
belief prior to the intervention. The PCPs will be fully informed of the project via Microsoft
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Office Outlook e-mail and will receive the detailed prostate cancer screening education
pamphlets to review before their primary care clinics (see Appendix C).
Evidence-Based Practice Methodology and Measurement

A quantitative pilot study design will be used to answer the PICO question. The
variables, reiterated in statistical terms, include the dependent variable of provider opinion on
whether the pamphlets offered guidance regarding prostate cancer informed decision making.
The independent variable is the prostate cancer screening educational pamphlets and
corresponding discussions. The extraneous variable is provider health belief. The survey (see
Appendix J) used to measure provider opinion about guidance provided by the pamphlet is
discussed in pages 31 to 33.
The Capstone Project is a quality improvement initiative with no defined research
question; it is a small-scale intervention linked to assessment of a prostate cancer screening
pamphlet. The quantitative data collected measures provider opinion about guidance provided
by the pamphlet. Anecdotal information received from provider e-mails describes Firm B PCPs’
screening practices without the pamphlet, the comparison data. The statistical method for
evaluation of the quantitative data collected in the survey is limited to frequencies. This analytic
option is appropriate because the purpose of data collection for this process improvement Project
is to implement evidence-based practice into primary care rather than to evaluate a research
project. In other words, the collected data and Project findings are used to measure a change in
practice rather than collecting data to make the project reproducible (Zaccagnini & White, 2011).
The Project’s ultimate goal is prostate cancer screening informed decision making resulting in
improved health outcomes for Denver VAMC male patients (Cassarett, Karlawish, & Sugarman,
2000).
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Protection of Human Rights Procedure Complete

The Belmont Report: Ethical Principles and Guidelines for the Protection of Human
Subjects of Research was developed in 1976 after four days of intensive discussions between
members of the National Commission for the Protection of Human Subjects of Biomedical and
Behavioral Research. The statement includes a distinction between research and practice; a
discussion of the three basic ethical principles of respect for persons, beneficence , and justice;
and remarks about applications of these principles through informed consent, assessment of
risks and benefits , and selection of subjects (Ryan et al., 1976). Some of these principles can be
applied to the dilemma of uninformed prostate cancer screening and the subsequent outcome of
using the detailed prostate cancer educational pamphlet. The ultimate impact is to stop the
intrusion into asymptomatic unsuspecting men’s lives with a harmful screening practice
disguised as preventative care.
Mass population PSA testing was initiated in the late 1980s without a persuasive
randomized trial or other compelling scientific evidence (Adami, Baron, & Rothman, 1994).
The novel screening practice resulted in an unprecedented cancer incidence increase from 1988
to 1992 followed by a steep and then modest decline (Adami, 2010). Because of cultural cancer
screening enthusiasm, the practice of prostate cancer screening preceded research. In October,
2011, the USPSTF upgraded their recommendation not to screen healthy men with a PSA blood
test because the test does not save lives and often leads to unnecessary testing, interventions, and
treatment (Bankhead, 2011).
Research and practice often occur together and according to the Belmont Report (Ryan et
al., 1976), “This need not cause any confusion regarding whether or not the activity requires
review; the general rule is that if there is any element of research in an activity, that activity
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shoulder undergo review for the protection of human rights” (p.3). The blurred distinction
between research and practice has resulted in a trial of prostate cancer screening in the western
world since 1988 without review for the protection of human rights (Adami et al., 1994).
The Capstone Project is about doing what is “Right” and “Proper” and about what the
evidence-based practice recommends. The moral and ethical principle of respect for persons
includes autonomy, or one’s right to choose, and protection for those with diminished autonomy
(Ryan, et el, 1976). Providing PCPs with a prostate cancer screening educational pamphlet will
result in patient informed decision making, a prerequisite for autonomy. Patient preference, or
autonomy, is the guiding principle here, and if a man wants to be screened, knowing the negative
consequences, that is his prerogative. On the other hand, health illiteracy and cognitive
impairment precludes autonomy, making the patient vulnerable. The truth of the matter is almost
all patients are vulnerable because, according to Suss (2008), “If thousands of doctors can’t
agree on whether PSA screening results in any benefit, then it makes no sense to ask the patient
to settle the dispute” (p. 1288). In other words, many patients may make foresighted decisions
not understanding that the ability to detect a disease by screening does not always equate to a
benefit to those screened (Gordis, 2009).
The principle of beneficence is about the balance of good versus harm. Offering
asymptomatic men a diagnostic intervention associated with increased cancer diagnosis, modest
mortality reduction, and substantial morbidity constitutes harm (Adami, 2010). The modest
absolute reduction in prostate cancer over time comes at the cost of diagnosing and treating
clinically irrelevant cancers (Pignone, 2009). Additionally, the harms of screening start
immediately; whereas, the potential benefits are not realized for years to come (Pignone, 2009).
The harms of treatment may include erectile dysfunction and urinary incontinence after radical
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prostatectomy, defecation problems following radiation therapy, and hot flashes/feminization
with hormone therapy (Hoffman, Fletcher, & Rind, 2010). Informed decision making is no
license to subject patients to harmful interventions (Adami et al., 1994); thus, prostate cancer
screening is not beneficent.
Justice is fair and moral treatment of people includes not basing treatment decisions on
demographics. Unfortunately, prostate cancer is not an equal opportunity disease, with older age,
race (black), and family history the only well-established risk factors (Jemal et al., 2011). The
introduction of the PSA test has led to a large percentage of African American males undergoing
aggressive treatments for cancers that may well be indolent. For example, increased screening in
active-duty air force personnel between 2005 and 2008 resulted in a three times higher rate of
prostate cancer among white servicemen, and eleven times higher rate for black servicemen,
compared to rates between 1991-1994 (Goldhagen, 2011,para 4 ). Of those with low risk
disease, significantly more active duty servicemen elected curative surgery than retirees (93% vs.
53%) (Goldhagen, para 6).
Telesca et al. (2007) estimated lead time and overdiagnosis associated with PSA
screening from prostate cancer incidence trends with lead times of 4.50 years for whites and 6.43
years for blacks (p.15). The finding of a longer lead time among blacks is surprising because of
the known higher incidence and poorer survival in blacks. The authors conclude that, in addition
to black men’s aggressive clinically detected cancers, they also may be subject to higher
frequency of latent disease because the higher incidence of aggressive prostate cancer in blacks
was based on data from symptomatic disease cases prior to the PSA era (Telesca et al.).
Information, comprehension, and voluntariness are part of the informed consent process.
The detailed prostate cancer screening educational pamphlet will satisfy the three elements of
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informed consent. The often perfunctory shared decision making will become more detailed
with the risks and benefits of prostate cancer screening clearly spelled out in the pamphlet.
Hopefully, vulnerable male veterans will be better equipped to make a systematic assessment of
the risks and benefits of screening.
Instrumentation Reliability/Validity and Intended Stats

Choosing the appropriate statistical test is necessary to answer the Project’s questions
about provider opinion about guidance offered. Surveying the providers will be the method of
data collection. The data gathered from each of the eight providers in the sample will describe
the guidance provided by the pamphlet, thus descriptive rather than inferential statistics is
appropriate. Providers’ opinions on guidance offered by the pamphlet are ordinal level
measurements of outcome data that can be ranked. The responses to the survey questions will
have verbal labels of yes, somewhat or maybe, and no with corresponding codes of 1, 2, and
3(see Appendix J). The numerical codes cannot be rearranged; therefore, the numbers are not
arbitrary. Since it is not meaningful to measure averages with variables measured on nominal
and ordinal scales, the analytic option for this Project is limited to frequencies (Polit, 2010).
Finally, generalizability of the outcomes will be limited, and clear conclusions about cause and
effect will not be possible because there is no randomization and no control group.
The survey (see Appendix J) was easily developed because the questions are intuitive. An
eighth question was added to assess the format of the pamphlet after Project implementation.
The eight survey questions are simple, direct, short, concrete, and single concept questions. The
survey is valid because it actually measured what was intended to be measured; provider opinion
on guidance offered by the pamphlet including format.

Finally, completion of the survey by the

eight Project participants will avoid nonresponce bias (Zatz, 2011).
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A frequency distribution will be constructed from the ordinal data measuring provider
opinion about guidance offered by the pamphlets. The data will be reported as percentages. A
bar graph will be constructed to display frequency information with the categories listed on the
horizontal axis and the frequencies or percentages on the vertical axis (Polit, 2010).
Comparison of the PCPs’ screening practices without the pamphlet and other
observations made during project implementation and application will be used to change
prostate cancer screening practices at the Denver VAMC including the Eastern Colorado
CBOCs. The treatment that will be done with the data collected includes continued
reinforcement about the requirement for informed prostate cancer screening, continued
education about the USPSTF recommendations not to screen healthy men with a PSA blood
test, and continued pamphlet production and distribution. In other words, completion of the
Capstone Project will be the beginning of prostate cancer screening evidence-based practice
within the ECHCS.
Timeframe, Budget, and Resources
The goal of assessing informed decision making with the guidance of a prostate cancer
screening educational pamphlet is to improve the process, outcomes, and efficiency of prostate
cancer screening practices at the Denver VA (Cassarett, et al., 2000).

The timeframe for this

Project is outlined in Appendix K followed by a chronological list of accomplishments in
Appendix L. There needs to be ten minutes of PCPs time to inform patients about the pros and
cons of screening using the detailed prostate cancer educational pamphlet; the design and
pamphlet production will be done by the ECHCS Medical Media Program Manager; and weekly
Microsoft Office e-mail messages/discussions will be sent to educate providers. These are the
three main resources needed for implementation and application of the evidence-based practice

33

Project. The budget is the hypothetical amount of money needed for the Project including
pamphlet production (see Appendix M).

Project Findings and Results

The first objective, to design and print a prostate cancer screening educational pamphlet
using the latest evidence-based practice began with the writing of the detailed pamphlet. The
mentor thought the detailed pamphlet was too long; therefore, the basic pamphlet was created for
patients, with four pre and post questions. The ECHCS Medical Media Program Manager
discussed the design and production of the prostate cancer screening educational pamphlets with
the author. The UpToDate Journal and Right’s manager was contacted for approval to use their
graphics, which he subsequently edited and approved. A fifth question was added to the basic
pamphlet to avoid bias because the Project mentor thought the pamphlet was slanted against
prostate cancer screening. Finally, the written portion of the pamphlets was complete, use of
UpToDate graphics was approved, and a picture of a can of worms representing the dilemma
caused by screening was added. The ECHCS Medical Media Program Manager created the
detailed pamphlet for COMIRB review using the can of worms picture for the cover and the
UpToDate graphics inside the folded pamphlet.
Two hundred detailed pamphlets were printed for the Project implementation. The
pamphlets went fast the first week because PCPs were sending patients home with them. On
January 7, 2012 a request was made for 500 to 1000 more pamphlets, but the request was put on
hold by the Project’s new mentor, a PhD-prepared RN, the Denver VAMC Patient Safety
Specialist. The mentor advised against distributing the pamphlets to the patients because the
purpose of the Project is to assess the pamphlet. The question, “Is the format of the pamphlet user
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friendly” was added to the survey (see Appendix J) to address the issue of pamphlet font and
format per the Project mentor’s advice. The survey now included assessment of the brochure
format in addition to measuring provider’s opinions about guidance provided by the detailed
pamphlet.
Sending a patient home with the detailed pamphlet is an ideal method to inform the
patient and his family about the often indolent natural history of prostate cancer, the limitations
of PSA testing, and the inconsistent evidence thus far from major prostate cancer screening trials
(Hoffman, 2011). According to Hoffman, “Decisions about prostate-cancer screening should be
based on the preferences of an informed patient” (p. 2017); therefore, public approval and
distribution of the pamphlet is imperative to ensure that evidence-based practice is the basis of
clinical care at the Denver VA.
The second outcome objective, to educate providers in Firm A Clinic and Saturday Intake
Clinic about the practice issue, began by sending the following Office Outlook e-mail message to
Denver VA PCPs:
Subject: Quality Improvement Project
In October, 2011 the United States Preventative Service Task Force recommended
against screening health men with a prostate specific antigen (PSA) blood test. Other
major medical organizations recommend informed or shared decision making prior to
offering PSA testing. A quality improvement initiative project will be done to assess
prostate cancer screening guidance provided by an educational pamphlet (see
attachment). Four volunteer primary care providers (PCPS) from Firm A, and four
volunteer PCPs from the Saturday Intake Clinic, are needed to assess the pamphlet. The
comparison group will be an assessment of the guidance provided from four volunteer
PCPs in Firm B without the uses of the educational pamphlet. Thank-you for your help in
implementing this evidenced based practice at the Denver VAMC (P. Hughes, personal
communication, December 22, 2011).
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Replies to the above message started the following day including one physician and four nurse
practitioners (NP)volunteering to test the pamphlet with age appropriate men during primary care
clinic visits.
The design of the Project was to have four PCPs in Firm A Clinic and four PCPs in the
Saturday Intake Clinic test the detailed prostate cancer screening educational pamphlet followed
by completing the eight question survey. Instead, only three PCPs in Firm A Clinic and five
PCPs in Saturday Clinic tested the pamphlet. The three study PCPs in Firm A included one
physician and NPs. The one participating Firm A physician personally responded to the email
request and the two participating Firm A NPs were personally recruited. The five study PCPs in
the Saturday Intake Clinic are NPS.
The Evidenced-Based Clinical Practice Guidelines/Clinical Quality Program Specialist
NP working for the VA Office of Quality & Safety participated in the email discussions. He was
the only provider to respond to the request for suggestions on the detailed pamphlet before it was
sent to public affairs for approval to distribute to patients and families. After the suggested
grammatical errors were corrected the pamphlet was sent to public affairs and was subsequently
approved for public use.
Each participating provider received copies of the detailed pamphlet, the latest NEJM
article on screening for prostate cancer ( Hoffman, 2011), the VA R&D Approval Letter, and
weekly Office Outlook email messages about the Project including prostate cancer screening
guidelines, dilemmas, and discussions. The messages and informative articles were also sent to
all Denver VAMC PCPs, the Chief of Ambulatory Care, the Chief of Urology, and the Nurse
Practitioner Supervisor. Unbeknownst to the author, providers in the ECHCS CBOCs received
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many of the email messages, leading to requests for posters and pamphlets from PCPs in
Colorado Springs and Pueblo.
Coincidently, the Deputy Chief of Staff’s poster on the Principles of Shared Decision
Making was displayed at the Denver VAMC in early February, just a few weeks after the Project
started. The Deputy Chief of Staff was familiar with the Project because of a former meeting in
April, 2011 when a return visit for informed consent prior to PSA screening was vetoed and the
Chief of Ambulatory Care was assigned as the initial Project mentor. It was timely and
advantageous that the poster was displayed at the same time as the Project; therefore, the
following message was sent to providers:
Dr. Lithium Lin’s poster on the Principles of Shared Decision Making is displayed in the
prosthetic hallway. Plan of care, participation, perception, pros & cons, and preferences
surround patient centered shared decision making. The 6 P’s (principles) of shared
decision making can be used for patients that request prostate cancer screening.
The American Urologic Association, American Cancer Society, U.S. Preventative
Services Task Force, and other major medical organizations recommend that providers
discuss the risks and benefits of prostate cancer screening before PSA testing is
performed by way of shared or informed decision making (Woolf & Krist, 2009).
According to Krist et al. (2007), per the US Preventative Services Task Force
(USPSTF), “A decision is shared when the patient (1) understands the risk of the disease
to be prevented; (2) understands the preventive service, including risk, benefit,
alternatives, and uncertainties; (3) weighs his values regarding the decision; and (4) is
engaged in the decision at the desired level” (p. 112-113).
References:
Krist, A., Woolf, S., Johnson, R., and Kerns, W. (2007). Patient education on prostate
cancer screening and involvement in decision making. Annals of Family Medicine.
5:112-119 (P. Hughes, personal communication, February 16, 2012).
Having the Deputy Chief of Staff on board is critical to the implementation of the evidencebased practice of informed prostate cancer screening because he is responsible for
communications with ECHCS medical staff and assisting with changes in medical practice
(Houser & Oman, 2011).
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Statistical Data

The third outcome objective, to measure participating PCP’s perception of guidance
provided by use of the detailed prostate cancer screening pamphlet with male veterans aged 5075 , was accomplished using an eight question survey (quantitative data) (see Appendix J). The
eight completed surveys indicated that the pamphlet did offer Denver PCPs guidance in
informing patients about prostate cancer screening. The survey also specified that the detailed
pamphlet format is appropriate (Figure 1). Eight (100 percent) PCPs found the detailed prostate
cancer screening pamphlet informative, with appropriate graphics and a user friendly format.
Seven (87.5%) PCPs found the pamphlet useful for family members; whereas, one (12.5%)
provider found the pamphlet somewhat, or maybe, useful for family members. Seven (87.5
percent) PCPs said the pamphlet was easy to read; whereas, one (12.5%) provider said the
pamphlet was somewhat, or maybe, easy to read. Seven (87.5 percent) PCPs found the pamphlet
to be unbiased; whereas, one (12.5%) provider found it biased. Half of the PCPs (n=4) thought
the brochure would change decisions of vets to get a PSA; whereas, three (37.5 percent) PCPs
though the brochure would somewhat, or maybe, change decisions of vets, and one PCP (12.5
percent) though the brochure would not change the decision of vets to get a PSA.
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Figure 1: Survey Results
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Reliability of Findings
Reliability refers to how consistently an instrument measures the attribute it is designed to
measure (Polit, 2010). The eight question survey (see Appendix J) is the instrument designed to
measure the attribute of guidance provided to PCPs by the pamphlet. Since the survey was filled
out by PCPs in close proximity to the time they used the pamphlet there was absolutely no recall
bias. Since the positive answer to question four is “no” the error of measurement which occurs
when a survey is filled out haphazardly did not occur (Polit, 2010). In other words, the seven
PCPs that found the pamphlet helpful answered “no” appropriately when asked if the pamphlet is
biased instead of haphazardly answering “yes”. Likewise, the one provider that holds a strong
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belief in the benefits of prostate cancer screening answered “yes”, the pamphlet is biased, instead
of haphazardly answering “no”. A provider’s health belief is a subjective bias which decreases
the reliability of prostate cancer screening brochure survey; for example, the provider that though
the pamphlet is biased also answered “no” the pamphlet would not change decisions of vets to get
a PSA.

The comparison data was received serendipitously when an e-mail message was sent,
asking for four volunteer PCPs in Firm B to discuss their prostate cancer screening practices
without the guidance of the attached pamphlet. The request was preceded by a detailed paragraph
describing the current prostate cancer screening dilemma and ended with an inaccurate statement,
“For example, today a PCP in Firm C told me that PSAs are routinely ordered on all male patients
over 50” (P. Hughes, personal communication, February 6, 2012). The incorrect statement
resulted in email rebuttals by two physicians followed by a discussion about the Project at the
physicians monthly Journal Club. Apparently none of the physicians routinely order PSAs
because it no longer is a clinical reminder. Some physicians are concerned about the potential
legal implications of not even talking about PSA screening and having the patient getting it done
somewhere else and being diagnosed with prostate cancer (and bringing a lawsuit against the VA
for not diagnosing it); therefore, some physicians will routinely have the discussion. A highly
respected physician recommends doing the right thing by following the USPSTF recommendation
not to screen healthy men. The ten Journal Club physicians are aware of the latest USPSTF
guidelines.
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In retrospect, the incorrect statement was a godsend because it caused indifferent
physicians to respond defensively. In fact, the above two physician responses were the only
responses received from the multiple providers on Firm B. Despite the response from only two
providers, instead of the requested four, the Capstone Project was unexpectedly the topic of
discussion at the physicians’ Journal Club on February 7, 2012. Since there were ten physicians
at the monthly Journal Club, and one physician stated that “None of the physicians routinely
order PSAs”; it is safe to assume that at least four Firm B Clinic physician providers do not
routinely order PSA tests on healthy veterans.
The potential legal implication of not discussing prostate cancer screening with patients is
a valid concern, resulting in some providers routinely ordering PSAs. For instance, in a study
aimed at identifying factors that facilitate or prevent prostate cancer screening discussions, three
physicians stated they will default to ordering a PSA due to medical-legal concerns if they are
unable to have a discussion with the patient (Guerra et al., 2007). Patient barriers that prevent
physicians from discussing prostate cancer screening include comorbidities, limited
education/health literacy, competing preventative health discussions, mental illness, and the
patients already deciding they want PSA screening (Guerra et al). Interestingly, being well
educated does not preclude problems with health literacy (Hoffman, 2009). The preceding
findings correlate with Denver VAMC providers’ reasons for ordering PSA tests without a
patient discussion.
The Chief of Ambulatory Care informed the Health Promotion Disease Prevention
(HPDP) Program Manager about the Project because the HPDP’s project was concurrently
taking place to reduce PSA screenings in men over 75 years. The first short meeting took place
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on February 28, 2012, followed by emails and phone communication. The HPDP Program
Manager was included in email messages about the Capstone project from then on.
In 2012, The HPDP Program Committee chose to address the potential over utilization
of PSA screening within the ECHCS because there was speculation that PSAs were routinely
being ordered in men over 75 years despite the VHA Clinical Recommendations against
screening for this population. Two physicians, a urologist, and a PCP worked with the HPDP
Program Manger to study the issue and develop interventions, if necessary. Data from the
Veterans Integrated Service Network (VISN) 19 Data Warehouse included ECHCS VA patients
≥ 75 years who had a PSA drawn November, 2010 to November, 2011. One thousand seven
hundred sixty nine patients ≥ 75 years had a PSA done within the 12 month time frame. Five
hundred and three patients with a history of prostate cancer were eliminated from the
denominator, assuming the PSA was used for monitoring not screening, leaving 1266 patients
having a PSA drawn for unknown reasons. A random sample of 50 patients from the 1266 was
indentified for chart review to look for reasons for PSAs being ordered; three were eliminated
because they were found to have prostate cancer. Eighty-seven percent (n=41) of PSAs done in
men ≥ 75 was for routine screening which is not in line with the VHA and USPSTF guidelines.
The planned interventions are to send out a MEMO to ECHCS providers about the
recommendations not to routinely screen men ≥ 75 years and to create a flag in the CPRS lab
package that would appear when a PSA is ordered for men ≥ 75 years without a diagnosis of
prostate cancer (L.Shainline, personal communication, March 6, 2012).
Results Discussed According to Evidence-Based Practice

The results of the preceding QI project correlate with clinical observations made over the
past 15 years. In other words, the vast majority of PSAs done at the VA ECHCS are randomly
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drawn, including being ordered on men too old to ever benefit from screening. The USPSTF has
recommended against screening men age 75 years or older for years (Lin et al., 2008), yet the
preceding project shows that screening in this group is quite routine. Despite the response from
the Journal Club physicians that PSAs are not routinely ordered, the evidence reveals quite the
opposite. Therefore, the Capstone QI Project is here just in time to educate providers about the
recommendations for prostate cancer screening informed decision making for men≤ 75 who
request to be screened. The Project will facilitate evidence -based practice by providing a
detailed pamphlet to guide providers and educate patients. The HPDP Program QI Project is here
just in time to ensure evidence -based practice at the ECHCS by educating providers not to order
PSAs on veterans ≥ 75 years, including flagging PSA orders placed for male veterans ≥ 75 years.
The Capstone Project helped improve the process of prostate cancer screening at the
Denver VAMC. The pamphlet, and corresponding discussions, educated providers about the
USPSTF recommendations not to screen healthy men, and provided a guide for providers to
inform patients who request to be screened (Bankhead, 2011; Lin et al., 2008). Public approval
of the pamphlet, followed by mass production and distribution in the ECHCS primary care
clinics, will ensure that the standard of care for prostate cancer screening is based on scientific
evidence. In other words, by using data from the two large ongoing randomized clinical trials of
PSA screening, the pamphlet will help bridge the gap between evidence and practice.
Additionally, public approval of the pamphlet will help ensure that male veteran patients do not
undergo PSA testing without the type of shared decision making that practice guidelines
recommend (Woolf & Krist, 2009).

43

Limitations, Recommendations, Implications for Change

Limitations
The limitations to the project are the small number of participants, particularly physician
participants. Recruiting Firm A Clinic physician volunteers to test the pamphlet and engaging
Firm B Clinic physicians in discussions about their prostate screening practices without the
pamphlet was difficult. The small number of PCPs and patient encounters may have prevented
new themes from emerging from the data (Guerra et al., 2007). In other words, since there were
only eight participants, there may be a wide range of experiences not captured (Clements et al
2007). Furthermore, VA providers care for patients who are mostly low income and/or service
connected; therefore, the findings are less generalizable to providers who care for a more affluent
and/or heterogeneous population.
The value of the qualitative findings obtained from providers’ discussions, and lack
thereof, increased the depth of understanding about prostate cancer screening practices at the
Denver VAMC. A common theme from PCP’s direct and indirect discussions is that routine
PSAs are not done at the Denver VA, although clinical experience and the VA HPDP Program
QI project reveal quite the opposite. Additionally, Denver VA medical specialist’s opinions
about PSA screening are far more optimistic than some of their PCP cohorts. For example, two
VA oncologists stated that PSA screening saves lives (T. Braun & E. Pajon, personal
communication, July, 2011), and the Chief of Urology agrees that PSAs should not be done on
men ≥ 75 years (E. Park, personal communication, August, 2011). The Chief of Urology’s
recommendation, through the HPDP Program QI Project, to stop PSA screening in men ≥ 75
years seems to be too little, too late. In other words, the USPSTF has recommended against
screening men ≥ 75 years for years (Lin et al., 2008) and now recommends ag ainst prostate
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cancer screening with a PSA test, regardless of age, race, or family history (Hoffman et al.,
2011).
Recommendations and Implications for Change

Improved healthcare outcomes depend on inter-professional collaboration in developing
uniform standards of care (Regis University Loretto Heights School of Nursing, 2010). The lack
of consensus about the utility of PSA screening among medical specialties leads to inconsistent
practice guidelines with the recommendation for shared decision making between patient and
clinician as the only standard of care (Hoffman et al., 2011). For example, the AUA
recommends offering PSA screening at age 40; the ACS recommends offering PSA screening
at age 50; and the USPSTF recommends not screening healthy men with a PSA because the test
does not save lives and often leads to downstream consequences of PSA testing (Hoffman, 2011;
Bankhead, 2011) . Major medical organizations need to come up with one standard prostate
cancer screening guideline instead of asking the patients to decide if they want to undergo PSA
testing. As Suss (2008) stated, “I don’t think it is a good idea for experts to ask their clients or
patients to make choices about means. If thousands of doctors can’t agree on whether PSA
screening results in any benefit, then it makes no sense to ask the patient to settle the dispute”
(p.1288); therefore, shared decision making is somewhat of a misnomer.
The USPSTF recommends against PSA testing in healthy men (Bankhead, 2011;
Hoffman, 2011). The AUA and the ACS recommend shared decision making about PSA
screening starting at age 40 and 50 respectively (Hoffman, 2011) . Medical specialists who
perform prostate surgeries and treat cancer are less skeptical about PSA testing than the
USPSTF, an independent committee of experts, supported by the U.S. Government. The
independent committee of experts undergoes a rigorous process to ensure that evidence is used
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for developing clinical practice guidelines for prevention and screening. The Task Force grades
its recommendations based on the strength of evidence from randomized clinical trials and the
magnitude of net benefit (benefits minus harms). Members include experts in primary care,
prevention, evidenced-based medicine, research methods, public health, and health policy
(Gordis, 2009). Therefore, it makes good sense to use the USPSTF recommendations as the gold
standard of care, rather than recommendations from medical organizations that stand to profit
from PSA screening.
Prostate cancer screening efficacy and safety involves both clinical and epidemiological
research. Distinguishing causation from association, establishing validity of outcome measures,
estimating lead time, and studying the natural history of prostate cancer are epidemiological
studies which can be used to critically appraise current practice, develop practice guidelines, and
drive organizational change in order to improve healthcare outcomes ( Regis University Loretta
Heights School of Nursing, 2010). Based on cancer epidemiology data (Etzioni et al., 1998;
Telesca et al), prostate cancer screening with a PSA should be abandoned because as Gordis
(2009) puts it, “Even the best of intentions and passionate evangelism cannot substitute for
rigorous evidence that supports or does not support the benefit of screening” (p.331). As of
October 2011, the rigorous evidence does not support the benefit of screening for prostate cancer
with a PSA blood test (Bankhead, 2011).
Evidence-based practice is based on clinical expertise, patient choice, and valid research
evidence (Tymkow, 2011). Cancer screening enthusiasm often leads to patient choice
conflicting with scientific evidence; such is the case for people committed to cancer screening
regardless of its implications. Addressing the social problem of cancer screening enthusiasm
requires assuming a leadership role to ensure accountability for quality, safe, evidenced based
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patient care (Regis University Loretta Heights School of Nursing, 2010). Health care marketing
must stop portraying screening as an obligation in order to reduce the public risk of over testing
and over treating (Schwartz et al., 2004). In other words, according to Woolf & Krist (2009),
“What is ultimately required is a deeper change in culture among providers and consumers of
health care to delay dissemination, resist the assumption that newer is better, wait for evidence,
tolerate observation over intervention, and accept uncertainty” (p. 1559).
Finally, changing health care policy will help reverse one of the major reasons behind
PSA screening, fear of liability. The change will result in cultural and organizational changes
which decrease or eliminate legal consequences for failing to diagnose cancer through screening.
The VAMC has already has made the change by excluding PSA screening from their
computerized view alerts. In other words, in order to encourage patients to participate in
screening decision making, the VAMC’s electronic medical record has built in physician
reminders and checklists related to preventative care and counseling. Since PSA screening is no
longer a clinical reminder, not ordering a PSA test should not be considered a malpractice error
of omission. Unfortunately, the community standard of care may not coincide with the VAMC’s
national standard of care.
The legal standard of health care is not defined uniformly through-out the United States
because state statutes define it. For states with no relevant statute, case law governs the standard
of care for providers in the state. Twenty-nine states and Washington D.C. use a national
standard of care and twenty-one states or jurisdictions use some version of the locality rule
(Lewis, Gohagan, & Merenstein, 2007). The 1880 locality rule protected rural physician based
on the premise that they did not have the same opportunities as their colleagues in the big cities;
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therefore, they were no held to the same standard of care. Even though many states abandoned
the locality rule by the 1970s, the rule is still invoked in medical malpractice case (Lewis, et al.).
The persistence of the locality rule has serious implications for providers and may serve
to promote the practice of substandard health care (Lewis, Gohagan, & Merenstein, 2007). The
“community standard” or “locality rule” has traditionally been a problem between plaintiffs and
defendants in medical malpractice cases leading to dozens of reported decisions from the
appellate courts (Ford, 2011). In a medical malpractice lawsuit, it is necessary for the plaintiff to
prove that the physician did not follow the necessary standard of care; however, the standard of
care can be different depending on where the provider works (Truglio et al., 2011). The courts
have never applied a consistent set of standards for the locality rule; in fact, a military lawyer
assigned to defend the veterans’ administration against malpractice claims, arising under state
law, gave up trying to decipher the inconsistent cases on the locality rule (Ford). Depending on
the jurisdiction, expert witnesses (health care providers) base their support or criticism of the
case on either the national or community standard. Since the author practices in Colorado and
Colorado still adheres to some form of the locality rule, it is necessary to be knowledgeable
about Colorado’s applicable standard of care.
According to Longest (2010), “Public policies do not exist in isolation” (p. 204);
therefore, analysis of the public policy environment is part of the larger external environment
which health care organizations need to evaluate to determine the externally imposed threats and
opportunities to their performance (Longest). Health care providers’ performance of the national
evidenced- based practice standard of prostate cancer screening informed decision is threatened
by the antiquated locality rule. Colorado’s version of the locality rule holds general practitioners
to a community standard; whereas, specialists are held to a national standard (Lewis, et al.,
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2007). Colorado’s locality rule and other states that adhere to some form of the locality rule
must be amended to national standards of care for all providers which will result in uniformity
and state wide evidence-based practice.
Prostate cancer screening is not evidence-based practice but customary care. Current
guidelines recommend against prostate cancer screening in healthy men (USPSTF, 2011) or
informed/shared decision making for those who want to be screened (Woolf & Krist, 2009).
Fear of litigation is one of the reasons providers continue with uninformed prostate cancer
screening. Fear of litigation is a valid concern because the structure of the United States legal
system supports local screening practices, and not ordering a PSA test can be considered a
malpractice error of omission (Guerra et al., 2007).

According to Keene (as cited in Sorrel,

2010), “medical standards should drive legal standards, not the other way around” (para, last).
Therefore, since it is the state’s responsibility to act as guardians of the public’s health and
regulators of the healthcare system and pursuit of health (Longest, 2010), it is time for the
Colorado Assembly to modify the locality rule to national standards.

Conclusion

In 2009, the first quantitative estimates of the survival benefit due to early detection of
prostate cancer have not been shown to have a significant impact on mortality (Adami, 2010).
Existing evidence from randomized controlled trials reveals that early detection of prostate
cancer through PSA screening comes at the price of additional testing, unnecessary invasive
treatments, and impaired quality of life yet to be quantified (Djulbegovic et al., 2010). However,
since the triad of evidence-based practice includes best scientific evidence, clinical experience,
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and patient preferences (Houser & Oman,2011) individual patients’ values are key factors in
deciding whether to offer screening( Djulbegovic et al.).
The success of evidence based practice depends on paying close attention to the synergy
of time and circumstance, critically analyzing results of studies which could improve patient
care, and then acting at the right time to change the organizational culture which supports
antiquated practices. Current guidelines recommend that PCPs discuss the advantages and
disadvantages of prostate cancer screening prior to testing, but this is not routine. Time, effort,
resources, fear of litigation, and cultural enthusiasm for cancer screening are some of the reasons
informed decision making is often not done (Woolf & Krist, 2009). The challenges in
implementing the required practice change of informed prostate cancer screening with the
guidance of the detailed pamphlet includes fostering commitment among those involved such as
patients, providers, and policy makers. Despite the challenges, the onus and moral obligation of
VAMC health care providers are to educate patients about the risks and benefits of screening
before undergoing PSA testing.
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prostate cancer
screening trial.
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Mortality Results
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Prostate Cancer
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The PSA testing
dilemma: GP's
reports of
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with Full Text
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Medical ethics,
opinion of
authority

Research
Design

Level of
Evidence

Study Aim /
Purpose

Randomized
controlled trial
across 10 study
centers in the
USA. Each study
center used
recruitment
sources and
strategies
appropriate to the
local situation.
Participants were
randomized 1:1.
Level 7: Opinions Level 2:RCTs
of authorities,
experts.

Semi-structured
telephone
interviews with
21 general
practitioners
(GPs) from 18
GP practices in
Oxfordshire.

This article is an
opinion of a
Urologist.

Level 6:
Qualitative
interview study.

Discusses the
ethics of a
prostate cancer
screening trial.

This study aimed
to elicit GPs
accounts of their
discussions with
asymptomatic
men who consult
with concerns
about prostate
cancer in order to
identify the
degree to which
the National
Health Service
Prostate Cancer
Risk
Management
Programme
(PCRMP)
guidance was
reflected in these
consultations.
The PCRMP has
recommended
that screening for
prostate cancer is
available for
asymptomatic
men, on the
understanding
that they have

Level 7:
Opinions of
authorities/
experts
The author
attempts to
answer what is
the best approach
to dealing with
the number one
cancer in men and
the second
leading cause of
male cancer
deaths.
Screening, PSA
as a marker, and
what to tell
patients are the
issues of focus.

The effect of
screening with
prostate-specificantigen testing
and digital rectal
examination on
the rate of death
from prostate
cancer is
unknown. This is
the first report
from the Prostate,
Lung, Colorectal,
and Ovarian
(PLCO) Cancer
Screening Trial
on prostatecancer mortality.
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been provided
with full and
balanced
information about
the advantages
and limitations of
the PSA test.
Guidance has
been distributed
to all GPs in
England and
Wales to assist in
the provision of
information to
men.

Not applicable

Population
Studied /
Sample Size
/ Criteria /
Power

Participants were
males aged 55 to
74 years. Men
with a history of
prostate, lung or
colorectal cancer
were excluded,
along with
participants
currently
receiving cancer
treatments. In
1995, men who
had undertaken
more than one
PSA blood test in
the previous three
years were also
excluded.
Screening group
38,343; control
group 38,350.

A purposive
Not applicable
sample of GPs
was identified
through first PSA
test requests
made for patients,
of any age, to the
Department of
Clinical
Biochemistry,
John Radcliffe
Hospital, Oxford.
As part of a
separate study,
questionnaires
had been sent to
the requesting
GPs. Of the 173
GPs who returned
a questionnaire,
94 indicated that
they would be
willing to take
part in a
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telephone
interview.
Consecutive GPs
were invited to
take part in this
study. 21 GPs,
from 18
surgeries, were
interviewed
within the time
frame of the
study.

Methods /
Study
Appraisal /
Synthesis
Methods

Discusses the
ethics of a
prostate cancer
screening trial by
comparing
screening for
prostate cancer
with screening for
breast cancer.
Points out that
cytological
screening for
cervical cancer
was introduced
20 years ago
without a
persuasive
randomized trial
or other
compelling
scientific
foundation.

Compared mass
screening for
prostate cancer to
no screening:
1993-2001,
76,693 men at 10
U.S. study centers
randomly
assigned for
annual screening
or usual care as
the control.
Screening group
was offered
annual PSA
testing for 6 years
and digital rectal
examination for 4
years. Numbers
of all cancers and
deaths and causes
of death
ascertained.

Semi-structured
telephone
interviews to
elicit i) the
content of
discussions GPs
have with
asymptomatic
men who consult
with concerns
about prostate
cancer/PSA
testing and ii) the
attitudes of GPs
toward the PSA
test. Data
analysis included
identification of
the key issues
within the data. A
transparent
coding scheme
and regular
discussions
between the
researchers
helped to ensure

Opinion of a
Urologist about
the usefulness of
the PSA blood
test.
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the credibility and
trustworthiness of
the findings.

Primary
Outcome
Measures
and Results

Discusses adverse
treatment effects
of prostate cancer
treatment.
Authors comment
that if a screening
tool with
inadequate
sensitivity and
specificity is used
to detect cancers
with an unknown,
often benign,
natural course,
and as a result
patients are
subjected to an
experimental
treatment with
substantial side
effects, the net
effect of
screening could
be harmful.

Primary outcome
was prostate
cancer mortality
at 7 and 10 years
follow up;
number of
prostate cancers
diagnosed
reported. After 710 years of
follow- up the
rate of death from
prostate cancer
was very low; did
not differ
significantly
between the two
groups.

All GPs reported
undertaking some
discussions with
asymptomatic
men about the
PSA test. They
described
focusing most of
the discussion on
the false-positive
and falsenegative rates of
the test, and the
risks associated
with a prostate
biopsy. They
reported less
discussion of the
potential for
diagnosing
indolent cancers,
the dilemmas
regarding
treatment options
for localized
prostate cancer
and the potential
benefit of testing.
Considerable
variation existed
between GPs in

The author notes
a correlation
between PSA,
cancer, and
benign prostatic
hypertrophy and
notes that a rapid
rise in PSA is
associated with
more aggressive
cancers. He then
goes on to state
"we" recommend
decreasing the
PSA threshold for
biopsy from
4ng/ml to 2ng/ml
because it
SEEMS to detect
more localized
cancers.
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their accounts of
the degree of
detail given, and
GP's presentation
of information
appeared to be
affected by their
personal views of
the PSA test.
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No prevention
trial is ethically
acceptable if the
purpose is simply
to provide
evidence of net
harm. To
intervene in
healthy people is
not ethical
without the
widespread
perception of a
net benefit. As of
yet the ethical
justification for
prostate cancer
screening trial has
Author
Conclusions/ yet to be heard.
Implications
of Key
Findings

After 7-10 years
of follow- up the
rate of death from
prostate cancer
was very low and
did not differ
significantly
between the two
study groups.

The GPs in this
study appear to
recognize the
importance of
discussions
regarding PSA
testing; however,
a full and
balanced picture
of the associated
advantages and
limitations does
not seem to be
consistently
conveyed. Factors
specific to PSA
testing which
appeared to have
an impact on the
GPs discussion
were the GPs
personal opinions
of the PSA test,
and the need to
counter men's
primarily positive
views of the
benefits of PSA
testing.
Awareness of
their views on the
consultations may
help GPs give
men a more
balanced
presentation of
the benefits and
limitations of the
PSA test.

The author
acknowledges
that the price of
detecting cancers
early comes at the
expense of more
biopsies,
treatment-related
morbidity, and
overtreatment of
some men but
then endorses
doing more
biopsies. He
concludes until a
better test comes
along PSA is here
to stay.
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Strengths are the
high
qualifications of
the authors.
Limitation is this
is an opinion.

Strengths/
Limitations

According to the
2010 Cochrane
Screening for
Prostate Cancer
(Review) there
was adequate
sequence
generation;
adequate
allocation
concealment;
intervention and
data on diagnosed
cancers and
mortality not
blinded;
incomplete
outcome data was
not addressed; it
was free of
selective
reporting and free
of other bias.

This study is the
first to address
the discussions
about PSA testing
that takes place
during GP
consultations
with
asymptomatic
men concerned
about prostate
cancer, and as
such provides a
valuable insight
into the extent to
which the
implications of
undergoing a
PSA test are
discussed. The
value of
qualitative
research lies in
the depth of
understanding
gained from
detailed
descriptions of
specific
experiences;
therefore the
number of
participants in a
qualitative study
is necessarily
small. The small
number of
participants may
mean that there
were a range of
experiences that
were not
captured.
Interviews reliant
on recall of
events can suffer
from recall bias.

This opinion of a
practicing
urologist is biased
with the author
talking out of
both sides of his
mouth.
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A further
limitation is that
GPs for this study
were recruited
from one regional
area.

No funding
source
mentioned.

Funding
Source

Supported by
contracts from the
National Cancer
Institute.
GlaxoSmith
Kline, Aeterna
Zentaris,
Antigenics,
Ferring
Pharmaceuticals,
Veridex,
AstraZeneca,
Momenta
Pharmaceuticals,
Genentech, and
Roche provided
lecture fees, grant
support, and
research support
to individual

GPs were paid 50
pounds as
reimbursement
for the time spent
in the telephone
interview. The
work was funded
by Cancer
Research UK and
the NHS cancer
Screening
Programmes
(grant number
C73/A2983).

The author
declares no
conflict of
interest.
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researchers.

Comments

Hans-Olov
Adami is highly
qualified to give
expert opinion.
He has a long
background as a
practicing
surgeon with a
focus on
oncology. He
conducts clinical
and
epidemiologic
research in
parallel. His
clinical research
includes
randomized trials,
prognostic
studies, and
studies of clinical
issues using an
observational
study design. His
focus is on cancer
epidemiology and
is currently
working on
prostate cancer
with research
ranging from
genetic
association
studies to
randomized trials
of radical surgical
treatment, and
prediction of
outcome using

Excellent large
randomized
control study with
low risk of bias.
One of two
(European trial)
ongoing
randomized trials
of PSA screening,
to provide the
first quantitative
estimate of the
survival benefit
due to early
detection of
prostate cancer.
This USA trial
found no survival
benefit from
annual PSA
screening
combined with
digital rectal
exam.

This article
identified barriers
faced by GPs in
providing PSA
screening
education
including time
constraints and
personal
opinions. GPs
were less likely to
discuss the
potential for
diagnosing
indolent cancers
and the lack of
evidence for the
effectiveness for
prostate cancer
treatments. An
interview study is
pending which
looks at
consultations
prior to PSA
testing from
men's
perspective.

This article is an
opinion of a
Urologist and was
written in 2005
when PSAs were
given more
credence than
today.
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molecular and
genetic markers.
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Article 24

Article 12

Article 22

Article 9

Patient-Centered
Discussion about
Prostate Cancer
Screening: A
Real-World
Approach.
Annals of Internal
Medicine

Author /
Year

Etzioni, R., Cha,
R., Feurer, R.,
Davidov, O.
(1998).

Gaster, B.,
Edwards, K.,
Brown Trinidad,
S., Gallagher, T.,
Braddock, C.
(2010)
Database:CINHL
with Full Text

Are physicians
discussing
prostate cancer
screening with
their patients and
why or why not?
A pilot study.
Journal of
General Internal
Medicine.
Guerra, C.,
Jacobs, S.,
Holmes, J., Shea,
J. (2007).

The prostate
cancer pseudoepidemic. Acta
Oncologica

Article Title
and Journal

Asymptomatic
incidence and
duration of
prostate cancer.
American Journal
of Epidemiology.

Database:CINHL
with Full Text

Database:CINHL
with Full Text

Key words in the
article include
prostate-specific
antigen; prostate
cancer screening;
mass screening;
physician practice
patterns;
physician-patient
relations;
communication
barriers; informed
decision making.

Key words (Major
subjects) include
early intervention,
health screening,
incidence, PSA,
prostatic
neoplasms

Database:CINHL
with Full Text

Database
and
Keywords

Keywords in the
article include
disease
progression;
natural history;
prevalence;
prostatic
neoplasms; SEER
program.
Article includes
19 references.

Keywords used
to search for the
article included
prostate cancer
screening, clinical
guidelines, shared
decision making.
Article includes
52 references

Article includes
39 references

Adami, HansOlov(2010)

Article includes
26 references and
six tables/charts
displaying
statistics.
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Single descriptive
study

Ideas and
opinions

Qualitative pilot
study involving
in-depth,
semistructured
interviews with
18 purposively
sampled,
academic and
community-based
primary care
physicians.

Level 6: Single
descriptive study.

Level 7 :
Opinions of
authorities/experts
Recent data
suggest that few
providers are
discussing
prostate cancer
screening with
their patients
despite national
guidelines that
recommend it.
The authors
propose a
process-approach
(Ask-Tell-Ask)
that promotes
tailored
conversations and
value-based
recommendations.

Level 6: Single
descriptive or
qualitative study
This study aimed
to identify factors
that facilitate or
prevent prostate
cancer screening
discussion.

Research
Design

Level of
Evidence

Study Aim /
Purpose

The goal of this
paper is to
estimate the
length of the
asymptomatic
period in prostate
cancer, that is, the
time of onset of
the disease until
the appearance of
symptoms leading
to its diagnosis.
Also estimate the
duration of the
preclinical period,
which the authors
define as the time
from onset of the
disease until its
clinical diagnosis,
whether due to
symptoms or not.

This article is a
lecture by Dr.
Adami, presented
at SOF meeting in
Uppsala, Sweden,
March 18-20,
2009. It is a
review of studies
of the natural
history and
treatment impact
of prostate cancer
carried out in
Sweden and other
Nordic countries
during the last
two decades.
Level 1:
Systematic review
To present
indirect evidence,
incidence and
mortality trends,
and summarize
studies of the
natural history
and treatment
impact of prostate
cancer.
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Estimate the agespecific incidence
of new (stage A1)
prostate cancers
using preclinical
prevalence data
from autopsy
studies performed
between 1941 and
1964 and clinical
incidence data for
the years 19601986 from the
Surveillance,
Epidemiology,
and End Results
(SEER) program
of the National
Cancer Institute.

Population
Studied /
Sample Size
/ Criteria /
Power

Not applicable

18 participating
physicians

The information
in this article is
extracted from
multiple studies:
One study of the
natural history of
early prostate
cancer involved
watchful waiting
of 223
symptomatic
patients in
Orebro County in
Sweden before
the PSA era
(19771984);Another
study of survival
benefit of radical
local treatment
includes a multicenter randomized
controlled trail of
695 men newly
diagnosed with a
clinically
localized prostate
cancer, and with a
PSA value less
than 50 PG/nl and
no evidence of
metastases
randomized to
radical
prostatectomy or
watchful waiting.
In 2009, the
European and
USA ongoing
randomized trials
of PSA screening
were mentioned
with 162,387 men
from seven
countries
followed for an
average of 9 years
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in the European
trial and 76 693
men in the USA
trial.

Methods /
Study
Appraisal /
Synthesis
Methods

Begin by
estimating the
number of new
cases of
asymptomatic
disease in any
given age interval
from the
incidence data
above. Then, the
preclinical
prevalence
estimates are
divided by the
derived
preclinical
incidence

Provides a timeefficient model
which emphasizes
the provider's role
as an interactive
guide rather than
a one-way
supplier of
information in
discussing the
pros and cons of
prostate cancer
screening.

Barriers and
facilitators of
prostate cancer
screening
discussions were
ascertained using
both interviews
and chartstimulated recall-a
technique
utilizing patient
charts to probe
recall and provide
context to
physician
decision-making
during clinic

Extrapolated
findings from
multiple studies
and incidence and
mortality trends.
Prostate cancer is
an extreme
example of
autopsy-detected
tumors. The
prevalence of
such lesions is
about 20%
already among
men aged 45
years and
increases with
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estimates to yield
estimates of the
average duration
of asymptomatic
disease.

Primary
Outcome
Measures
and Results

The estimated
mean duration
among white men
is between 11 and
12 years and
appears to be
approximately 1
year shorter for
blacks than for
whites.
Comparison of
the lifetime risks
of preclinical and
clinical disease
suggests that
approximately
75% of prostate
cancers will never
become diagnosed
if clinical
incidence remains
at levels observed
in 1984-1986,
prior to the
introduction of
PSA screening in
the population.

Ask-Tell-Ask
approach will
improve the
quality of care by
encouraging more
informed
decisions about
prostate cancer
screening.

encounters.
Analysis was
performed using
consensus
conferences based
on grounded
theory techniques.

age; these lesions
detected at
autopsy did not
cause symptoms
or contribute to
death.

All 18
participating
physicians
reported that they
generally
discussed prostate
cancer screening
(PCS) with
patients, though 6
reported
sometimes
ordering PSA
tests without
discussion. A
PCS discussion
occurred in only
16(36%) of the 44
patient-physician
encounters when
patients were due
for PCS that also
met criteria for
chart-stimulated
recall. Barriers to
PCS discussion
were patient
comorbidity,
limited
education/health
literacy, prior
refusal of care,
physician
forgetfulness,
acute-care visits,

Orebro study with
continued follow
up beyond 20
years; as of 2001,
9% of men still
alive, only 16%
had died from
prostate cancer,
whereas 75% had
died from other
causes. Multicenter trial of 695
men at 12 years
follow-up, 47
(12.5%) of the
surgery group and
68(17.9% of the
watchful waiting
group had died of
prostate cancer
yielding a relative
risk of 0.65
comparing
watchful waiting
to radical
prostatectomy.
The absolute risk
reduction at 12
years was 5.4 %
which translates
into 19 patients
needing to be
treated with
radical
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and lack of time.
Facilitators of
PCS discussion
included patientrequested
screening, highly
educated patients,
family history of
prostate cancer,
African American
race, visits for
routine physicals,
review of
previous PSA
results, extra time
during
encounters, and
reminder systems.

prostatectomy in
order to avert one
prostate cancer
death. The
absolute risk
difference in the
European trial
was 0.71 cancer
deaths/1000 men
screened,
meaning that
1410 men must be
screened and 48
cases of prostate
cancer treated to
avert one death.
At 10 years in the
US trial there
were 92 prostate
cancer deaths
among 38343
men randomized
to screening but
only 82 among
38350 men
randomized to no
screening; the
difference was not
statistically
significant.
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The asymptomatic
incidence and
sojourn time
estimates are
biologically
plausible and are
consistent with
the literature on
PSA growth in
prostate cancer
cases. They
confirm what has
already been
suspected for
some time,
namely, that
Author
prostate cancer is
Conclusions
a relatively slow/
growing
Implications
neoplasm, and
of Key
they suggest that
Findings
among whites, 5075 percent of new
cases are unlikely
to surface
clinically. The
estimates should
be useful to
researchers
studying the
natural history of
the disease and
designing
effective and costeffective
screening
programs.

Shared decision
making about
prostate cancer
screening is
crucial, given the
continued
uncertainty about
its risks and
benefits.

Prostate cancer
screening
discussions
sometimes do not
occur. Important
barriers to
discussion are
inadequate time
for health
maintenance,
physician
forgetfulness, and
patient
characteristics.
Future research
should explore
using educational
and decision
support
interventions to
involve more
patients in PCS
decisions.

The prostate
cancer mortality
rate has varied
little over 40
years, but the
detection of
clinically
insignificant
cancers through
PSA testing has
entailed a drastic
increase in the
recorded
incidence. For
ethical and
scientific
reasoning-reinforced by
recommendations
from respected
authoritiescareless PSA
testing among
men who are
poorly informed
or ignorant that
PSA is analyzed
in their blood
sample must
come to an end.
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Strengths/
Limitations

Limitations: The
mathematical
relation, average
duration equals
prevalence
divided by
incidence, has a
long history in the
epidemiologic
literature. An
implicit
assumption is that
the condition of
interest is
progressive in the
sense that it will
terminate unless
prevented, for
example by
competing
mortality.
Therefore, this
approach is not
valid for nonprogressive
diseases or for
diseases that can
regress. Given the
possibility that
prostate cancer
cases may exist in
whom the tumor
might remain
indolent no matter
how long they
lived (infinitely
indolent), this is a
limitation of the
approach.

This model is
based on
emerging theory
and evidence in
the field of patient
communication
with the goal of
engaging patients
and addressing
their concerns.

Strengths of this
study include the
open- ended
interview and
chart-stimulated
recall which
allowed for the
identification of
many important
barriers to PCS
discussion. Chartstimulated recall
is an innovative
method by which
to achieve
triangulation in
qualitative
research when
conducting
physician
interviews and
increases the
validity of data
obtained by
physician
interview. Also
helps address the
discrepancy
between
physicians '
perceived and
actual behavior
related to
recommending
cancer screening
tests as well as
recording bias
inherent in
methods based on
chart abstractions.
The study is
limited because of
the small number
of physicians and
patient encounters
which may have
prevented the

In this
groundbreaking
article, the author,
Professor,
Department of
Epidemiology,
Harvard School of
Public Health,
former practicing
surgeon with a
focus on
oncology, states
that future
historians may
indeed consider
the prostate
cancer pseudoepidemic a
disaster of
modern medicine.
There are no
limitations to this
study.
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authors from
reaching thematic
saturation, the
point at which no
new themes
emerged from the
data. The study
was conducted in
1 large health
system with a
predominantly
urban and
suburban sample
of physicians
therefore the
results are not
generalizable.
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Comments

Epidemiologist
have a much
better handle on
the true nature of
screening
including lead
time bias, false
positive and
negatives, and the
prevalence of
indolent disease.
Epidemiologists
try to understand
the natural history
of a disease in
order to develop
efficient screening
strategies.

Much needed
educational tool
which encourages
evidence based
practice.

This study
confirms the fact
that prostate
cancer screening
education is
sporadic and
random and
therefore evidence
based practice is
not occurring.

The author is
highly qualified
since he is
working
predominantly on
prostate cancer
with research
ranging from
genetic
association
studies to
randomized trials
of radical surgical
treatment, and
prediction of
outcome using
molecular and
genetic markings
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Article Title
and Journal

Author /
Year

Database
and
Keywords

Article 26
Health care
reform: Prostate
cancer screening
decisions: Results
from the national
survey of medical
decisions
(DECISIONS
Study). Archives
of INTERNAL
MEDICINE.
Hoffman, R.,
Couper, M.,
Zikmund-Fisher,
B., Levin, C.,
McNaughtonCollins, M.,
Helitzer, D.,
VanHoewyk.
Barry, M. (2009).

Article 6
Screening for
prostate cancer
(Review) The
Cochrane
Collaboration

Article 17
Global cancer
statistics.
http://caonline.a
mcancersoc.org/c
gi/content/full/ca
ac.20107v1. CA
Cancer J Clin
2011 doi:
10.3322/caac.201
07

Ilic D., O'Connor, Jamal, A., Bray,
D., Green S.,
F., Center, M.,
Wilt,TJ.(2010)
Ferlay, M., Ward,
E., Forman,
D.(2011).

Incidence data
Database: CINHL Database: CINHL (the number of
with Full Text.
with Full Text.
newly diagnosed
cases each year)
Keywords used to The authors did
are derived from
search for the
population based
electronic
article include
cancer registries.
searches of the
prostate cancer
Although the
PROSTATE
screening and
quality of
registrar (made
decision making. available by the
information from
most of the
Cochrane
Prostatic Diseases developing
Article includes
countries might
and Urologic
33 references.
be considered, in
Cancers Group
and the Cochrane relative terms, of
limited quality, it
Central Register
often remains the
of Controlled
only source of
Trials
information
(CENTRAL),
available on the
MEDLINE,
profile of cancer
EMBASE,
and as such
CANCERLIT
provides valuable
and NHS EED.
information. The
Hand searching
of five prominent total number of
urology journals
cancer deaths by

Article 16
Natural history of
early, localized
prostate cancer.
Journal of
American
Medical
Association.

Johansson, J.,
Andren, O.,
Andersson, S.,
Dickman, P.,
Holmberg, L.,
Magnuson, A.,
Adami, H.
(2004).
.
Database: CINHL
with Full Text.
Keywords used to
search for the
article include
prostate cancer,
prostate cancer
mortality

Article includes
26 references.
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and Cancer
journal.
Keywords not
mentioned.

Research
Design

Level of
Evidence

A randomly
selected national
sample of 3010
English-speaking
US adults 40
years and older.
Included in the
survey were 375
men who had
either undergone
or discussed
(with health care
providers) PSA
testing in the
previous 2 years.
Level 6: Single
descriptive or
qualitative study.

country is made
available by the
World Health
Organization.
Incidence and
Keywords used to mortality rates
search for the
(number of cases
article include
or deaths per
prostate cancer
100,000 persons
screening and
per year) were
systematic
estimated in
review.
GLOBOCAN by
country, using the
most recently
available data
collected at the
International
Agency for
Research on
Cancer or
available in
routine reports
from the
registries
themselves. 168
references.
Systematic
Description of
review of 205
global cancer
potentially
statistics with
relevant articles
incidence data
with 5 RCTs
derived from
meeting the
population-based
inclusion criteria cancer registries.
for meta-analysis.

Level 1:
Systematic
reviews/metaanalysis of all
RCTs

Level 6: Single
descriptive or
qualitative study

Population-based,
cohort study with
a mean
observation
period of 21
years.

Level 4: Cohort
study.
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Study Aim /
Purpose

Population
Studied /
Sample Size
/ Criteria /
Power

Methods /
Study
Appraisal /
Synthesis
Methods

Objectives were
to characterize
the decisionmaking process
and evaluate
factors associated
with discussing
screening before
a making a PSA
testing decision
and undergoing
PSA testing
following a
discussion.
A randomly
selected national
sample of 3010
English-speaking
US adults 40
years and older.
Included in the
survey were 375
men who had
either undergone
or discussed
(with health care
providers) PSA
testing in the
previous 2 years.

To determine
whether
screening for
prostate cancer
reduces prostate
cancer-specific
mortality, allcause mortality,
and its impact on
quality of life,
including adverse
events.

Provide an
overview of the
global cancer
burden, including
the estimated
number of new
cancer cases and
deaths in 2008
and the incidence
and mortality
rates by region
for selected
cancer sites.

To examine the
long-term natural
history of
untreated, early
stage prostate
cancer.

Five RCTs with a
total of 341,351
participants were
included in this
review. All
involved PSA
testing, though
the interval and
threshold for
further evaluation
varied across
trials. The age of
participants
ranged from 50 to
74 years and
duration of
follow up from 7
to 15 years.
The DECISIONS This updated
study consisted of version of the
a random-digit2006 review
dial telephone
identified 106
survey of a
potentially
national
relevant articles
probability
for full text
sample of
review in
English-speaking addition to the 99
US adults 40
in 2006 resulting
years and older.
in review of 205
Participants
articles. Two
completed a set
RCTs in 2006
of screening
and three more in
questions and
2010 met the

Global cancer
statistics: About
12.7 million
cancer cases and
7.6 million cancer
deaths are
estimated to have
occurred
worldwide with
56% of the cases
and 64% of the
deaths in the
economically
developing
world.

A consecutive
sample of 223
patients (98% of
all eligible) with
early-stage (TOT2 NX MO
classification),
initially untreated
prostatic cancer.
Patients with
tumor
progression were
hormonally
treated (either by
orchiectomy or
estrogens) if they
had symptoms.

National
incidence rates
were estimated
using one of
several methods,
dependant on the
availability and
quality of data, in
the following
order of
priority:1)
National
Incidence data,
2)National
mortality data

Setting:
Regionally welldefined catchman
area in central
Sweden
(recruitment
March 1977
through February
1984). The TNM
system and the
World Health
Organization
classification of
malignant
diseases were
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were then eligible
for decisionspecific question
modules if they
had taken a
medical action or
discussed taking
that action with
health care
providers for 1 of
9 common
medical decisions
within the past 2
years. Modules
covered decisions
related to cancer
screening tests
for prostate,
colorectal, or
breast cancer as
well as other
topics.

inclusion criteria.
Data from the
trials were
independently
extracted by two
authors. The
methodological
quality of three of
the studies had a
high risk of bias.

and local registry
data, 3)Regional
incidence data
from one or more
cancer registries
but no mortality
data, 4)
Frequency data,
5) No data
available.
Country-specific
incidence and
mortality rates
were prepared for
27 types of
cancer, by sex
and 10 age
groups. A full
description of the
data and methods
used for each
county are
available in
GLOBOCAN
2008.

used. PSA was
not available
when the cohort
was recruited. A
total of 654 cases
of prostate cancer
were diagnosed
and 223 patients
were ultimately
included in the
cohort study and
followed up from
diagnosis until
death of the end
of the observation
period. Scheduled
tests were
performed to
follow the
progression of
disease and the
medical records
of all diseased
patients were
reviewed.
Progression and
survival rates
were determined
and multivariable
analyses were
used to quantify
the independent
effects of followup time, age at
diagnosis, grade,
and stage.
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Primary
Outcome
Measures
and Results

Overall, 69.9% of
subjects
discussed
screening before
making a testing
decision,
including 14.4%
who were not
tested. Health
care providers
most often
(64.4%) raised
the idea of
screening, and
73.4%
recommended
PSA testing.
Health care
providers
emphasized the
pros of testing n
71.4% of
discussion but
infrequently
addressed the
cons (32.0%).
Although 58.0%
of subjects felt
well-informed
about PSA
testing, 47.8%
failed to correctly
answer any of the
3 knowledge
questions. Only
54.8% of subjects
reported being
asked for their
screening
preferences. A
health care
provider
recommendation
(odds ratio, 2.67;
95% confidence
interval, 1.086.58) was the

Primary
outcomes prostate
specific and allcause mortality.
Secondary
outcomes:
incident prostate
cancers by stage
and grade at
diagnosis;
metastatic disease
at follow up;
quality of life;
harms of
screening; and
costs associated
with screening
programs. No
statistically
significant
reduction in
prostate cancerspecific or allcause mortality
among the whole
population of
men randomized
to screening
versus controls.

Breast cancer in
females and lung
cancer in males
are the most
frequently
diagnosed cancer
deaths for each
sex in both
economically
developed and
developing
countries, except
lung cancer is
preceded by
prostate cancer as
the most frequent
cancer among
men in
economically
developed
countries. The
increased
incidence of
breast cancer in
developed
countries is due
in part to
postmenapausal
therapy or oral
contraceptives.
Prostate cancer
incidence rates
vary by more that
25-fold
worldwide, with
the highest rates
recorded
primarily in the
developed
countries of
Oceania, Europe,
and North
America largely
because of PSA
screening which
detects clinically
important tumors

After complete
follow-up, 39
(17%) of all
patients
experienced
generalized
disease. Most
cancers had an
indolent course
during the first
10-15 years.
Follow-up from
15(when 49
patients were still
alive) to 20 years
revealed a
substantial
decrease in
cumulative
progression-free
survival (45.0%
to 36.0%),
survival without
metastases (from
76.9% to 51.2%),
and prostate
cancer-specific
survival (from
78.7% to 54.4%).
The prostate
cancer mortality
rate increased
from 15 per 1000
person-years
during the first 15
years to 44 per
1000 personyears beyond 15
years of followup.
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only discussion
characteristic
associated with
testing Valuing
HCP information
was also
associated with
testing (odds
ratio, 1.26; 95%
confidence
interval, 1.041.54).

as well as other
slow-growing
tumors which
might otherwise
escape diagnosis.
In contrast, males
of African
descent in the
Carribean have
the highest cancer
mortality rates in
the world.
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Recommendation
s and information
from health care
providers
strongly
influenced testing
decisions.
However, most
prostate cancer
screening
decisions did not
meet criteria for
shared decision
making because
subjects did not
receive balanced
discussions of
decision
consequences,
had limited
knowledge, and
Author
were not
Conclusions
routinely asked
/
for their
Implications
preferences.
of Key
Findings

Prostate cancer
screening did not
significantly
decrease prostate
cancer-specific
mortality in a
combined metaanalysis of five
RCTs. Only one
study (ERSPC)
reported a benefit
in a subgroup of
men aged 55 to
69. Within this
subgroup it was
determined that
1410 men needed
to be invited to
screening and 48
additional men
subsequently
diagnosed with
prostate cancer
needed to receive
early intervention
to prevent one
additional
prostate cancer
death at 10 years.
Any benefits
from prostate
cancer screening
may take up to 10
years to accrue;
therefore, men
who have a life
expectancy less
than 10 t0 15
years should be
informed that
screening for
prostate cancer is
unlikely to be
beneficial.

The global
burden of cancer
continues to
increase largely
because of the
aging and growth
of the world
population and an
increasing
adoption of
cancer-causing
behaviors,
particularly
smoking, within
economically
developing
countries. A
significant
proportion of the
worldwide
burden of cancer
could be
prevented
through the
application of
existing cancer
control
knowledge,
implementing
programs for
tobacco control,
vaccination(for
liver and cervical
cancers), and
early detection
and treatment, as
well as public
health campaigns
promoting
physical activity
and healthier
dietary patterns.
Much needs to be
learned about the
causes of several
major cancers
including prostate

Although most
prostate cancers
diagnosed at an
early stage have
an indolent
course, local
tumor
progression and
aggressive
metastatic disease
may develop in
the long term.
These findings
would support
early radical
treatment,
notably among
patients with an
estimated life
expectancy
exceeding 15
years.
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and colorectal
cancers.
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Strengths/
Limitations

The study had
several important
limitations. The
results were
susceptible to
recall bias
because authors
relied on patient
self-report to
characterize the
testing process
and there could
be up to a 2-year
lag time from the
discussing
screening to
being surveyed.
Another
limitation was the
lack of
assessment of
health literacy,
defined as "the
degree to which
individuals have
the capacity to
obtain, process,
and understand
basic health
information and
services needed
to make
appropriate health
decisions" .
Patients with
health literacy
deficits have
greater difficulty
understanding
and recalling
complex medical
information and
are less likely to
actively
participate in the
decision-making
process.

Excellent
comprehensive
systemic review.
The
methodological
quality of three of
the studies had a
high risk of bias.

Limitations: The
global and
region-specific
estimates are
built for 182
countries or
territories,
together with a
set of methods
based on the
availability of
cancer incidence
and mortality
data at the
country or
regional level.
Therefore the
estimates
presented in
GLOBOCAN
2008 are variable
in accuracy,
depending on the
extend and the
validity of
available data by
country, ranging
from real and
valid counts of
cases and deaths,
to estimates
based on samples,
through to those
based on
neighboring rates.
Strengths include
provision by the
World Health
Organization of
country specific
cancer mortality
estimates by sex
and age group for
2008, based on
broad cause-ofdeath models.
These data were

Strengths: High
internal validity
of this population
based study
because there was
complete followup and
standardized
procedures were
used for clinical
examination,
ascertainment of
disease
progression, and
classification of
death. The slight
difference
between causespecific and
relative survival
times were
largely consistent
over time.
Limitation:
Difficult to
validate survival
data in any new
cohort study of
watchful waiting
since aggressive
treatment of
prostate cancer
has become more
routine than 25
years ago when
the cohort was
assembled.
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Strengths include
addressing an
important timely
topic with
recommendations
to provide
alternate
strategies, such as
decision aids, to
ensure a process
that engages
patients in
decision making,
provides them
with information
about alternative
strategies, and
facilitates the
incorporation of
their preferences
and values into
the medical plan.
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is supported by a
career
development
award from the
American Cancer
Society (MRSG-

used in
estimating the
overall burden of
cancer is several
countries were no
or very limited
information was
available.

No known
declarations of
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Funding not
mentioned. The
authors report no
conflicts of
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The study was
supported by
grants from the
Orebro County
Council Research
Committee, the
Orebro
University
Hospital
Research
Foundation,
Obrebro, Sweden,
and the Swedish
Cancer Society.
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06-130-01CPPB).

The DECISIONS
study reaffirms
that men are not
receiving
adequate
information and
their provider's
opinion is often
the deciding
factor.
Comments

Excellent updated
systematic review
of all randomized
controlled trials
of screening
versus no
screening was
eligible for
inclusion in this
review. This
article is an
update of the
2006 Cochrane
review which
identified
insufficient
evidence to either
support, or
refutes the use of
routine mass,
selective or
opportunistic
screening for
prostate cancer.

The roles of PSA
testing in the
reduction of the
prostate cancer
mortality rates at
the population
level have been
difficult to
quantify. Older
age, race (black),
and family
history remain
the only wellestablished risk
factors and there
are not
established
preventable risk
factors for
prostate cancer.
Much remains to
be learned about
the cause of
prostate cancer.

This study
advocates for
aggressive cancer
treatment but this
was prior to PSA
testing, and no
screening for
activities for
prostate cancer
took place during
the period when
this cohort was
recruited.
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Article Title
and Journal

Author /
Year

Article 5
15-Year follow
up of a
population based
prostate cancer
screening study.
The Journal of
Urology

Article 20
Patient education
on prostate
cancer screening
and involvement
in decision
making. Annals
of Family
Medicine.

Article 4
Screening
decreases prostate
cancer death: first
analysis of the
1988 Quebec
prospective
randomized
controlled trial.
Prostate

Kjellman, A.,
Akre, O.,
Norming, U.,
Tornblom, M.,
Gustafsson,
O.(2009)

Krist, A, Woolf,
Labie F., Candas
S., Johnson.,
B., Dupont A.,
Kerns, W. (2007). Cusan L., Gomez
J., Suburu, R. et
al.(1999)

Article 19
Clinical
Guidelines:
Benefits and
harms of
prostate-specific
antigen screening
for prostate
cancer: An
evidence update
for the U.S.
Preventative Task
Force. Annals of
Internal
Medicine.
Lin, K., Lipsitz,
R., Miller, T.,
Janakiraman, S.
(2008).
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Database:
Cochrane Library
Keywords in the
article are
prostate; prostatic
neoplasm;
mortality;
outcome
assessment
(healthcare),
mass screening.
Article includes
17 references

Database
and
Keywords

Database:
Cochrane Library

Keywords:
Prostatic
neoplasm;
decision making;
patient
education/method
s; guideline
adherence/statisti
cs & numerical
data; prostatespecific
antigen/blood;
mass
screening/method
s;
prevention/cancer
; information
management.
Article includes
includes 39
references

Database:
PubMed
Keywords in the
article are
prostate cancer;
screening; PSA;
hormonal
therapy.

Article includes
49 references

Data Sources in
the identified in
the article:
PubMed and the
Cochrane Library
(search dates,
January 2002 to
July 2007),
referenced lists of
retrieved articles,
and expert
suggestions.
Keywords for
three topics.
1) Evidence on
health outcomes
associated with
PSA screening:
prostate
neoplasm,
screening,
prostate-specific
antigen, early
diagnosis, PSA
velocity, PSA
doubling time,
prostate specific
antigen doubling.
2) Evidence on
the harms of
screening for
prostate cancer:
prostate
neoplasm,
screening, false
positive
reactions, adverse
effects, mass
screening/adverse
effects, mass
screening/psychol
ogy, anxiety,
quality of life,
health
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knowledge,
attitudes,
practice.
3) Evidence on
natural history
of PSA-detected,
nonpalpable,
localized prostate
cancer: prostatic
neoplasms,
natural history,
epidemiology,
disease
progression,
survival analysis,
watchful waiting,
active
surveillance,
population
surveillance,
expectant
management,
conservative
management.

Research
Design

Randomized
controlled trial in
Stockholm,
Sweden. Male
participants were
identified through
census records.
The study reports
on a 15 year
follow -up of
participants on
prostate cancer
outcome.

Randomized
controlled study
comparing paperbased and Webbased decision
aids vs. no
previsit education
as a control.

Randomized
controlled trial in
Quebec, Canada.
Participants were
men identified
from electoral
roles and
allocated 2:1 in
favor of
screening. The
study reports on
an 11-year
follow-up of
participants on
prostate cancer
outcome. Men
age 45-80 years

Data extraction:
Studies were
reviewed,
abstracted, and
rated for quality
by using
predefined U.S.
Preventative
Services Task
Force criteria.
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with screening
group 31,133 and
control group
15,353.

Level 2:RCTs
Level of
Evidence

Study Aim /
Purpose

Population
Studied /
Sample Size
/ Criteria /
Power

Level 2:
Evidence from
one or more
RCTs.

Level 2:RCTs

Level 1:
Systematic
reviews/metaanalysis of
randomized
controlled trials.
Report on a 15Many clinicians
Evaluate the
To examine new
year follow up of lack resources to impact of prostate evidence on
participants on
engage patients in cancer screening
benefits and
prostate cancer
shared decision
on cancerharms of
outcome;
making for
specific mortality screening
evaluating the
prostate cancer
asymptomatic
long-term
screening. This
men for prostate
survival in
study evaluated
cancer with PSA.
attendees and
whether previsit
nonattendees of a educational
onetime
decision aids
screening for
facilitate shared
prostate cancer.
decision making.
Participants were A total of 497
46,486 men aged Systemic Review
all men aged
men participated 45-80 years
of articles
between 55-70
(75 control, 196
registered in the
addressing three
years living in the brochures, 226
electoral roll of
questions: 1)
catchment area of Web site).
the Quebec city
Health outcomes
Stockhom South
area were
associated with
Hospital. Men
randomized in
PSA screening,
with an earlier
1988 between
390 potentially
diagnosis of
screening and no relevant articles,
prostate cancer
screening.
2) Harms of
were excluded
Screening
prostate cancer
from the study.
included
screening, 421
Numbers include
measurement of
potentially
screening groupserum PSA using relevant articles,
2374 and control
3.0ng/ml as upper 3) Natural history
group 24,772
limit of normal
of PSA-detected
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Methods /
Study
Appraisal /
Synthesis
Methods

Primary
Outcome
Measures
and Results

Compare mass
screening for
prostate cancer to
no screening:
Interventions
were one time
screening versus
control (not
invited for
screening). The
screening
consisted of
DRE, PSA test
and TRUS.
TRUS guided
biopsies were
performed if
abnormal
findings occurred
during the DRE
and/or TRUS. A
repeat TRUS was
performed if the
PSA was greater
than 7ng/nl.
Incidence rate
ratios were
calculated using
Poisson
regression
models. Increased
risk of death in
nonattendees and

and digital rectal
examination
(DRE) at first
visit. At followup visits, serum
PSA only was
used.

prostate cancer,
91 potentially
relevant articles.

Men aged 50 to
70 years
undergoing a
health
maintenance
examination at a
large family
practice were
enrolled.

Compared mass
screening for
prostate cancer to
no screening:
Interventions
were annual
screening versus
control (not
invited for
screening). TRUS
biopsy was only
performed if PSA
was above
3.0ng/ml for the
first time or
increased by
more than 20%
from last
measurement.

Randomized,
controlled trials
and meta-analysis
of PSA screening
and crosssectional and
cohort studies of
screening harms
and of the natural
history of
screeningdetected cancer
were selected to
answer the three
aforementioned
questions.

The primary
outcome was
patient-reported
level of control
over the decision
to be screened.
Secondary
outcomes

Primary outcome
was prostate
cancer mortality
at 11 years
follow-up. Also
reported was
prostate cancer
death incidence

No good-quality
randomized,
controlled trials
of screening for
prostate cancer
have been
completed. In one
cross-sectional
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decreased
mortality in
screening
attendees. The
difference
mortality rate was
attributable to
death from causes
other than
prostate cancer.

included
frequency of
screening, patient
knowledge,
decisional
conflict, and time
spent discussing
screening.
Patients exposed
to either aid were
no more likely
than control
patients to report
collaborative
decision. 36% of
patients in each
group reported
equally sharing
decision
responsibility.
Exposure to
either decision ad
increased
patients'
involvement in
decision making
compared with
the control
condition (Web
site, P=.03;
brochure, P= .03).
Only 46% of
control patients
reported an active
decision-making
role, compared
with 56% of Web
site and 54% of
brochure patients.
Patients exposed
to a decision aid
answered a
greater
percentage of
knowledge
questions
correctly(54%

rates in screened
versus
unscreened
cohorts, and
clinical stage and
choice of therapy
in men diagnosed
with prostate
cancer.

and two
prospective
cohort studies of
fair to good
quality, falsepositive PSA
screening results
caused
psychological
adverse effects
for up to one year
after the test. The
natural history of
PSA-detected
prostate cancer is
poorly
understood.
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No evidence was
found of a
beneficial effect
of the screening
procedure.
Significant lower
life expectancy in
non-attendees in
Author
a population
Conclusions
based prostate
/
cancer screening
Implications
study.
of Key
Findings

control vs 69%
Web site, P <
.001, and vs. 69%
brochure, P <
.001) and were
less likely to be
screened (94%
control vs. 86%
Web site, P = .06,
and vs. 85%
brochure, P= .04).
Patients in the
decision aid
groups were more
informed and
more engaged in
the screening
decision than
their control
counterparts.
Exposure did not
promote shared
decision-making
control, however.
Whether shared
decision making
is the ideal model
and how to
measure its
occurrence are
subjects for
further research.

Strong support
for early
diagnosis and
treatment. Early
diagnosis
combined with
treatment of
localized disease
decreased death
from prostate
cancer by 62%.

Prostate-specific
antigen screening
is associated with
psychological
harms, and its
potential benefits
remain uncertain
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Strengths/
Limitations

Funding
Source

According to the
Cochrane
Screening for
prostate cancer
(Review)
adequate
sequence
generation was
unclear; no
allocation
concealment;
blinding is not
possible to the
screening
intervention ;
incomplete
outcome data was
addressed;
unclear if free of
selective
reporting; free of
bias and data was
analyzed
according to the
intention-toscreen -

Limitations: 1)
Outcomes
measured by
patient and
physician
questionnaires as
opposed to direct
observation or
interview, 2) A
well-educated,
computor-savvy
patient population
was studied , 3)
In July 2003, the
study practice
lost a wellpublicized
malpractice case
involving shared
decision making
and prostate
cancer screening,
4) 46% of the
control patients
reported that they
viewed
educational
material before
the office visit, 5)
Study was
underpowered to
detect differences
between the
brochure and
Web site groups.
Supported by the Funding support:
Stockholm
This work was
County Council
funded by the
and the Thure and American
Brita Grafstrom
Academy of
Foundation.
Family
Grant from Odd
Physicians
Fellows and
Foundation under
Karolinska
the Joint Grant
Institute.
Awards Program.

According to the
Cochrane
Screening for
prostate
cancer(Review)
unclear adequate
sequence
generation; no
mention of
allocation
concealment; not
possible to blind
intervention;
incomplete data
was addressed;
unclear if free of
selective
reporting; not
free of bias, data
was not analyzed
according to the
intention-toscreen principle

Limitations: Few
eligible studies
were identified.
Long-term
adverse effects of
false-positive
PSA screening
test results are
unknown.
Strengths:
Nonrandomized
studies of PSA
screening
excluded.

Funding not
mentioned

Potential
financial conflicts
of interest: None
disclosed.
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Contradictory
results

Comments

Simple paper and
Web-based
decision-making
aides were
equally effective
at promoting
patient activation
in the decisionmaking process.
Further research
can be done to
define and
measures shared
decision making
and usefulness of
aids.

According to the
2010 Cochrane
Screening for
prostate cancer
(Review)
crossover and
contamination
were issues;
From a total of
31,133 men
randomized to the
screening group
only
7348(23.6%)
were actually
screened and of
the 15,353
randomized to the
control group,
1122(7.3%) were
screened for
prostate cancer.

The USPSTF
recommendation
for prostate
cancer screening
has consistently
been a grade I;
The evidence is
insufficient to
recommend for or
against routinely
providing (the
service).
Evidence that
(the service) is
effective is
lacking, of poor
quality, or
conflicting, and
the balance of
benefits and
harms cannot be
determined. It is
fascinating that
wide-spread
testing for PSA
among
asymptomatic
men continues
when the
USPSTF has
consistently given
prostate cancer
screening, the
service, such a
low
recommendation.
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Article 7
Prostate-specific
antigen: friend or foe.
Urologic Nursing

Article Title
and Journal

Linn, M., Ball, R.,
Maradigiegue,A.(2007)
.
Author /
Year

Database: CINHL with
Full Text

Database
and
Keywords

Author’s database
includes systematic
review of 52 references
from 1991-2007 using
Evidence-Based
Medicine Reviews,
Medline, and CINAHL.
Author’s keywords are
prostate-specific
antigen, PSA, prostate
cancer, prostatectomy,
prostatic hyperplasia,
prostate cancer
screening, and prostate
cancer costs.

Article 23
Randomized
trial examining
the effect of
two prostate
cancer
screening
educational
interventions
on patient
knowledge,
preferences,
and behaviors.
Journal of
General
Internal
Medicine.
Partin, M.,
Nelson, D.,
Radosevich, D.,
Nugent, S.,
Flood, A.,
Dillon, N.,
Holtzman, J.,
Haas, M., Wilt,
T.(2004).
Database:
CINHL with
Full Text
Author’s
keywords are
prostate
neoplasm;
prostatespecific
antigen; mass
screening;
decisionmaking; patient
education.

Article 13
Cancer part 1:
Prevention and
screening Cancer
screening 2009:
Setting evidencebased priorities.
Audio-Digest
Internal
Medicine

Article 29
Editorial:
Health care
reform:
Weighing the
benefits and
downsides of
prostatespecific antigen
screening. Arch
Intern Med

Perez-Stable.
(2009)

Pignone,M.
(2009)

From the 37th
Annual
Advances in
Internal
Medicine,
presented by the
University of
California, San
Francisco, and
School of
Medicine. No
mention of key
words.

Database:
Google Scholar
Keywords to
find article PSA
screening

Article includes
17 references s
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Research
Design

A review of the
medical evidence and
controversy related to
PSA screening. A
search of Evidence
Based Medicine
Reviews, Medline, and
CINHL along with
government statistics
and research material is
the methodology
employed. Included
are CEU, exam
questions, review,
tables/charts
Level 4: Case study

Level of
Evidence

Study Aim /
Purpose

The purpose of this
article is to review the
medical evidence and
controversy
surrounding PSA
screening

This is a review article
and did not study a
population

Population
Studied /
Sample Size
/ Criteria /
Power

Randomized
controlled trial.

Lecture

Editorial

Level 2:
Evidence from
one or more
RCTs
To assess the
effect of video
and pamphlet
interventions
on patient
prostate cancer
screening
knowledge,
decisionmaking
participation,
preferences,
and behaviors.
One thousand,
one hundred
fifty-two male
veterans age 50
and older with
primary care
appointments at
participating
facilities were
randomized and
893 completed
follow-up.
Setting four
Midwestern
Veterans

Level 7:
Opinions of
authorities/
experts
Setting evidencebased priorities
for cancer
screening in
2009.

Level 7:
Opinion of
expert/authority

Examined
criteria for
cancer screening
including
evidence based
recommendation
s for colon,
breast, lung, and
prostate cancer
screening.

This is an
editorial but a
table was
presented with
outcomes for 2
cohorts of 1000
men aged 60
years and at
average risk to
demonstrate the
balance of
benefit versus
harm of PSA
screening.

To weigh the
benefits and
downsides of
prostatespecific antigen
screening
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Affairs medical
facilities.

Methods /
Study
Appraisal /
Synthesis
Methods

In addition to
reviewing relevant
literature this article is
a comprehensive
review of PSA
screening history and
background to include:
PSA history; Screening
recommendations;
Epidemiology;PSA
screening movements
Cochrane Review
screening
Controversies;
Financial
considerations; and
Case study of medicolegal considerations.

Interventions:
Patients were
randomized to
mailed
pamphlet,
mailed video or
usual
care/control.
Outcomes
assessed by
phone survey 2
weeks
postinterventio
n included a
10-iten
knowledge
index; correct
responses to
question on
prostate cancer
natural history,
treatment
efficacy, the
PSA's
predictive
value, and
expert
disagreement
about the PSA;
whether
screening was
discussed with
provider;
screening
preference; and
PSA testing
rates.

Lecture

Editorial.
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This is a review article
and did not have
primary outcome
measures and results.

Primary
Outcome
Measures
and Results

Mean
knowledge
index scores
were higher for
video and
pamphlet,
subjects versus
controls. Video
and pamphlet
subjects
reported
significantly
higher
percentages of
correct
responses
relative to
controls to
questions on
prostate cancer
natural history,
treatment
efficacy, and
expert
disagreement,
but not PSA
accuracy.
Pamphlet
subjects were
more likely that
controls to
discuss
screening with
their provider
but video
subjects were
not. Video and
pamphlet
subjects were
less likely to
intend to have a
PSA, relative to
controls. PSA
testing rates did
not differ
significantly
across groups.

Approximately
80% of men
between 50 and
80 year of age
have had PSA
test.
Approximately
15% lifetime
risk;
approximately
30% of men have
prostate cancer at
autopsy. Studies
show similar
survival
associated with
watchful waiting
and active
therapy.

Table of 1000
cohorts
compared
diagnosed as
having prostate
cancer:
screening (53)
versus (23) not
screened;
biopsies
required ( 39)
versus (23) ;
adverse effects
( impotence,
incontinence or
both) (26)
versus (12) ;
prostate cancer
deaths (3
)versus (4);
other deaths(
113) versus(
113) .
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Although PSA testing
has become a primary
screening method for
prostate cancer in the
US, this test has come
under scrutiny. PSA
screening lacks a high
level of specificity due
to frequent falsepositive results.
Additionally, major
health organizations
differ in their screening
recommendations for
use of the PSA test.
The medical
community and
patients must
understand the benefits
and possible detriments
of this screening test.
Author
Providers should
Conclusions
approach each man
/
individually when
Implications
recommending a PSA
of Key
test, noting that many
Findings
risk factors must be
considered in a
screening protocol for
prostate cancer.

Mailed
interventions
enhance patient
knowledge and
self-reported
participation in
decision
making, and
alter screening
preferences.
The pamphlet
and video
interventions
evaluated are
comparable in
effectiveness.
The lower-cost
pamphlet
approach is an
attractive
option for
clinics with
limited
resources.

Public opinion
about screening
is that finding
cancer early
usually or always
saves lives; 56%
of those
surveyed want
screening, even
for clinically
irrelevant
cancers.

The decisions
about whether
to be screened
for men aged
50 to 75 years
hinges on
whether the
known
downsides of
overdiagnosis
and treatmentrelated adverse
effects are
counterbalance
d by a
sufficiently
large chance
that screening
will result in a
reduction in the
risk of death
from prostate
cancer. Two
recently
reported
randomized
trials conclude
that, at best,
prostate cancer
screening leads
to a modest
absolute
reduction in
prostate cancer
mortality
overtime.
However, this
benefit comes
at a large cost
in terms of
increasing the
diagnosis and
treatment of
cancers that
would not have
gone on to
cause any
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problems.
Moreover, the
harms of
screening begin
to accrue
immediately,
whereas the
potential
benefits are
realized only
many years
later.

This systematic review
of 52 references from
1991-2007 is
comprehensive, reliable
and objective.

Strengths/
Limitations

Strengths
include
providers
blinded to the
fact that their
patients were
participating in
a trial. Followup interviewers
were blinded
from
intervention
assignment, but
the statisticians
conducting the
analysis were
not. All authors
were involved
in the
development of
the pamphlet
but none were

Interesting
informative
nonbiased
lecture.

Strength is a
succinct
summary of
harms and
benefits with an
illustrative table
of cohort of
1000 men.
Limitation is
level 7
evidence.
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involved in the
development of
the video.
Limititations
include the
generalizability
to the
population
since this
involved VA
patients who
are usually low
income and/or
service
connected.

Funding
Source

Urologic Nursing
Editorial Board
Statements of
Disclosure: Bradway,
PhD, RN is on the
Consulting Board for
Boehringer Ingelheim
Pharmaceuticals;
Gaines, MS,
ARNP,CUNP is on the
Speakers' Bureau for
Pfizer, Inc., and
Novertis Oncology;
Russell, MN, CMSRN
is on the Advisory
Board for
Roche/Abbott Labs

Funded by VA
Health Services
Research and
Development
Service grant #
11R 99 277-1
to the Center
for Chronic
Disease
Outcomes
Research,
Veterans
Affairs Medical
Center,
Minneapolis
Minn.

Faculty
disclosure: In
adherence to
ACCME
Standards for
Commercial
Support, AudioDigest requires
all faculty and
members of the
planning
committee to
disclose relevant
financial
relationships
within the past
12 months that
might create any
personal
conflicts of
interest. For this
program, the
faculty and
planning
committee
reported nothing
to disclose.

Dr. Pignone is
supported by
Established
Investigator
Award 5K05
CA129166
from the
National
Cancer Institute
and by the
Foundation for
Informed
Medical
Decision
Making.
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Comments

This systematic review
of 52 referenced from
1991-2007 is
comprehensive, reliable
and objective.
Informative article that
traces the origins of the
PSA and lists the
inconsistent
recommendations for
prostate cancer
screening among nine
major health care
organizations.

This study hit
close to home
because it took
place at four
Midwestern
Veterans
Affairs medical
facilities. A
low-cost
pamphlet is an
attractive
option because
it is easy to
implement.

This informative
lecture about
setting evidencebased priorities
is in line with
promoting
evidence based
practice.

Excellent
editorial which
simplifies the
issue.
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Article Title
and Journal

Author /
Year

Article 3
Clinical
consequences of
screening for
prostate cancer:
15 years followup of a
randomized
controlled trial in
Sweden
European
Urology
Sandblom,G.,
Varenhorst, E.,
Lofman, O.,
Rosell,J.,
Carlson, P.
(2004)
Database
searched:
Cochrane Library

Database
and
Keywords

Keywords in the
article are
prostate cancer;
screening;
survival; tumour
stage; treatment;
digital rectal
examination;
prostate-specific
antigen
Article includes
17 references and
two editorial
comments.

Article 1
Screening and
Prostate-Cancer
Mortality in a
Randomized
European Study
The New
England Journal
of Medicine

Article 25
Enthusiasm for
cancer screening
in the United
States. JAMA.

Article 28
Risk profiles and
treatment patterns
among men
diagnosed as
having prostate
cancer and a
prostate-specific
antigen level
below 4.0 ng/ml.
Arch Intern
Medicine.
Schroder, F.,
Schwartz, L.,
Shao, Y.,
Hugosson, J.,
Woloshin, S.,
Albertson, P.,
Roobol, M.,
Fowler, F.,
Roberts, C.,
Tammela, T.,
Welch, G. (2004). Yong, L., Mehta,
Ciatto, S., Nelen,
A., Stein, M.,
V.,…Auvinen,A.(
DiPaola, R., Lu2009).
Yao, G. (2010).
Database
Database
Database
searched:CINHL searched:
searched:
CINHL with Full CINHL with Full
and Cochrane
Text.
Text.
Library
Keywords used to
Keywords used to
Keywords used to search: Cancer
search include:
search include:
screening.
prostate cancer,
prostate cancer,
cancer screening,
cancer screening,
prostate specific
prostate specific
antigen (PSA),
antigen (PSA),
and clinical
and clinical
guideline.
guideline
The article
includes 31
references.

The article
includes 26
references.

109

Research
Design

From the total
population of
men aged 50-69
years in
Norrkoping
(n=9026) every
sixth man
(n=1494) was
randomly
selected to be
screened for
prostate cancer
every third year
over a 12-year
period. The
remaining 7532
men were treated
as controls .In
1987 and 1990
only DRE was
performed, in
1993 and 1996
DRE was
combined with a
test for PSA.
Level 2: RCTs

Level of
Evidence

Study Aim /
Purpose

To characterize
prostate cancers
detected in a
population-based
screening
programme and
to evaluate the
effectiveness of
screening with
three-year
intervals.

Randomized
,multicenter trial
of screening for
prostate cancer,
with the rate for
death from
prostate cancer as
the primary
outcome

Survey using a
national
telephone
interview of
adults selected by
random digit
dialing,
conducted from
December 2001
through July
2002.

Data from the
Surveillance,
Epidemiology,
and End Results
system were used
to describe
patient
characteristics
and treatment
patterns in men
with newly
diagnosed
prostate cancer.

Level 2 :
randomized
controlled
trials(RCTs)
The European
Randomized
Study of
Screening for
Prostate Cancer
was initiated in
the early 1990s to
evaluate the
effect of
screening with
prostate-specificantigen (PSA)
testing on death
rates from
prostate cancer.

Level 6: Single
descriptive or
qualitative study.

Level 6: Single
descriptive or
qualitative study.

To determine the
public's
enthusiasm for
early cancer
detection.

To determine the
risk profile and
treatment patterns
among men
diagnosed as
having prostate
cancer and a
prostate-specific
antigen level
below 4.0 ng/ml.
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Population
Studied /
Sample Size
/ Criteria /
Power

Methods /
Study
Appraisal /
Synthesis
Methods

Participants were
Norrkoping males
aged 50-69 years
of age. The
screened cohort
diminished from
1492 men at the
start of the study
to 1118 in 1996
due to migration
and death. Data
on survival was
complete for the
whole cohort
including those
who migrated.

Compared mass
screening for
prostate cancer to
no screening;
RCT in
Norrkoping,
Sweden.
Interventions
were screening
every 3 years
versus control
(not invited for
screening). The
1st and 2nd
rounds of
screening were
DRE; the 3rd and
4th rounds were
DRE and PSA
test.
Transurethral
ultrasound biopsy
was performed if
DRE abnormal or
PSA > 4.0ng/ml.

A total of
162,387 men in
the core age
group underwent
randomization; of
these men 72,952
were assigned to
the screening
group and 89,435
to the control
group. A total of
62 men in the
screening group
and 82 men in the
control group
died between
identification and
randomization.
Compared mass
screening for
prostate cancer to
no screening: The
researchers
identified
182,000 men
between the ages
of 50 and 74
years through
registries in seven
European
countries for
inclusion in the
study. The men
were randomly
assigned to a
group that offered
PSA screening at
an average of
once every 4
years or to a
control group that
did not receive
the screening.

Five hundred
individuals
participated
(woman aged >/=
40 years and men
aged >/= 50
years; without a
history of
cancer).

123934 men
identified from
the SEERS
system with
newly diagnosed
prostate cancer
from 2004 to
2006.

Responses to a
survey with 5
modules: a
general screening
module (e.g.,
value of early
detection, total body computed
tomography); and
4 screening test
modules:
Papanicolaou
test;
mammography;
PSA test; and
sigmoidoscopy or
colonoscopy.

Age-standardized
treatment rates
were calculated
in 5-year age
strata. Logistic
regression was
used to quantify
the odds ratio of
men with lowand high- risk
disease and the
use of radical
prostatectomy or
radiation therapy.

111

Primary
Outcome
Measures
and Results

Primary outcome
was prostate
cancer mortality
at 15 years
follow-up. Also
reported was
clinical stage and
choice of therapy
in men diagnosed
with prostate
cancer across
both screened and
control groups,
and number of
prostate cancers
diagnosed. There
was no
significant
difference in total
or prostate
cancer-specific
survival between
the groups.

Primary outcome
was prostate
cancer mortality
and number of
prostate cancers
diagnosed. Rate
ratio for death
from prostate
cancer in the
screening group,
compared with
the control 0.80.
The absolute risk
difference 0.71
death per 1000
men. 1410 men
would need to be
screened, 48
additional cases
of prostate cancer
need to be treated
to prevent one
death from
prostate cancer.

Most adults
(87%) believe
routine cancer
screening is
almost always a
good idea and
that finding
cancer early
saves lives(74%
said most or all
the time). Less
than one third
believe that there
will be a time
when they will
stop undergoing
routine screening.
Thirty-eight
percent of
respondents had
experienced at
least 1 falsepositive screening
test; more than
40%
characterized that
experience as
"very scary" or
the "scariest time
of my life". Yet,
looking back,
98% were glad
they had the
initial screening
test. Most had a
strong desire to
know about the
presence of
cancer regardless
of its
implications: and
56% said they
would want to be
tested for
pseudodiseases.
Seventy-three
percent would

Men with a PSA
level of 4.0 ng/ml
or lower
represent 14% of
incident prostate
cancer cases.
Fifty-four percent
of men diagnosed
as having prostate
cancer and PSA
levels lower than
4.0 ng/ml harbor
low-risk disease,
but over 75% of
them received
radical
prostatectomy or
radiation therapy.
Men with screendetected prostate
cancer and PSA
values lower than
4 ng/ml were
1.49 and 1.39
times more likely
to receive RP and
RT, respectively,
and were less
likely to have
high-grade
disease than men
who had nonscreen-detected
prostate cancer.
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prefer to receive a
total-body cat
scan instead of
$1000 in cash.

Although PSA
had not been
introduced in the
clinical practice
at the start of the
study, still able to
show that
possible to
perform a longAuthor
Conclusions term populationbased randomized
/
Implications controlled study
with standardized
of Key
management and
Findings
that screening in
general practice
is an efficient
way of detecting
localized prostate
cancer.

PSA-based
screening reduced
the rate of death
from prostate
cancer by 20%
but was
associated with a
high risk of
overdiagnosis.

The public is
enthusiastic about
cancer screening.
This commitment
is not dampened
by false-positive
test results or the
possibility that
testing could lead
to unnecessary
treatment. This
enthusiasm
creates an
environment ripe
for the premature
diffusion of
technologies such
as total-body
CAT scans,
placing the public
at risk of over
testing and

Most men
diagnosed as
having prostate
cancer with a
PSA threshold
below 4.0ng/ml
had low-risk
disease but
underwent
aggressive local
therapy.
Lowering the
biopsy threshold
but retaining our
inability to
distinguish
indolent from
aggressive
cancers might
increase the risk
of overdiagnosis
and
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overtreatment.

overtreatment.
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According to
the 2010
Cochrane
Screening for
prostate cancer
(Review) there
was no
adequate
sequence
generation; no
allocation
concealment;
not blinded to
the screening
intervention;
unclear
incomplete
outcome data
addressed;
unclear if free
of selective
reporting
Strengths/
Limitations

According to the
2010 Cochrane
Screening for
prostate cancer
(Review) there
was adequate
sequence
generation;
allocation
concealment
unclear;
intervention not
blinded but
causes of death
evaluated in a
blinded manner;
incomplete
outcome data was
addressed; it was
free of selective
reporting but
unclear if the
study was free of
other bias.

Potential
limitations: 5%
of adults living
in households
without phones
were not
represented.
Although
response rate
was good, 72%
among
individuals
known to be
eligible and
51% among
those estimated
to be eligible,
systematic bias
between
respondents
and
nonrespondents
is still possible.
Findings about
false-positive
PSA tests
results are
based on only
10 men and
should be
interpreted
cautiously.

The analysis
was limited by
the nature of
the data source.
The SEER
system collects
information
from all
patients in 16
registries. The
Gleason scores
and PSA values
recorded by the
SEER system
reflect the
information
that was used
to make
clinical
decisions. The
SEER system
does not record
information
such as
percentage of
free PSA or the
number of
positive scores
found on
biopsy
analysis. The
major strength
is the large
sample size
that is
population
based and
includes
patients from
defined
geographic
areas in all
clinical settings
rather than
selected
institutes.
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Comments

Excellent large
randomized
control study
with complete
follow up data
at 15 years but
high risk of
bias. This
study shows it
is possible to
perform a
randomized
controlled study
of prostate
cancer
screening, with
a registration
allowing for
unbiased
comparisons
between the
screened group
and control
group. This is
the first
published
populationbased
randomized
controlled trial
on prostate
cancer
screening with
complete data
on tumor stage,
tumor grade
and treatment
for the control
group as well as
the intervention
group.

Excellent large
randomized
control study
with low risk of
bias. To prevent
1 death from
prostate cancer
1410 men would
need to be
screened and 48
additional cases
of prostate cancer
would need to be
treated; that
seems like a high
price to pay.

The public’s
enthusiasm
about cancer
screening is
short sighted
and is driven in
part by a
paternalistic
health care
system.
Medicine and
health care
needs to get out
of the business
of prediction,
including
tampering with
Mother Nature,
and back into
the business of
healing. The
increased breast
cancer
incidence
observed in
many Western
countries in the
late 1980s and
1990s was due
in part to use of
postmenopausal
hormone
therapy. Oral
contraceptive
use is
associated with
increased breast
cancer
incidence.
Prostate cancer
is a hormone
driven disease,
yet some men
are treated with
testosterone.
The
counterintuitive

By doing
biopsies on
patients with
PSA values in
the "normal"
range the
sensitivity and
specificity of
the PSA test
can be
determined.
Usually
patients with
low PSA levels
are not brought
back for
sequential
and/or
simultaneous
testing because
prostate
biopsies and
transrectal
ultrasounds are
no fun,
expensive, and
invasive. Data
will now be
available in 4
cells which is
precisely what
is needed to
determine the
validity of the
PSA test.
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practice of
treating normal
physiologic
states, such as
fertility, painful
periods,
menopause, and
andropause
with hormones
know to cause
cancer is what
the public
should be
enthusiastic
about stopping.
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Article Title
and Journal

Author /
Year

Article 15
Urinary and
sexual function
after radical
prostatectomy for
clinically
localized prostate
cancer. The
prostate cancer
outcomes study.
Journal of the
American
Medical
Association.
Stanford, J.,
Feng, Z.,
Hamilton, A.,
Gilliland,
Stephenson, R.,
Eley, J., Potosky,
A. (2000).
Database
searched:
CINAHL with
Full Text.

Article 11
The Fall in
Incidence of
Prostate
Carcinoma: On
the Down Side of
a Prostate
Specific Antigen
Induced Peak in
Incidence--Data
from the Utah
Cancer Registry.
Cancer

Article 8
Reflection: The
problem with
choice: What my
mechanic taught
me about PSA
screening.
Canadian Family
Physician

Article 14
Estimating lead
time and
overdiagnosis
associated with
PSA screening
from prostate
cancer incidence
trends. The
International
Biometric Society

Stephenson.
Smart, C.,
Mineau, G.,
James, B.,
Janerich, D., &
Dribble, R.
(1995).
Database
searched: Google
Scholar

Suss,R.(2008)

Telesca, D.,
Etzioni, R.,
Gulati, R.(2008).

Database
searched:
CINAHL with
Full Text.

Database
searched:
MEDLINE

Author’s database
includes Utah
Cancer Registry,
and Surveillance,
Epidemiology,
and End Results
Author’s database (SEER) national
includes
registry.
population-based
cancer registries
Keywords
in six geographic include prostate
areas of the
carcinoma,
United States.
screening,
incidence,
The article
mortality, and
includes 20
prostate specific
references.
antigen.
Keywords:
Prostate cancer
treatment , side
effects

Database
and
Keywords

The article
includes 50
references

Keywords:
decision making,
health screening,
PSA, prostatic
neoplasms

The article
includes 2
references.

Author’s database
includes prostate
cancer incidence
trends derived
from the
Surveillance,
Epidemiology
and End Results
(SEER) registry
of the National
Cancer Institute
Key words
include Additive
models; Cancer
screening;
Convolution
models; Lead
time Distribution;
Penalized
likelihood.
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The article
includes 23
references

The Prostate
Cancer Outcomes
Study, a
population-based
longitudinal
cohort study with
up to 24 months
of follow up.

Tracked ageadjusted prostate
carcinoma
incidence trends
from the
population-based
Utah Cancer
Registry and
compared them
with rates from
the Surveillance,
Epidemiology,
and End Results
(SEER) Program.

The journal
article is a letter
by Dr. Suss, a
Canadian Family
Practice Doctor
and Assistant
Professor in the
Department of
Family Medicine
at the University
of Manitoba in
Winnipeg

Level 4: Cohort
study.

Level 6:Single
descriptive study

To measure
changes in
urinary and
sexual function in
men who have
undergone radical
prostatectomy for
clinically
localized prostate
cancer.

The Utah Cancer
Registry data
were examined
for a decrease in
prostate cancer
incidence.

Level 7:
Opinions of
authorities/
experts
The author
questions whether
it is right to ask
patients to decide
if they want to be
screened for
prostate cancer.

Research
Design

Level of
Evidence

Study Aim /
Purpose

Research design:
Conceptualized
observed
incidence as the
sum of the
secular trend in
incidence, which
reflects incidence
in the absence of
PSA, and the
excess incidence
over and above
the secular trend,
which is a
function of
population
screening patterns
and unknown
lead time.
Level 6: Single
descriptive or
qualitative study
The primary goal
is to estimate the
lead time
distribution
associated with
PSA screening
utilizing
population
screening and
disease incidence
trends to make
inferences.
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Population
Studied /
Sample Size
/ Criteria /
Power

Methods /
Study
Appraisal /
Synthesis
Methods

A total of 1291
black, white, and
Hispanic men
aged 39 to 79
years diagnosed
as having primary
prostate cancer
between October
1, 1994, and
October 31, 1995,
and who
underwent radical
prostatectomy
within six months
of diagnosis for
clinically
localized disease.
Men diagnosed as
having primary
prostate cancer
between
10/1/1994 and
10/31/1994 who
were residents of
areas covered by
6 population
based SEERs
registries. A total
of 11137 eligible
cases were
identified, and
5672 were
randomly
sampled for
PCOS. Of the
sampled cases,
4736(83.5%)
were contacted
and invited to
participate, and
3533(62.3%)
completed a 6and/or 12-month
survey. Medical
record abstracts
were completed
for 3486 (98.7%)

Conservatively
Not applicable
estimated Utah
prostate
carcinoma
incidence for
1994. The state of
Utah had a
current
population of
1,907,936 with
167,840 men
older than age 50
years.

Not applicable

Rapid case
ascertainment
methods used to
estimate Utah
prostate
carcinoma
incidence for
1994.

The present
analysis includes
men aged 50-64,
whereas the
previous study
considered only
men aged 65 and
above. After
conceptualizing
observed
incidences two
likelihood models
were developed:
likelihood model
for the excess
incidence given
the secular trend
and used it to
estimate the mean
lead time under
specified
distributional
assumptions and
a likelihood
model for
observed
incidence and use
it to
simultaneously
estimate the mean

Reflection
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of the sampled,
participating
cases. For
analysis of
surgery, all PCOS
patients aged 39
to 79 years with
histologically
confirmed,
clinically
localized prostate
cancer who
underwent radical
prostatectomy as
primary treatment
within 6 months
of diagnosis date
and who had both
survey and
medical records
data(n=1301).

Primary
Outcome
Measures
and Results

Primary outcome
measures are
distribution of
and change in
urinary and
sexual function
measures
reported by
patients at
baseline and 6,
12, and 24
months after
diagnosis. At 18
or more months
following radical
prostatectomy,
84.4 % of men
were incontinent
and 59.9% were

lead time together
with a smooth
secular trend.
Variances and
confidence
intervals are
estimated using
via a parametric
bootstrap.

A rapid and
highly correlated
rise in prostate
carcinoma
incidence has
been observed in
both SEER and
Utah incidence
rates between
1988 and 1991,
the last year for
which SEER data
are available. In
1992, Utah
incidence rates
peaked at 236.2
per 100,000. In
1993 and 1994,
Utah incidence

Dr. Suss uses the
analogy of his car
mechanic asking
him what type of
fuel filter he
wants. He knows
nothing about
fuel filters (the
means), he knows
he wants his car
to run well at a
reasonable price
(the end). A
healthy 50-yearold male wants to
live as long as
possible without
incontinence and
impotence (the

Outcome
measures and
results: Estimates
correspond to
overdiagnosis and
frequencies of
approximately
22.7% and 34.4%
for screendetected whites
and blacks,
respectively.
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impotent.

Study suggests
that radical
prostatectomy is
associated with
significant
erectile
dysfunction and
some decline in
urinary function.
These results may
be particularly
helpful to
physicians and
their patients with
prostate cancer
Author
Conclusions who face difficult
treatment
/
Implications decisions.
of Key
Findings

rates fell to 195.0,
and an estimated
164.0 per
100,000
respectively.

end) so why ask
him whether he
wants a PSA
screening test.

Population-based
data from the
Utah Cancer
Registry indicates
the incidence of
prostate
carcinoma is
decreasing
rapidly after a
similarly rapid
increase.
Documented
increases in
incidence for
years prior to
1992, as well as
projections for
1992 through
1995, raised
concerns
including
economic impact,
rising rate of
treatment without
documented
therapeutic
efficacy,
treatment related
morbidity, and
screening leading
to identification
and treatment of
clinically or
biologically

The author
contends we
should leave the
means to the
experts, such as
car mechanics
and doctors, and
the ends with
individuals who
are experts at
what they want. It
is difficult to do
this though when
the American
Cancer Society
recommends
discussing the
pros and cons
with patients so
they can make an
informed decision
about having a
PSA screening
test (means).

Likelihood-based
approach allows
authors to make
formal inferences
about the lead
time and
overdiagnosis
associated with
PSA screening in
the United States.
The model
provided the first
glimpse of a
secular trend in
disease incidence
and finally the
authors provided
some provocative
insights about
racial disparities
in prostate
cancer.
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unimportant
cancers.

Strengths/
Limitations

This study
provided the first
description of
outcomes
experienced by a
cohort of
unselected,
population-based
patients who have
undergone radical
prostatectomy. In
addition to its
population based
design, strength
of the study is the
large number of
patients.
Limitations
include only
62.3% sampled
men participating
and a 24-month
survey was not
completed by
19.2% of those
who had
completed an
earlier survey.
Recall bias is

Quantitative data
comparing
prostate cancer
rates from two
reputable sources
showing that the
increase in
prostate
carcinoma
incidence
between 1984 1991 was largely
attributed to the
increased use of
PSA in prostate
carcinoma
detection and
screening
including media
coverage.

The author
concludes that it
is unreasonable to
have patients
make choices
about means
when thousands
of doctor’s can’t
agree if PSA
screening results
in any benefit.

Strengths and
limitations: This
article presented
a novel method
for making
formal inferences
about lead time
and overdiagnosis
from population
incidence trends
in the context of
PSA screening.
The model
approach is based
on the additive
relationship
between the
excess incidence,
which depends on
the lead time, and
the secular
incidence trend;
this provides a
formal method
for inferring a
plausible secular
trend. The
limitations to the
analysis are
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another potential
limitation since
baseline
(prediagnosis)
function was
assessed on the 6month survey.

Funding
Source

The study was
supported by
contracts from
the National
Cancer Institute
in Bethesda,
Maryland

uncertainty about
the PSA
screening
frequencies and
cancer detection
rates thus the
confidence
intervals are
narrow. A
second limitation
is the use of a
specified
parametric
distribution for
the lead time.

1996 American
Cancer Society.
Presented at the
90th Annual
Meeting of the
American
Urological
Association, Las
Vegas, April 26,
1995.

Competing
interests: None
declared

Funding source:
The article was
supported by the
grants from
Cancer
Intervention and
Surveillance
Network
(CISNET) and
from the National
Cancer Institute.
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Informative
population-based
longitudinal study
with up to 24
months of followup.

Comments

A screening
phenomenon
called a "cull
effect” explains
the shortcomings
in prostate cancer
incidence
predictions
starting in 1992.
When a testing
method is applied
to a relatively
static population
of prevalent
disease, an initial
rapid rise in
detection and
hence incidence
will be observed.
As the cull effect
removes
individuals with
prostate cancer
from the
population, the
population
becomes
progressively
depleted of
detectable cases.

This journal
reflection is very
insightful and a
delight to read.

Technical article
with multiple
graphs of
incidence trends
and statistical
formulas throughout.
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Article Title
and Journal
Author /
Year

Database
and
Keywords

Research
Design
Level of
Evidence

Study Aim /
Purpose

Population
Studied /
Sample Size
/ Criteria /
Power

Article 21
Trials of decision aids for prostate
cancer screening: A systematic
review. American Journal of
Preventative Medicine.
Volk, R., Hawley, S, Kneuper, S.,
Holden, W., Stroud, L., Cooper, C.,
…Pavlik, V. (2007)
Medline was searched with key words
"prostate cancer screening" and
"decision making" for articles
published through 2006. A 2003
Cochrane review, a 2002 evidence
report by the Agency for Healthcare
Research and Quality, and a review
by Evans et al. were examined to
identify studies on prostate cancer
screening decision making. Reference
lists from relevant articles were also
reviewed. Finally, published abstracts
and subsequent full papers from
annual meetings of the Society for
Medical Decision Making, the
American Society of Preventive
Oncology, and the Society of
Behavioral Medicine were examined.
A systematic review

Article 30
Editorial: Health care reform: Shared
decision making for prostate cancer
screening: Do patients of clinicians
have a choice? Arch Intern Med
Woolf, S., Krist, A. (2009).

Level 1: Systematic review

Level 7 :Opinion of expert/authority

Patient decision aids are used to
promote informed decision making.
This review examines the methods
and findings of studies that have
evaluated the impact of prostate
cancer screening decision aids on
patient outcomes.

The uncertainty of PSA testing -and
thus the logic for shared decision
making (SDM)--persists, but there are
questions about whether SDM occurs
in practice, how well it is performed,
and whether clinicians support SDM
or find it feasible. This editorial aims
to see if patients of clinicians have a
choice.
This is an editorial. Discussed
Hoffman et al's telephone survey of
375 men who had either undergone
PSA testing or discussed prostate
cancer screening with a clinician in
the previous 2 years.

Eighteen eligible trials, involving
6221 participants, were identified.
Sixteen studies enrolled primary care
patients, while the remaining two
studies were community based.

Database searched: CINAHL with
Full Text.
Keywords: decision making, health
screening, PSA.
Article has 20 references

Editorial
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MEDLINE, the Cochrane Registry,
reference lists, and abstracts from
Methods /
professional meetings were searched
Study
through December 2006. Studies were
Appraisal /
included if a patient education
Synthesis
intervention for prostate cancer
Methods
screening had been evaluated against
a control condition.
Summary of outcome findings from
18 published controlled trials of
patient decision aids for prostate
cancer screening are listed on five
horizontal pages. Knowledge of
prostate cancer screening was the
most common outcome, with 14 of 18
studies including such a measure.
Intention to be screened was lower
among decision-aid participants than
control participants in six of the nine
studies. The patient decision aides
improved patient knowledge and
Primary
made patients more confident about
Outcome
their decisions. The aids appeared to
Measures
and Results decrease interest in PSA testing and
screening behavior among patients
seeking routine care (relative
risk=0.88, 95% confidence interval,
p=0.008); the aides had no impact on
the screening behavior of patients
seeking screening services. Patients
who received patient decision aids
were more likely to prefer watchful
waiting as a treatment option if they
were found to have prostate cancer
than were controls(RR=1.53, 95%
CI=1.31-1.77, p <0.001)
Prostate cancer screening decision
aids enhance patient knowledge,
decrease decisional conflict, and
promote greater involvement in
Author
Conclusions/ decision making. The absence of
Implications outcome measures that reflect all
elements of informed decision making
of Key
continues to limit the field.
Findings

Editorial

According to Hoffman's study 70%
recalled a discussion that preceded the
testing decision, but only one-third
remembered discussing any
counterarguments to screening.

The larger cultural context helps
explain the inertia of the health care
system in implementing SDM.
Making SDM feasible also requires
changes in the practice environment,
beginning with tort reforms that
protect clinicians who give patients an
informed choice about cancer
screening , as well as reimbursement
reform to facilitate the time
investment for such counseling.

128

Strengths/
Limitations

Funding
Source

Comments

This level one study had no apparent
limitations. The strength relates to its
in depth review with 18 trials,
involving 6221 participants, and high
quaility searches including Cochrane
reviews.
The project was funded in part by
grants from the Centers for Disease
Control and Prevention and the
Agency for Healthcare Research and
Quality.
Decision aids help patients take a
more active role in making a decision
about prostate cancer screening. There
needs to be aids for patients with low
health literacy.

Provocative editorial. Limitation is
Level 7 evidence.

No financial disclosure

Points out the problems implementing
shared decision making.

Systematic Review Evidence Table Format (adapted with permission from Thompson, C.
(2011). In J. Houser & K.S. Oman (Eds.), Evidence-based practice: An implementation guide
for healthcare organizations (p.155). Sudbury, MA: Jones and Bartlett.

Reference:

Tymkow, C. (2011). Clinical scholarship and evidence-based practice. In M.E. Zaccagnini &
K. W. White, K. W (2011). The doctor of nursing practice essentials: A new model for
advanced practice nursing (pp. 61-136). Sudbury, MA: Jones and Bartlett.
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Appendix B
Basic Prostate Cancer Screening Educational Pamphlet

Let’s see what you know:
1) Can the PSA test help find prostate cancer early at a stage when potentially curative
treatments can be offered?
Check Only One: Yes  No 
2) Does prostate cancer usually lead to death?
Check Only One: Yes 
No 
3) Does all prostate cancer cause harm?
Check Only One Yes  No 
4) Is the prostate-specific antigen (PSA) blood test a good cancer screening test?
Check Only One: Yes No 
5) What are the major side effects of prostate cancer treatments?
Check Only One: None Impotence and Incontinence  Bowel Problems  Nausea

Screening for prostate cancer with a Prostate Specific Antigen (PSA) blood test starting
at age 50, and age 45 for high risk men, means looking for cancer before it causes symptoms.
Men with serious health problems, or age 75 or older, should not be offered screening. Prostate
cancer screening can find cancers early when a cure may be possible but it often finds cancer
which would never have caused problems. It is very important to know about the risks and
benefits of screening before the decision to be screened or not is made.
The prostate gland is approximately the size of a walnut. It is located in front of the
rectum, directly below the bladder, encircling the urethra, the tube which empties urine from the
bladder (figure 1). The back of the prostate gland can be felt during a digital rectal exam (figure
2). The prostate gland helps control urine flow and normal sexual function. Prostate cancer
treatment can lead to urinary incontinence and impotence, the inability to have sex.
Prostate cancer is the second leading cause of cancer death in U.S. males next to lung
cancer. For an American male, the lifetime risk of developing prostate cancer is 16 men out of
100, but the risk of dying of prostate cancer is only 3 men out of 100.

130

(http://seer.cancer.gov/csr/1975_2004). Black men, and men with a first degree relative
diagnosed with prostate cancer before age 65, are at increased risk.
The key points therefore to be aware of prior to undertaking a PSA test are the following:
•
•
•
•
•
•
•
•

The PSA test facilitates the early detection of prostate cancer at a stage when potentially
curative treatments can be offered.
There is currently no strong evidence that PSA testing reduces death from prostate
cancer.
Not all men with raised PSA will have prostate cancer/the PSA test will not detect all
prostate cancer.
Prostate cancer is diagnosed through a prostate biopsy which can be uncomfortable or
painful.
Prostate biopsies will not detect all prostate cancers.
Prostate cancers range from aggressive to slow growing forms-slow growing tumors may
not result in symptoms or shorten life expectancy.
There is no evidence about the optimum treatment for localized prostate cancer.
Some treatments for prostate cancer can have significant side effects.

(Clements et al. BMC Family Practice 2007 8:35 doi: 10.1186/147-2296-8-35)
Ask yourself about how you feel about the possible benefits and harms of being screened:
•
•
•
•
•

Do I want to know if I have prostate cancer, even if the cancer might never do me any
harm?
Would I be treated if I learned that I had prostate cancer?
How do I feel about the risks of being treated for prostate cancer?
How do I feel about the risks of getting a deadly or aggressive form of prostate cancer?
Would I be willing to accept a high risk of side effects from treatment in return for a
small chance of living longer?

(Patient information: Prostate cancer screening (PSA tests) (The Basics) 2011 UpToDate,
www.uptodate.com)

Let’s see what you now know:
1) Can the PSA test help find prostate cancer early at a stage when potentially curative
treatments can be offered?
Check Only One: Yes  No 
2) Does prostate cancer usually lead to death?
Check Only One Yes No 
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3) Does all prostate cancer cause harm?
Check Only One: Yes No 
4) Is the prostate-specific antigen (PSA) blood test a good cancer screening test?
Check Only One: Yes No
5) What are the major side effects of prostate cancer treatments?
Check Only One: None Impotence and Incontinence  Bowel Problems  Nausea

132

Prostate gland

Figure B - 1: Prostate Gland
This drawing shows the male anatomy and a close-up of the prostate gland. Reproduced with
permission from: Patient information: Prostate cancer screening (PSA tests) (The Basics). In:
UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA, 2011. Copyright © 2011 UpToDate,
Inc. For more information visit www.uptodate.com.
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Figure B - 2: Rectal Exam
During a digital rectal exam, the doctor or nurse puts a finger inside your rectum and feels your
prostate gland. That way he or she can see how big it is and whether it has bumps or dents or
anything unusual. Reproduced with permission from: Patient information: Prostate cancer
screening (PSA tests) (The Basics). In: UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA,
2011. Copyright © 2011 UpToDate, Inc. For more information visit www.uptodate.com.
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Appendix C
Detailed Prostate Cancer Screening Educational Pamphlet

Screening for prostate cancer with a Prostate Specific Antigen (PSA) blood test starting
at age 50, and age 45 for high risk men, means looking for cancer before it causes symptoms.
Prostate cancer screening leads to increased cancer diagnosis, modest mortality reduction
(death), and substantial morbidity (illness). It is imperative therefore to be well informed about
the risks and benefits of screening before the decision to be screened or not is made.
The prostate gland is approximately the size of a walnut. It is located in front of the
rectum, directly below the bladder, encircling the urethra, the tube which empties urine from the
bladder (see picture). The back of the prostate gland can be felt during a digital rectal exam.
The prostate gland helps regulate bladder control and normal sexual function (erection and
ejaculation), including storage and production of seminal fluid, a white milky substance which
nourishes sperm.
The prostate gland is prone to problems. Prostatitis, inflammation of the gland, can cause
painful urination and ejaculation. Benign Prostatic Hypertrophy (BPH), a condition common to
aging men, is caused by the slowly enlarging prostate gland putting pressure on the urethra
making it difficult to urinate. And finally, the prostate gland can develop cancer, ranging from a
silent condition which does not spread and/or cause symptoms, to invasive disease spreading to
nearby organs and bone, ultimately leading to death.
Prostate cancer is the second most frequently diagnosed cancer and the sixth global
leading cause of cancer death. Incidence rates vary by more that 25-fold worldwide; the highest
rates are in developed countries that utilize PSA testing which detects clinically important
tumors as well as other slow growing cancers that may never have caused problems [1]. In the
U.S. in the late 1980’s when prostate cancer screening with a PSA blood test came into vogue
incidence rates rose from 84.4/100,000 cases in 1984 to 163/100,000 cases in 1991 [2]. Since
the early 1990’s prostate incidence has been declining although it is still the second leading
cause of cancer death in U.S. males next to lung cancer. For an American male, the lifetime risk
of developing prostate cancer is 16 percent, but the risk of dying of prostate cancer is only 2.9
percent [3].
Most prostate cancers detected in the U.S. are asymptomatic, clinically localized, and
found on routine PSA testing [4]; this correlates with the new cases of prostate cancer at the
Denver VA. Prostate cancer data for 2008-2010 was obtained from the Eastern Colorado Health
Care System Tumor Registry. There were 209 cases of prostate cancer diagnosed since 2008
except for new patients arriving with the diagnosis. At least 75% of the cases were clinically
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localized. The largest groups of men to receive the diagnosis (76%) were in their fifties and
sixties.
PSA is a glycoprotein found in both normal and cancerous prostate glands. The absolute
value of serum PSA is used to determine the extent of prostate cancer and a patient’s response to
treatment. The use of PSA as a screening test is controversial because its’ ability to identify
correctly those who have the disease (sensitivity) is overestimated and its’ ability to identify
correctly those who do not have the disease (specificity) is underestimated [5].
Mass population PSA testing was initiated in the late 1980’s without well-conducted
randomized clinical trials to support the benefit of screening. In 2009, two ongoing randomized
trials of PSA screening provided the first quantitative estimates of the survival benefits due to
early detection. The prostate arm of the National Cancer Institute-sponsored Prostate, Lung,
Colorectal, and Ovarian Cancer Screening Trial found no survival benefits from annual PSA
screening combined with digital rectal exam. A larger similar European trial of men aged 50 to
74 years found a 20% reduction in prostate cancer mortality following PSA screening every four
years. This means that 1410 men needed to be screened, and 48 men needed to receive early
treatment in order to prevent one cancer death at ten years [6]. Both trials found clear evidence
of overdiagnosis.
Diseases diagnosed earlier by screening, versus later when symptoms develop, lead to
earlier treatments (lead time). Unfortunately patients often die at the same time, thus all lead time
did was cut off quality years of life. One of the pitfalls of the PSA test is that it markedly
increases the lead time resulting in overdiagnosis because death from other-causes precedes the
date of symptomatic disease and/or occurs during the lead time [7]. Therefore the modest
absolute reduction in prostate cancer over time comes at the cost of treating clinically irrelevant
cancers. Additionally, the harms of screening start immediately whereas the potential benefits
are not realized for years to come [8].
The key points therefore to be aware of prior to undertaking a PSA test are the following:
•
•
•
•
•
•
•

the PSA test facilitates the early detection of prostate cancer at a stage when potentially
curative treatments can be offered\
there is currently no strong evidence that PSA testing reduces mortality from prostate
cancer
not all men with raised PSA will have prostate cancer/the PSA test will not detect all
prostate cancer
prostate cancer is diagnosed through a prostate biopsy which can be uncomfortable or
painful
prostate biopsies will not detect all prostate cancers
prostate cancers rage from aggressive to slow growing forms-slow growing tumors may
not result in symptoms or shorten life expectancy
there is no evidence about the optimum treatment for localized prostate cancer
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•

some treatments for prostate cancer can have significant side effects [9].
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Figure C - 1: Detailed Pamphlet (Front Side)

Figure C - 2: Detailed Pamphlet (Back Side)
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Appendix D
Conceptual Model for Informed Prostate Cancer Decision Making

Denver VAMC male
patients starting at 50
years old and 45 years
old for high risk

Perceived threat of prostate cancer:
Mass Media Advice from others
Illness of friends and family
Health provider’s advice

Prostate Cancer
Screening Informed

Decision Making

Prostate cancer screening
educational pamphlet

Less PSAs Drawn
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Appendix E
Conceptual Model for Informed Decision Making with the Guidance of Two
Prostate Cancer Screening Educational Pamphlets

Denver VAMC PCPs
in Saturday Intake
Clinic and Firm A

Perceived threat of prostate
cancer:
Mass media
Advice from others
Philosophy of life
Illness of friends and family
Health provider’s advice

Prostate cancer screening
educational pamphlets

Prostate Cancer
Screening Informed
Decision Making
Guidance

Detailed

Basic

Pamphlet

Pamphlet
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Appendix F
Conceptual Model for Informed Decision Making with the Guidance of a Prostate
Cancer Screening Educational Pamphlet

Denver VAMC PCPs
in Saturday Intake
Clinic and Firm A

Prostate Cancer
Screening Informed
Decision Making
Guidance

Detailed
Pamphlet

Perceived threat of prostate
cancer:
Mass media
Advice from others
Philosophy of life
Illness of friends and family
Health provider’s advice

Prostate cancer screening
educational pamphlet
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Appendix G
Logic Model for Prostate Cancer Screening Informed Decision Making (Initial
Capstone)

RESOURCES
Chief of
Ambulatory
Care and
Urology

ACTIVITIES
Approve Prostate
cancer screening
pamphlets
Pamphlets made
and distributed to
clinics

OUTPUTS
# of patients to
receive the prostate
cancer screening
educational pamphlet

OUTCOMES
Perceived
threat of
prostate
cancer
(decreased)

Providers will be
educated about the
Evidence Based
Requirement for
informed decision
making including
the pros and cons
of screening
Number of PSAs
drawn will be
recorded

# of providers
engaging in shared
decision making

Asymptomatic Prostate cancer
men deciding incidence
to be screened (decreased)
for prostate
cancer
(decreased)

# of patients
diagnosed with stage
I and II prostate
cancer (# of prostate
biopsies)

Overdetection
(decreased)

Death rates
(no change)

Urology
Department

Number of
patients referred
for elevated PSA
leading to prostate
biopsy will be
recorded

Overdetection
and treatment
(decreased)

Quality of life
(increased)

Eastern
Colorado
Health Care
System
Tumor

Prostate cancer
data including the
accession year,
date of diagnosis,
clinical stage,

# of patients
diagnosed and treated
for stage I and II
prostate cancer
(watchful waiting,
surgery, radiation,
cryoablation,
androgen deprivation
therapy, highintensity focused
ultrasound therapy )
# of patients
undergoing radical
prostatectomy or
radiation treatment

Treatment
(decreased)

Treatmentrelated urinary,
sexual, and
bowel
dysfunction

Printing
company
Vista and
Microsoft
Office
Outlook Email

Chemistry lab

IMPACTS
Prostate cancer
screening
recommendations
(decreased)
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Registry

pathologic stage,
treatment, and age
at diagnosis will
be recorded

Primary Care
Providers
(PCPs)

PCPs will continue
to educate patients
about the risks and
benefits of
screening and
treatment
PCPs will continue
to educate patients
about the risks and
benefits of
screening and
treatment
PCPs will continue
to educate patients
about the risks and
benefits of
screening and
treatment

Primary Care
Providers
(PCPs)

Primary Care
Providers
(PCPs)

(decreased)

# of patients
diagnosed and treated
for asymptomatic
prostate cancer

Psychological
and physical
stress
(decreased)

Ability to
continue work
(increased)

# of patients visiting
urology and radiation
oncology for
localized prostate
cancer

Surgery and
radiation
(decreased)

Hospitalization
rates
(decreased)

# patients undergoing
prostate biopsies,
surgery, radiation,
cryoablation,
androgen deprivation
therapy, highintensity focused
ultrasound therapy

Health care
dollar use
(decreased)

Efficient use of
health care
dollars
(increased)
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Appendix H
Logic Model for Informed Decision Making with the Guidance of Two Prostate
Cancer Screening Educational Pamphlets (Revised Capstone)

RESOURCES
ACTIVITIES
Colorado
Approve prostate
Multiple
cancer screening
Institutional
pamphlets
Review Board
(COMIRB)

OUTPUTS
Shawn Fury, ECHCS
Medical Media
Program Manager,
produces a few
Detailed and Basic
prostate cancer
screening pamphlets
for the Project.

PCPs in
Saturday
Intake Clinic
(S2) and
PCPs in Firm
A Clinic

# of PCPs to
participate in the
small scale
intervention

Vista and
Microsoft
Office
Outlook Email

PCPs in S2
and Firm A
Clinic after
pamphlet use

Informed about the
Project, a quality
improvement
initiative linked to
assessment of the
two prostate
cancer screening
educational
pamphlets
Providers in Firm
A and S2 will be
educated about the
Evidence Based
Requirement for
informed decision
making including
the latest USPSTF
recommendation
not to screen
healthy men
Discussions about
the usefulness of
the Detailed and
Basic pamphlets

OUTCOMES
Primary Care
Providers
(PCP) in S2
and Firm A
receive
Prostate
educational
materials
(increased)
PCPs use
educational
pamphlets to
guide
informed
decision
making
(increased)

IMPACTS
PCPs receive
guidance from
prostate cancer
screening
educational
pamphlets
(increased)

Prostate cancer
screening
recommendations
(decreased)

# of providers
engaging in shared
decision making

Asymptomatic Prostate cancer
men deciding incidence
to be screened (decreased)
for prostate
cancer
(decreased)

PCPs evaluation of
the prostate cancer
screening educational
pamphlets

The Detailed
and Basic
pamphlet
guided PCPs
with prostate
cancer

The Denver
VAMC adopts
the use of the two
prostate cancer
screening
educational
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Shawn Fury,
ECHCS
Medical
Media
Program
Manager

The pamphlets are
mass produced for
use by the Denver
VAMC

Denver
VAMC PCPs

PCPs will
routinely educate
male veterans
about the risks and
benefits of
screening and
treatment using
the guidance of the
two prostate
cancer screening
pamphlets

All Denver VAMC
PCPs participate in
prostate cancer
screening education
through Vista
Microsoft Outlook Email. (Requirement
for informed decision
making including the
latest USPSTF
recommendation not
to screen healthy
men).
Less number of
asymptomatic
patients undergoing
PSA testing

informed
decision
making
(increased)

pamphlets.

All Denver
VAMC
engage in
informed
decision
making with
the use of the
two pamphlets
(increased)

Asymptomatic
Denver VAMC
men deciding to
be screened for
prostate cancer
(decreased)

Unnecessary
Quality of life
testing,
(increased)
interventions,
and treatments
(decreased)
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Appendix I
Logic Model for Provider Opinion about Guidance Provided by a Prostate Cancer
Screening Educational Pamphlet (Final Capstone)

RESOURCES
ACTIVITIES
Colorado
Approve prostate
Multiple
cancer screening
Institutional
pamphlet
Review Board
(COMIRB)

OUTPUTS
Shawn Fury, ECHCS
Medical Media
Program Manager,
produces Detailed
prostate cancer
screening pamphlets
for the Project.

PCPs in
Saturday
Intake Clinic
(S2) and
PCPs in Firm
A Clinic

# of PCPs to
participate in the
small scale
intervention

Vista and
Microsoft
Office
Outlook Email

PCPs in S2
and Firm A
Clinic after
pamphlet use

Informed about the
Project, a quality
improvement
initiative linked to
assessment of a
Detailed prostate
cancer screening
educational
pamphlets
Providers in Firm
A and S2 will be
educated about the
Evidence Based
Requirement for
informed decision
making including
the latest USPSTF
recommendation
not to screen
healthy men
Discussions about
the usefulness of
the Detailed
pamphlets

OUTCOMES
Primary Care
Providers
(PCP) in S2
and Firm A
receive
Prostate
educational
material
(increased)
PCPs use
educational
pamphlet to
guide
informed
decision
making
(increased)

IMPACTS
PCPs receive
guidance from
prostate cancer
screening
educational
pamphlet
(increased)

Prostate cancer
screening
recommendations
(decreased)

# of providers
engaging in shared
decision making

Asymptomatic Prostate cancer
men deciding incidence
to be screened (decreased)
for prostate
cancer
(decreased)

PCPs evaluation of
the prostate cancer
screening educational
pamphlet

The Detailed
pamphlet
guided PCPs
with prostate
cancer
informed
decision
making
(increased)

The Denver
VAMC adopts
the use of the
Detailed prostate
cancer screening
educational
pamphlet.
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Shawn Fury,
ECHCS
Medical
Media
Program
Manager

The pamphlet is
mass produced for
use by the Denver
VAMC

Denver
VAMC PCPs

PCPs will
routinely educate
male veterans
about the risks and
benefits of
screening and
treatment using
the guidance of the
Detailed prostate
cancer screening
pamphlet

All Denver VAMC
PCPs participate in
prostate cancer
screening education
through Vista
Microsoft Outlook Email. (Requirement
for informed decision
making including the
latest USPSTF
recommendation not
to screen healthy
men).
Less number of
asymptomatic
patients undergoing
PSA testing

All Denver
VAMC
engage in
informed
decision
making with
the use of the
Detailed
pamphlets
(increased)

Asymptomatic
Denver VAMC
men deciding to
be screened for
prostate cancer
(decreased)

Unnecessary
Quality of life
testing,
(increased)
interventions,
and treatments
(decreased)
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Appendix J
Measurement Tool

Prostate Cancer Screening Brochure Survey Questions:
1. Is the pamphlet easy to read?
Yes [ ] Somewhat or Maybe [ ] No [ ]
2. Is the pamphlet informative?
Yes [ ] Somewhat or Maybe [ ] No [ ]
3. Is the pamphlet biased?
Yes [ ] Somewhat or Maybe [ ] No [ ]
4. Do you think it would change decisions of vets to get a PSA?
Yes [ ] Somewhat or Maybe [ ] No [ ]
5. Would you be willing to distribute this out to your patients?
Yes [ ] Somewhat or Maybe [ ] No [ ]
6. Are the graphics appropriate?
Yes [ ] Somewhat or Maybe [ ] No [ ]
7. Will the pamphlet be useful for family members?
Yes [ ] Somewhat or Maybe [ ] No [ ]
8. Is the format of the pamphlet user friendly?
Yes [ ] Somewhat or Maybe [ ] No [ ]
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Appendix K
Time Table Chart

Capstone Project Timeline
8/31/2010
DNR NR 701 Paper
Review of Literature
CITI Training
IRB Process
Proposal Presentation
Project Implementation
Survey Completion
Analysis and Writing
Final Document
Presentation / Defense

3/1/2011

8/30/2011

2/28/2012
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Appendix L
Detailed Time Table of Accomplishments

September 2010-March 2012
September 2010 The author generated a practice safety issue (idea), specifically, the controversy
of screening for prostate cancer with a PSA blood test.
September October 2010

The author developed a problem statement that men over 40 years old who
undergo prostate cancer screening with a PSA blood test, compared to men who
do not undergo screening, suffer more morbidity and decreased quality of life.

September October 2010

The author considered the following questions about prostate cancer that need to
be answered: Does a prostate cancer screening educational pamphlet, proceeded
and followed by the same four test questions, result in informed decision
making, and if so, does informed decision making result in less PSA blood tests
drawn ?

September October 2010

The author developed the PICO: the population of interest is Denver VAMC
males between ages 50-70; the intervention is a prostate educational pamphlet
with returned visit with informed consent; the comparison is the number of PSAs
drawn in a comparable time period without informed decision making; the
outcomes of interest are informed decision making and less PSAs drawn.

September
2010- April
2011
March 2011April 2011

The author conducted a literature review which supported the problem statement.

March 2011April 2011

The author contacted Nelson Jones for prostate data for 2008-2010 from the
Eastern Colorado Health Care System (ECHCS) tumor registry.

The author conducted a needs assessment of Denver VAMC male veterans
including collecting data from the Veteran’s Health Study, an observational
study of health outcomes in patients receiving VA ambulatory care between
1993-1996 in four VA Boston are outpatient clinics (Selim et al., 2004).

January 2011- The author contacted, or met with, Dr. Hans-Olov Adami (Harvard School of
September 2011 Public Health, Department of Epidemiology); VA Research Coordinators; VA
Health System’s Specialist; VA Education personnel; two nurse practitioners in
Urology; Planetree, a consultant firm hired by the VA to improved patient
centered care, and; finally, a meeting with the Assistant to the Chief of Staff and
the Chief of Ambulatory Care in April, 2011 followed by communication with
the Chief of Urology, two VA Oncologists, and continued meetings with the
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Chief of Ambulatory Care.
May 2011

The author revised the Capstone after the April meeting because a return visit for
informed consent is not practical.

June 2011

The author developed two prostate cancer screening educational pamphlets.

June 2011

The author completed Regis Collaborative Institutional Training Initiative (CITI)
training in preparation for starting the Regis IRB process.

July 2011

The author met with Shawn Fury, the ECHCS Medical Media Program Manager,
to discuss design and production of the two prostate cancer screening
educational pamphlets.

July 2011

The author began the Regis and VA IRB process including the Exempt
Application for Colorado Multiple Institutional Review Board (COMIRB).

July –August,
2011

The author contacted Jason Davis, the Journal and Right’s manager at UpToDate
, for approval to use their graphics which he subsequently edited.

August –
September,
2011
September,
2011

The author added a fifth question to the Basic pamphlet to avoid bias.

SeptemberNovember,
2011
SeptemberOctober, 2011

The author communicated and met with a VA Research PhD, RN

tember, 2011

The author changed and simplified the Capstone Project after the (IRB) prereview at the Denver Veteran Affair Medical Center (VAMV) on September 14,
2011.

September,
2011

The author changed the PICO to: the population of interest are PCPs at the
Denver VAMC; the intervention is providing a Detailed (Appendix A) and Basic
(Appendix B) prostate cancer screening educational pamphlet to primary care
providers (PCPs) in two Denver Veteran Affair Medical Clinics (VAMC); the
comparison is the incidence of prostate cancer screening informed decision
making in Denver VA Firm B Primary Care Clinics without the guidance of the
pamphlet ; the outcomes of interest are to be quantified are the provider’s
pamphlet preference (Basic or Detailed) and their opinion ( yes or no) about
whether the prostate cancer screening educational pamphlets offered guidance

The author’s mentor, the Chief of Ambulatory Care backed out of the project,
and was replaced by a PhD RN mentor working in patient safety.

The author completed VA and UCHSC CITI courses in the Protection of Human
Research Subjects and Health Insurance Portability and Accountability Act
(HIPPA) and completion of a security course on the VA Talent Management
System.
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for informed decision making.
September,
2011

The author met with Ita Leitner, the COMIRB exempt/expedited coordinator at
University of Colorado Health Sciences Center (UCHSC).

October, 2011

The author upgraded the Detailed pamphlet to include graphics, including a “can
of worms”, to represent the dilemma caused by screening.

October, 2011 The author worked with Shawn Fury, the ECHCS Medical Media Program
Manager, to create the Detailed pamphlet for COMIRB review.
October, 2011

The author received VA clearance letter on 10/5/2011 and Regis IRB approval
as an exempt study on 10/18/2011.

October,2011

The author submitted the IRB Application, VA Clearance Letter, and pamphlets
to COMIRB on 10/11/2011(running 5-7 weeks out for review).

November,2011 The author received a COMIRB Minor Modification Request on 11/02/2011.
November,
2011

The author received COMIRB approval for the Project, protocol 11-1514, on
11/9/2011 as Not Human Subject Research—Quality Assurance.

The author waited for approval by the VA Research and Development
NovemberDecember, Committee scheduled to meet on 12/14/2011. The Protocol went for review as
scheduled because there were no Conflict of Interest issues.
2011
December,
2011

The author received VA Eastern Colorado Health Care System Authorization
to Recruit & Conduct a Not Human Subjects Research Study (12/15/ 2011)
signed by Dr. Keith, the Associate Chief of Staff , Research and Development
Service on 12/20/2011.

December ,
2011

The author sent a message via Office Outlook to Denver VAMC PCPS about the
October, 2011 United States Preventative Services Task Force (USPSTF)
guidelines not to screen healthy men for prostate cancer; major medical
organizations recommendations for informed decision making; a copy of the
Detailed prostate cancer screening pamphlet, and; a request for four volunteer
PCPS in Firm A and four PCPS in Saturday Clinic to test the pamphlet on
12/22/2011.

December,
2011

The author received a word of caution from her former mentor, “I just want to be
sure that you have followed the proper channels and rules to keep you and VA
out of trouble…” (D. Weinshenker, personal communication, December 23,
2011). Received responses from three nurse practitioners (NPs) and one MD
from the Aurora Clinic interested in testing the pamphlet.
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December,
2011
January, 2012

January 2012

January 2012

January 2012

February, 2012

February, 2012
February, 2012

February, 2012

February, 2012

February, 2012

March, 2012

The author received a response from former mentor after he saw the VA R&D
approval letter, “Sounds like everything is in order. Good luck with the project!
Don” (D. Weinshenker, personal communication, December 26, 2011).
The author sent out a second Email message requesting four volunteers in Firm
A and one more volunteer in Saturday Clinic. A message was sent to
participating PCPs to document that informed prostate cancer screening took
place. Hoffman’s (2011) article about prostate cancer screening in the NEJM
was sent to participating providers.
The author personally recruited two NPs and one physician from Firm A to
participate on January 4, although the physician ignored the request. The project
started in Saturday Clinic on January 7 when four NP PCPs used the pamphlet
for the first time. A request was placed for 1000 more pamphlets because
providers were giving the pamphlets to patients to take home.
The author met with her mentor and was advised not to distribute the pamphlets
yet. Further pamphlet production was halted and the participants were advised of
the change. A third Email request was sent to providers in Firm A to participate
in the project. One physician personally volunteered and two physicians
personally declined.
The author sent a message to PCPs about how fear of litigation is a valid concern
because the structure of the U.S. legal system supports local screening and not
ordering a PSA can be considered a malpractice error of omission (Guerra et al.,
2007). Lewis, Gohagan, and Merenstein’s (2007) article on the locality rule and
Adami’s (2010) article on the prostate cancer pseudo-epidemic was sent to all
PCPs .
The author sent a message to all providers about the prostate cancer screening
project and requested four PCPs in Firm B to discuss their prostate cancer
screening practices without the use of the pamphlet. This led to a rebuttal by
two physicians and subsequently became a topic of discussion at the physicians
monthly Journal Club, leading to the comparison data needed.
The author distributed the survey to the eight participating participants resulting
in collection of the quantitative data.
The author was contacted by the Health Promotion Disease Prevention Program
Manager; a meeting took place to discuss a QI project currently in progress to
reducing PSA screenings in men over 75 years.
The author sent a message to all providers about how Dr. Lithium Lin’s poster
on the Principles of Shared Decision Making can be used for patients that
request PSA screening. This message resulted in four providers from Colorado
Springs and Pueblo requesting copies of the poster and Detailed prostate cancer
screening pamphlet.
The author contacted Shawn Fury for help in sending posters to the southern
CBOCs. A message was sent to the CBOC providers to contact Shawn with the
measurements they needed and further discussions followed.
The author sent providers an Executive Summary of the project and asked for
comments about the Detailed pamphlet before it was sent to Public Affairs for
approval for public use. One provider highlighted a few typos, grammatical
errors.
The author sent the Detailed brochure to Public Affairs and received approval
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March, 2012

March, 2012

for public distribution the following day. “Patricia-This looks fine and I approve,
but with one question: In the first paragraph of the “‘Looking for Cancer”
section, the second sentence said “screening leads to…substantial morbidity
(illness).” It reads as if screening leads to illness. If the sentence is correct,
you’re good to go” (G. Clark, personal communication, March 6, 2012).
The author responded to Mr. Clark that the sentence is correct and messages
were sent to all providers about the Detailed pamphlet approval for public use.
Shawn Fury was contact to produce 1000 pamphlets who responded, “We are
temporarily of hospital printing funds. I will process your request as soon as
funds become available (S. Fury, personal communication, March,, 8, 2012).
The author received the following email: “Yes, Funds are now available and
your order for 1000 Prostate brochures was placed earlier this week. It should
take 2 or more weeks for delivery” (S. Fury, personal communication, March 16,
2012).
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Appendix M
Budget and Resources

Resources needed for project
Category of Resource

Type of Resource

Staff time

Clinical staff time to assist with project
Librarian time to assist with literature search
Information technology time to assist with Microsoft

Consultants

Research design consultants (VA research office and
two PhD- prepared nurse mentors)
ECHCS Medical Media Program Manager
Primary care Provider’s input

Information technology

ECHCS computers with Microsoft Word
Computers with internet access

Supplies and materials

Detailed pamphlet production

Resource Sheet is adapted from Houser, J.H. (2011). Evidence-based practice in health care. In
J.H. Houser and K.S. Oman (Eds) Evidence-Based Practice: An Implementation Guide for
Healthcare Organizations. (Table 2-2, p. 27). Sudbury, MA: Jones and Bartlett Learning.
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Budget Estimates for Prostate Cancer Informed Decision Making Project
Costs
•
Labor
•
Office supplies
•
Commute/gas
Phones/communications
•
Internet access
•
IT support
•
Library support
•
Membership

•

•

Pamphlet production
•
Media Manger
•
Consultation fees
Total Costs

Billed per project
$50/hour
$50/project
$.65/mile
$150/month
$30/month
$50/hour
$0/hour
$200/professional
membership
1000 pamphlets
$69/hour
$75/hour

Projected variable Costs
$50 x 80 hours = $4000
$50
$.65 x 350 miles = $ 227
$150 x 3 months = $450
$30 x 3 months =$90
$50 x 10=$500
$0/hourx10=$0
$200
$900
$69 x 24 hours = $ 1656
$75 x 5 hours=$375
$8448.00

.
Variable Fixed and Direct Costs is adapted from Cleverley, W.O., Song, S.H., & Cleverly, J.O.
(2011). Cost Measurement. In W.O., Cleverley, S.H. Song, and J.O. Cleverly (Eds.) Essentials
of health care finance (pp.324-325). Sudbury MA: Jones and Bartlett Learning.
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Appendix N
CITI Collaborative Institutional Training Initiative

Human Research Curriculum Completion Report
Printed on 6/11/2011
Learner: Patricia Hughes (username: hughestish)
Institution: Regis University
Department: nursing
Contact
Information Email: hughes.tish@gmail.com
Social Behavioral Research Investigators and Key Personnel:
Stage 1. Basic Course Passed on 06/11/11 (Ref # 6161464)
Required Modules

Date
Completed

Introduction

06/10/11

no quiz

History and Ethical Principles - SBR

06/10/11

4/4 (100%)

The Regulations and The Social and Behavioral Sciences SBR

06/10/11

5/5 (100%)

Assessing Risk in Social and Behavioral Sciences - SBR

06/11/11

5/5 (100%)

Informed Consent - SBR

06/11/11

5/5 (100%)

Privacy and Confidentiality - SBR

06/11/11

5/5 (100%)

Regis University

06/11/11

no quiz

For this Completion Report to be valid, the learner listed above must be affiliated
with a CITI participating institution. Falsified information and unauthorized use of
the CITI course site is unethical, and may be considered scientific misconduct by
your institution.
Paul Braunschweiger Ph.D.
Professor, University of Miami
Director Office of Research Education
CITI Course Coordinator
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Return
Appendix O
Human Research CITI Training
........ ' ..Y'"''''''

.~

.. Y'"

• "roo;; • u, ..

•

CITI Collaborative Institulional Training Initiative
Human Research Curriculum Completion Report
Printed on 9/29/2011
Institution: Denver, CO-554
Contact
Department: emergency
iIriormiItion
r'hone: ;;u~o ext 2425
Email: hughes.tish@gmail.com

VA Human Subjects Protection and Good ClinIcal Practices:

Behavioral Research for Biomedical

Module 3:

Clinical Practice and VA

FOt' thIS compietlon Report to be valid, the learner listed above must be
affiliated with a ern participating Institution. Falsified information and

https:Jlwww.citiprogram.orglmembersllearnerslIlcrbystage.asp?strKeyID=-72B38530-A80...

912912011
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,u , '

CITI Collaborative Institutional Training Initiative
.:" , ;.;=-.:::,:.;: '''''.:::::.;:''•.::: -:.:__ ;~~

~!..~·~H!PS)·!:':!.Irriculum

Completion

Report
Printed on 101312011
Leamer: Patricia Hughes (usemame: EOGHANI
Institution: University of Colorado at Colorado Health Sciences Center - COMIRB

Contact
intonnatJon

Department: Emergency
pnone: jUj.-jli\H$OlU extl41~
Email: hughes.tish@gmail.oom

cm Health Infonnation Privacy and Security (HIPS) for Students and
Instructors: I hiS course 101" :stuaents ana Instruct0f'8 wm satrsfy. me marKIate
for basic training in the HIPAA. In addition other modules on keeping your
computers, passwords and electronic media safe and secure are included.

Federal and

,:: ~!:IiII Com;:Hetion RaDOn to De valid. the learner Usted above must be
affiliated with a cm participating Institution. Falsified infonnation and
unauthorized use of tha CIT! course site Is unetflieal, and may be
cons1d8Nd sclentltk misconduct by your Institution.

Paul Braunschweiger Ph.D.
P~ssor, University

of Miami

Director Office of Research Education

CITI Course Coordinator

hnps:llwww.citiprogram.org!memberslleamersIllctbystage.asp?strKeylD='D6F2A63O-903... 1012/201 J
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CITI Collaborative Institutional Training Initiative
Human R.... rch Curriculum Completion Report
Printed on 10/0U2011
i:dNN'ner.f·,;or...::.J. U; ...... i;<'"_....-'l.:,.r.i'T.:;",,, rf~'-i.~...-.: •.
Inatitution: UniversitY of Colorado at Colorado Health Sciences Center - COMIRB
Contact
Department: Emergency
,iR:iPJ.mlliian-

r.nCIOe:

3Oj-JW~O

ext 24'1~

Email: hughes.tish@gmail.com
Group 2 Social and BehavJoral R...arch:

.. or aua ~omoMtOOn KeDOn 10 De vallO. me teamer I_tad aboY1J mv:ai 0;;:;
afflliamd with a em JNlrticipating institution. Fafslfieci Information and
unauthorized u•• of the cm cou .... aita is unethical, and may be
conslO8l'8d 8clenUftc mlSConauct by your ln8tttut1on.
Paul Braunsehweiger Ph.D.
P mfAAAnt IlnlvAJ'!II.iN of Mi::lmi

Director Office of Research Education
CITI Course Coordinator

bttps:llwww.citiprogram.orgImem~auner-sllfabystage . asp?str~ey l D-9FE9890S-S2A...

101312011
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Appendix P
VA Clearance Letter

VA Claarance LaHar
(Pwp.. ..........,.)
0...: DetiDbef S, 201 1
To:

Pftnci!* IlWMdpIDrtPrImUy contact

Frvm: VA R_rdI orne.

-I!utem CoIcftdo HNIth CaNlIyst.m (ECHCS)

ThII form Mn'M to notify the Colorado Multfple IMtHutionel Review Board (COIIIIRB) that 1he
abow-enUtllld ~ .... been PN.......ww.cI by the VA RMMrch otnoe for VA
Nquit........ ""'- aAeo Includw a ,..... for edentlflc quality & mertt and VA
~ by • member of tM R&D CommltlH. 1M ReO mamber'a N\iiew add,......

. . foIowdi . . . . .:
• The ~h us. procedw. con.iatltnt .... 1Iound rMMrch ......
• The,...rch ~ .. sound enough 110 yIekI tIM! exptCtiId ~.
AttaoMc; II the Prtvacy and Securtty I'eYtw v.rtfIcatIon report.

ThenfoN, COIIIRB II authorlzitd
COIIIRB ponc," &nd procedurw.

to Pf'OCMCI

wtth the ...,.., and approv.l proeMS per

""Is\"
i

i

RF'SI>ER; ntIS IS f!ilI 1lE R6D cO.... alEE APPROVAL lETTER. YOU MUST RECEIVE
co.RB APPROVAL LET1ER, VA sueco.rnB! ON RESEARCH SAfnY (8RS)
APPROVAL, AND THE R&OCO.P, , i & APPROVAL LETTER (PLUS R&D STAMPS> VA

CONSENT FORM, 1,- APPUCABLE) PRIOR TO INITlAllNG YOUR STUDY.

co.EHT8 (if appIlcMla): VA."..rev_ ~ the protocol be aummIIrtud UncMr
ProIocoIlnfomNItioni full protocol wu lnc~ within Apptlcatton.
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FE

twgr;

--------•"
•

-

..........
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Appendix Q
Regis IRB Approval Letter
Academic Altai ..
~cG •• ntl

U N

V E R S I

IRB - REGIS UNIVERSITY

October 18, 2011

Patricia Hughes
279 Cottonwood Drive
Evergreen, CO 80439
RE:

lRB N: 11 ·298

Dear Patricia:
Your applicatiooto the Regis IRB for your project "Informed Decision Making with the
Guidancc: of Two Prostate Cancer Screening Educational Pamphlets" was approved as exempt on
October 18,2011.
Supporting reference information from the: chair: ..... approved as an excmpt study under
45CFR46.1 01(bXl Xii) (health education curricula).
The designation of "exempt," means no further IRB review of this project, as it is currently
designed, is needed.
If changes are lJlllde in the research plan that significantly alter the involvement of human
subjects from that which was approved in the named application, the new research plan must be
resubmitted to the Regis IRB for approval.

/ ~~"7-~~=-'--=--------

Si~

~

rl'iIniel Roysden,
Chair, Institutional Review Board
cc:

Patricia Mullen, Ph.D.

A JESUIT UNIVERSITY
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Appendix R
COMIRB Modification Letter
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Minor Modifitations Required
02-Nov-2011
Inv•• lIgstor:
Sponaor(a):
Sub)ecl:
Rav",w Data:

TltIs:

Patricia Hughes

COMIRB ProtocoI,,-1514Inilial Application
01 · Nov-2011
Informed DecIsIon Making Woth The Guidance or Two Prostate Cancer Sorooning Educational

" .......

eommOltoo sees no problem or unaecep\3b1e risks in the protocol and consent. but stipulated changes to certBin documents
are needed. These are <UI&eribed In \he reviewer oommenls below. The propOsal will not be approved unlil these stipulated
changes lIre """'" and~.
If Ihe modifications am not rooeivad in COMIRe within 30 days, your proIocoI will be WITHDRAWN.
No research actMtie8 may begin on this protoooI until fi",,1 approval is received.

j) ~

Comments:

1. Your sample will not allow you to do the stalisticat analysis you are proposing.
2. Do you want this reviewed as a 01 proje<:I? Your proIocoI and documents mention both research and Qllhroughoul. II
you want this ~ 8 5 01 , \Ile<1 you can not pul)4;sh the results under re8(illrch. only as a QI project.
3. MOffl 'eWow ""'Y be required if this ia a research p<ejecI.

PAPER SUBM ISSION· HOW TO RESPOND TO A DETERMINATION OF MINOR MOOIFICATIONS:
1. Plttaae enSure all documents a,(I 'ingl9-$idlKl aod ~ the PIM;"'s name and COMIRe protoooI number on them.
2. Submit one COllY 01 an
Changes you mada.

~emIz&d

cove. letter desaibing

yQ<.I'

response 10 each ism;e raised by the .ev>ewe. aod the

3. Exempt Re'liew' If changes are made 10 the Requesl kit Exemption Ioml, rellUbm~ one copy and enter revision dale on

",

4. Expedrted Rew.w:
a. If changes are requested 10 any pari of the Application for Protocol Review. or anyone of 1M applicalion atlachfTl9fll$ {A,
F. H. etc.), msubmlt one copy of the revised Application Ioml and All the application attachments. enl'" revision date on
PII. 1. &&Ction A, and the same vtI ... ion date on all application attachments.
1:>. If changes are requested to the Protocol. subm~ one highlighted copy of the revilHld protocol.
5. Exempt and Expedited Review: H changes a"• •equested 10 &ubject materials (consent. assent. questionnaire, survey.
advertiMmant, ote.l. subm~ one highlighted copy showing changes made and 000 doan copy of each revised document.
For consent revisions. onl9. new version dala and v8fSion II in the header.
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Appendix S
COMIRB Approval Letter

103.124.1055

{P~onel

303 .n4 .0990 [Fax)
COt-1! BE! HOme p AAe (Web]
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t.In i VO/'$H ~ 01 CoiOOlIOO Mot.pltal
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of Col"....cIc Dell..... '
P...... /lUon Cent...

Not Human Subject Research
09-Nov·2011
Inv(latl~tor.

Patricia Hughes

SponsOl'(s):

Subject:

COM1RB Protocol 11-1514 Initial Application

Effective Date:

08-Nov-2011

TItle:

Informed Decision Making With The Guidance Of Two ~rO$tate Cancer Screening Educational Pamphlets

Not Human Research

Your research project submitted to COMIRB under protocol number "·1514 has been reviewed and our determination Is thalli is not human
research as deflneo by our policies and current regulations and In accordance with OHRP and FDA guidelines .
•Therefore , you may proceed wflh the projecl strictly ronewing the protocol as submitted and reviewed by COMIRS. No continuing review of the
project will be required , however, you must resubmil ihe protocol to COMIRS for approval If any substantive changes are made to the protocol!n
question.

Reylew Cornments·

COMlRB dc:tennined project to be Not Hwnan Subject Research Quality Assurance.
Please note that any publications cannOt use the tenn'research' under DHHS regulations but l)1USt clearly indicate that this is a
Quality Assurance project only and that its results are not generalizable.
.
These docwnents were reviewed for detennination of Not Human Subject Research:
Application
Application FOl" Review!Approval (Word Vcrsion, Fonn A)
Appendix B - Prostate Detailed Educational Pamphlet
Appendix C - Basic Prostate Cancer Screening Pamphlet
V A Prostate Cancer Brochure - for Providers
VA Prostate Educational Pamphlet - for Providers
VA - Be Informed before opening the prostate cancer screening can ofworrns
Sincerely,

UCO Panel A
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Appendix T
VA Eastern Colorado Health Care System Authorization Letter

ElFI'.\ ~T:'Ill:"T 01' \'E-:TER -\ .' " _\"FAIRS
[.\STER;'>i CULOIt,\I)() IIE,\LTII C\IU: ,,\ 'STF:~I
1055 Ckrltlun! S!r,'t·'

Oclt\'n, Clllnrndn 1111210
30;t<W9-XIJ20
\1,-" .,',1 C,''''"
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" " "";"""~ 1 "n~
'e,-."

Date: December 15, 2011

Ic..-,,,.c~ .'"

I't'"

I', .. ,,·,.O''''~:<'
;.,!.),. ... ",:"

.'".

To: Patricia Hughes

''''''_ ' ''.''l J;. , •..
~
.' ..... · ,... (;, ~ .·I"""
! ....,!o~~ , u
'! ''-~_<_ 7!'"

From: Associate Chief of Staff. Research and Development Service (151)

" l-W\T!r'l

Protocol Title: 11 -1514 Informed Decision Making with the Guidance
of Two Prostate Cancer Screening Educational Pamphlets

I
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,.~~ [).· 1_,,,11~
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-;~'_'_ . l ~"" ",

I.".'" f.

·,".',Y"

'li"''''rr'

COMIRB Determined Not Human Subjects Researcl'l: November 8, 2011
SRS # and Approval Date: 5-113251E October 6, 2011
R&D Approval Date: December 14, 201 1
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VA Eastern Colorado Health Care System
AuthorIZation to Recruit & Conduct a
Not Human Subjects Research Study
This notice authorizes the above-referenced investigator to conduct
Ul9 above referenced not human research protocol as approved by
!he Subcommittee 00 Research Safety and R&D Committee,
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This authorization remains in effect until such time lhat anyone of the
folklwing occur:
•
SRS or R&D Gommitte& withdraws approval for any reason
•
The research project is closed by the Investigator or sponsor
•
The invesllgator fails to maintain a current approved
continuing review by R&D Committee,
•
The VA ECHCS determines that the research ]XC/ect can no
longer be conducted atlhe VA ECHCS for failure to comply with any
applicable regulation or local policy or deviation from the approved
protocol.

If multiple sites are involved with this study the VA R&D Committee has
only approved the VA C{)mponenl of this protocol.

~

v£!

Robe Keit M.D.
Associate
lei of Staff, R&D
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GIll<li l- Proje!;t Closure

Pagclofl

Tl l5h Hughes <hughes.tll5h@gmall .eom>

Project Closure
2 messages
Tish Hughes <hughes.llsh@gm ail.com>
To: "Leitner. Ita" <ita,leitn-er@ucdenver,edu>

Tue, Mar 13, 2012 at 9:05 AM

Dear Ms. Leilner,
The project, p(otocol number 11-1514, was completed March, 2012. The
prostale cancer screening educalional pamphlet was approved for pu~lc
use. Can you close the project with COMIRB.
Thank-you for your courtesy and cooperation,
Patricia Hughes
l eitner, Ita <lla.Leilner@ucdenver,edu;.
To: Tish Hughes chughes .tish@gmail.com>

Tue , Mar 13, 2012 at 9:47 AM

Good Morning Tish,
As it was determined to be Not Human Subject Resear!;h no need to do any additional paper work for II. As
we review ~ once and II you are don-e, thai is r,ne .
Thanks for the notice arid Congratulation on oompletlog this project!

'10
Ita Leitner

ita leilner@u_C(l_~
ExempVExpediled Coordinator
303-724-1068, fax 303-724-0990
Mailing Add ress:COMIRB. Mall Stop F490
13001 E. 17th Place, Room N3214
Aurora, CO 80045

IOw' ...

'e",....,.....)

https:llmail.googlc.com/muil/hl lwbz53wOwh7chl? &va=pt&th'" I 360cbe85c48eb84

3/ 1512012
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